"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_PADOVA",2000,24,7.45833333333333,2.75,0.625,0.291666666666667,0.583333333333333,1.13793103448276,1.07142857142857,0.875,1.07692307692308,0.291666666666667,0,13,4,2,5,0.54,0.17,0.08,0.21,27.08,0.597457517019175,NA,0.0833333333333333,0.666666666666667,0.3,0.19,0.107,0.198,"DARIO CASARA;ALBA A. BRANDES;CARLO RICCARDO ROSSI;S. MONFARDINI;LAURA BONALDI;MARIO STRAZZABOSCO;MARCO MONTAGNA;RENZO MAZZAROTTO;CHIARA MENIN;EMILIO RAMAZZINA;ROSSELLA PAOLINI;MARIA CRISTINA MONTESCO;MARIA SANTACATTERINA;ANNAROSA DEL MISTRO;SERGIO ZAMBONI;EMMA D’ANDREA;M. LISE;ALESSANDRO POLETTI;G. ZAVAGNO;ADRIANO BONAZZA","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","ALBA A. BRANDES;MARIO STRAZZABOSCO;PASETTO LM;S. MONFARDINI;CARLO SPIRLÌ;LARA MARIA PASETTO;E TOGNONI;P BOCCACCIO;ÁKOS ZSEMBERY;FRANCA MOCCIA;LAJOS OKOLICSÀNYI;J. GRAF;DARIO CASARA;RENZO MAZZAROTTO;LAURA BONALDI;MARINA DE PRÀ;PAOLO NALIN;MARCO MONTAGNA;ALESSIO BOREAN;CHIARA MENIN","0.93;0.67;0.5;0.43;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.29;0.2;0.2;0.2;0.2;0.2;0.2","DARIO CASARA;ALBA A. BRANDES;S. MONFARDINI;MARIO STRAZZABOSCO;RENZO MAZZAROTTO;ANNAROSA DEL MISTRO;ALESSANDRO POLETTI;DEBORA LANARO;O. LORA;S. SCAPPIN;SALVATORE PUCCIARELLI;CARLO SPIRLÌ;ROBERTA VENTURINI;MARIO PLEBANI;ALESSANDRA TODESCO;PATRIZIA PAVEI;F. BUIN;ANTONIO TIENGO;ANNA MARIA CATTELAN;STEFANO MERIGLIANO","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","ALBA A. BRANDES;MARIO STRAZZABOSCO;S. MONFARDINI;CARLO SPIRLÌ;ÁKOS ZSEMBERY;FRANCA MOCCIA;DARIO CASARA;RENZO MAZZAROTTO;ALESSIO BOREAN;ANNAROSA DEL MISTRO;ALESSANDRO POLETTI;O. LORA;ALESSANDRA TODESCO;M. G. CESARO;E. FRASCELLA;GUIDO SOTTI;DOMENICO RUBELLO;MODESTO CARLI;ANGELO ROSOLEN;SALVATORE PUCCIARELLI","0.93;0.67;0.43;0.33;0.33;0.33;0.32;0.29;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14","ALBA A. BRANDES;S. MONFARDINI;BIANCA GUGLIELMI;CARLA CAROLLO;DANIELA DANIELI;G PINNA;LORENZO VOLPIN;MARINA GARDIMAN;PIETRO AMIST�;S. TURAZZI;RENZO MAZZAROTTO;DARIO CASARA;J. GRAF;MARIO STRAZZABOSCO;ÁKOS ZSEMBERY;ALBERTO FERLIN;ANDREA BETTELLA;ANDREA GAROLLA;B BUSNARDO;CARLO FORESTA","157;156;109;109;109;109;109;109;109;109;87;63;63;63;63;60;60;60;60;60","ALBA A. BRANDES;MARINA GARDIMAN;S. MONFARDINI;RENZO MAZZAROTTO;DARIO CASARA;MARIO STRAZZABOSCO;ÁKOS ZSEMBERY;M. R. PELIZZO;MARIO PLEBANI;A. FORNASIERO;ELISABETTA MARCHIORI;MARIA LUISA FRISO;MARIO LISE;PAOLA TOPPAN;SALVATORE PUCCIARELLI;SANDRO CARNIO;ALBERTO RUOL;ERMANNO ANCONA;F. BUIN;G. F. PETRIN","157;109;109;87;63;63;63;60;60;59;59;59;59;59;59;59;52;52;52;52","ALBA A. BRANDES;DARIO CASARA;ALESSANDRO POLETTI;ANNAROSA DEL MISTRO;MARIO STRAZZABOSCO;RENZO MAZZAROTTO;A. FORNASIERO;ADOLFO FAVARETTO;ALBERTO RUOL;ALESSANDRA TODESCO;ALESSIO BOREAN;ANA CLAUDIA MANSANO GIROTTO;ANGELO ROSOLEN;ANNA MARIA CATTELAN;ANTONIO TIENGO;DOMENICO RUBELLO;E. FRASCELLA;ELISABETTA MARCHIORI;ERMANNO ANCONA;F. BUIN","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATHEMATICS;SOCIOLOGY","24;7;4;2;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ENDOCRINOLOGY;ONCOLOGY;BIOCHEMISTRY;CANCER RESEARCH;GENETICS;PATHOLOGY;ANESTHESIA;DERMATOLOGY;ENVIRONMENTAL HEALTH;OPTICS;PALEONTOLOGY;PHARMACOLOGY;ANDROLOGY;BIOPHYSICS;CHROMATOGRAPHY;DEMOGRAPHY;HORTICULTURE;INTENSIVE CARE MEDICINE;MATHEMATICAL ANALYSIS;NUCLEAR MEDICINE;PSYCHIATRY;UROLOGY;VIROLOGY","19;10;6;5;5;4;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CHEMOTHERAPY;CANCER;RADIATION THERAPY;BIOPSY;DISEASE;CLINICAL TRIAL;HORMONE;INCIDENCE (GEOMETRY);LEUKEMIA;LYMPHOMA;THYROID;TRANSPLANTATION;ABDOMINAL SURGERY;ALBUMIN;ALLERGY;ANAMNESIS;ANASTOMOSIS;ANEMIA;ANTIBODY;BICARBONATE;BILE DUCT;BILIARY TRACT;BLOOD VOLUME;BONE MARROW;BONE REMODELING;BONE RESORPTION;CALCIUM;CAPILLARY ELECTROPHORESIS;CARCINOMA;CHLORIDE CHANNEL;CHOLANGIOCYTE;CHOLESTASIS;COLD STORAGE;CONTEXT (ARCHAEOLOGY);CYSTIC FIBROSIS;DIABETES MELLITUS;DISTENSION;DISTRIBUTION (MATHEMATICS);DRUG;ENZYME;EXTRACELLULAR;GENE;GLIOMA;GROUP A;GROUP B;HEPATOLOGY;HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HYDROXYETHYL STARCH;IMMUNE SYSTEM;INSULIN;INTERFERON;LUNG;LUNG CANCER;LYMPHOCYTOSIS;MAGNETIC RESONANCE IMAGING;MELANOMA;MEMBRANE;METHYLPREDNISOLONE;OSTEOPOROSIS;OSTEOSARCOMA;PANCREAS;PERFUSION;PHARMACOKINETICS;PLATELET;POISON CONTROL;POPULATION;PREGNANCY;PSYCHOACTIVE SUBSTANCE;PSYCHOTROPIC AGENT;RECEPTOR;RECTUM;REGIMEN;RESORPTION;SARCOMA;SECRETION;SPERM;SPERMATOGENESIS;STAGE (STRATIGRAPHY);STEM CELL;STENOSIS;STIMULATION;SUCROSE;SURGICAL ONCOLOGY;TOXICITY;TYPE I COLLAGEN;ULTRASOUND","8;6;5;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CYCLOPHOSPHAMIDE;HAIRY CELL LEUKEMIA;TEMOZOLOMIDE;THYROIDECTOMY;ADENOCARCINOMA;ALKALINE PHOSPHATASE;ALPHA INTERFERON;ANAPLASTIC CARCINOMA;APHERESIS;AUTOIMMUNE DISEASE;BASAL (MEDICINE);BILE DUCT DISEASES;BISPHOSPHONATE;BLEOMYCIN;BRACHYTHERAPY;CD34;CENTRAL NEUROCYTOMA;CHEMOTHERAPY REGIMEN;CISPLATIN;COLORECTAL CANCER;COMPLETE REMISSION;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;DIDS;DRUGS OF ABUSE;ESOPHAGEAL CANCER;ETOPOSIDE;EXTERNAL BEAM RADIATION;FOOD ALLERGY;GEMCITABINE;GENETIC DIVERSITY;GENOTYPE;GLIBENCLAMIDE;GLICLAZIDE;GLIPIZIDE;GOITER;GONADOTROPIN;INFERTILITY;INJURY PREVENTION;INTRAHEPATIC BILE DUCTS;KIDNEY TRANSPLANTATION;LEUKOPENIA;LIVER TRANSPLANTATION;LUTEINIZING HORMONE;METASTASIS;METASTATIC MELANOMA;MICELLAR ELECTROKINETIC CHROMATOGRAPHY;MYCOSIS FUNGOIDES;NEUTROPENIA;ONCOTIC PRESSURE;OSTEOCLAST;PACLITAXEL;PARATHYROID HORMONE;PHASES OF CLINICAL RESEARCH;PRIMARY SCLEROSING CHOLANGITIS;PROGRESSIVE DISEASE;PSYCHOTROPIC DRUG;PURINERGIC RECEPTOR;RADICAL SURGERY;RAFFINOSE;REFLUX;SKIN BIOPSY;SULFONYLUREA;T CELL;THYROID CANCER;THYROID CARCINOMA;TOLBUTAMIDE;TYPE 2 DIABETES;VIASPAN;VIRAL DISEASE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SENTINEL LYMPH NODE;SENTINEL NODE;ABDOMINOPERINEAL RESECTION;ALCOHOL INTOXICATION;AXILLA;BILIARY ATRESIA;BILIARY CIRRHOSIS;CARBOPLATIN;CUTANEOUS LYMPHOMA;CUTANEOUS T-CELL LYMPHOMA;DAPAGLIFLOZIN;DRIVING UNDER THE INFLUENCE;ESOPHAGECTOMY;EXTERNAL BEAM RADIOTHERAPY;FOLLICLE-STIMULATING HORMONE;GENETIC VARIANTS;INTRAVENOUS DRUG;LEUKAPHERESIS;MALE INFERTILITY;OSTEOCALCIN;PANCREAS TRANSPLANTATION;PAPILLARY THYROID CANCER;PERIPHERAL T-CELL LYMPHOMA;TERIPARATIDE","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;BRAIN NEOPLASMS;LUNG NEOPLASMS;MALE;FEMALE;NEOPLASM RECURRENCE, LOCAL;MIDDLE AGED;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PACLITAXEL;ADENOCARCINOMA;ANTINEOPLASTIC AGENTS, ALKYLATING;ANTINEOPLASTIC AGENTS, PHYTOGENIC;CARCINOMA, NON-SMALL-CELL LUNG;GLIOMA;NEUROCYTOMA;SKIN NEOPLASMS;THYROID NEOPLASMS;","19;12;11;11;10;10;9;8;6;6;6;5;5;5;5;5;5;5;5;4","GLIOMAS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;COLORECTAL CANCER RESEARCH AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MALE REPRODUCTIVE HEALTH;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MELANOMA;MOLECULAR RESEARCH ON BREAST CANCER;NEUROBLASTOMA RESEARCH AND TREATMENT;ORIGINS AND FUTURE OF MICROFLUIDICS;PATHOGENESIS AND MANAGEMENT OF BILIARY ATRESIA;PATHOGENESIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;SKIN SENSITIZATION AND CONTACT ALLERGY RESEARCH;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIFFERENTIATED THYROID CANCER;MEDULLARY THYROID CANCER;NEUROPROTECTIVE STRATEGIES;T-CELL LYMPHOMA;TEMOZOLOMIDE;THYROID NODULES;ABDOMINOPERINEAL RESECTION;ADJUVANT CHEMOTHERAPY;AIRWAY STENOSIS;ALCOHOL INTOXICATION;ANAMNESIS;ANAPLASTIC CARCINOMA;ANASTOMOTIC LEAKS;AXILLA;BASAL (MEDICINE);BICARBONATE;BILE DUCT DISEASES;BILIARY CIRRHOSIS;BONE REMODELING;BREAST CANCER","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL LEUKEMIA;HAIRY CELL;NODE BIOPSY;SENTINEL NODE;ACQUIRED FACTOR;ADVANCED NON-SMALL-CELL;ALCOHOL DRUGS;ALL-TRANS RETINOIC;ANAPLASTIC THYROID;ANASTOMOTIC STENOSES;BEAM RADIOTHERAPY;BICARBONATE SECRETION;BILIARY EPITHELIUM;BLOOD STEM;BREAST CANCER;C-TELOPEPTIDE FRAGMENTS;CANCER PRELIMINARY;CANCER SUCCESSFUL;CANCER SURGERY;CAPILLARY ELECTROPHORESIS;CARCINOMA STUDY;CASUPSUPACTIVATED CLSUPSUP;CELL COLLECTION;CELSIOR SOLUTION;CENTRAL NEUROCYTOMA;CIRCULAR STAPLING;CLODRONATE THERAPY;CLSUPSUP CHANNELS;COLLAGEN TYPE;COMBINED RADIOTHERAPY","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABDOMINAL DISTENSION;ADVANCED NSCLC;AXILLARY NODES;BREAST CANCER;FEMALE PATIENTS;HORMONAL STATUS;IBS PATIENTS;INTERNAL STANDARD;SN BIOPSY;ANALYSES DISCLOSED;ANDOR PUTATIVE;B-CELL INTERSTITIAL;B-CELL LYMPHOMA;B-CELL NON-HODGKINS;BIOPSY SURPRISINGLY;BLOT ANALYSIS;BONE MARROW;CELL LEUKEMIA;CELLS SUPPORTED;CIRCULATING NEOPLASTIC;CUTANEOUS DISEASE;CUTANEOUS FORM;CUTANEOUS ITCHY;DAYSWEEK -DAYSWEEK;EVENTS ANDOR;FUNGOIDES MF-LIKE;GENOTYPIC ANALYSES;GRADE B-CELL;HAIRY CELL;HEMATOL WILEY-LISS","3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,8,663.89,15.52,0,0,24.33,0,0,3,0,4,0,1,1,0,9,0,0,0,0,0,0,0,8,1,0,9,0,0,0,0,0,0,0,0,0,"Belgium;Italy","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","8;6;4;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;ORPHAN DRUG;RARE DISEASES;UROLOGIC DISEASES;INFECTIOUS DISEASES;KIDNEY DISEASE;LUNG;LUNG CANCER;PEDIATRIC;PREVENTION;AGING;ANTIMICROBIAL RESISTANCE;BRAIN CANCER;BRAIN DISORDERS;BREAST CANCER;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE","9;9;6;5;5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;INFECTION;RENAL AND UROGENITAL;CARDIOVASCULAR","6;2;2;1","6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","8;1;1;1","LUNG CANCER;BRAIN TUMOR;BREAST CANCER;OVARIAN CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;1;1",1,1176528,15899.03,6,74,14,1,10,2649.83783783784,9.05715801068908,"ANDALUSIAN HEALTH SERVICE;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AZIENDA OSPEDALIERA DI PADOVA;BAMBINO GESÙ CHILDREN'S HOSPITAL;CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT-PIERRE;CHILDREN'S HEALTH IRELAND AT CRUMLIN;DÉLÉGATION PARIS 11;EALING HOSPITAL NHS TRUST;ERASMUS MC;GUY'S AND ST THOMAS' NHS FOUNDATION TRUST;HEINRICH HEINE UNIVERSITY DÜSSELDORF;HOSPICES CIVILS DE LYON;HOSPITAL DE BASURTO;HOSPITAL DE DONA ESTEFÂNIA;HOSPITAL DEL MAR;HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN;HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE;HOSPITAL UNIVERSITARIO 12 DE OCTUBRE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES;PEDIATRIC","1;1;1;1;1","INFECTION","1","5.1 PHARMACEUTICALS;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT);6.1 PHARMACEUTICALS;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","1;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2001,33,7.18181818181818,2.48484848484849,0.515151515151515,0.181818181818182,0.515151515151515,1.22388059701493,1.0625,1,1.0625,0.151515151515152,2,12,7,3,10,0.36,0.21,0.09,0.3,34.45,0.754053706313018,NA,0.121212121212121,0.666666666666667,0.401,0.358,0.327,0.358,"MARIO PLEBANI;DARIO CASARA;DOMENICO RUBELLO;ALBA A. BRANDES;LUIGI BONAVINA;MARZIA FRANZETTI;R SPOSETTI;H. KOUSSIS;C. CAROLLO;S. MONFARDINI;LUIGI CHIECO‐BIANCHI;LAURA BONALDI;A BERGAMASCO;MASSIMILIANO BONAFÉ;VANNA CHIARION‐SILENI;ANNA MARIA CATTELAN;STEFANO MERIGLIANO;GIOVANNELLA BAGGIO;ALBERTO RUOL;­ROSARIO ­TUMINO","5;5;5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MARIO PLEBANI;DARIO CASARA;DOMENICO RUBELLO;G TOMASELLA;S. MONFARDINI;C. CAROLLO;DIEGO SERRAINO;ALBA A. BRANDES;PELIZZO MR;LUCIA FRATINO;VITTORINA ZAGONEL;GIORGIO SALADINI;SARA LONARDI;C. ASCHELE;A BERGAMASCO;ANDREA PIOTTO;­ROSARIO ­TUMINO;SUSANNA VITARELLI;FRANCO LUMACHI;VALERIO RAMAZZOTTI","1.51;1.39;1.39;1;0.43;0.39;0.39;0.37;0.36;0.33;0.33;0.33;0.33;0.33;0.31;0.31;0.31;0.31;0.27;0.25","MARIO PLEBANI;DARIO CASARA;DOMENICO RUBELLO;ALBA A. BRANDES;MARZIA FRANZETTI;R SPOSETTI;H. KOUSSIS;C. CAROLLO;S. MONFARDINI;LUIGI CHIECO‐BIANCHI;LAURA BONALDI;VANNA CHIARION‐SILENI;ANNA MARIA CATTELAN;STEFANO MERIGLIANO;GIOVANNELLA BAGGIO;ALBERTO RUOL;ROBERTA BERTORELLE;ANNAROSA DEL MISTRO;A TORRISI;EMANUELA BONOLDI","5;5;5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MARIO PLEBANI;DARIO CASARA;DOMENICO RUBELLO;G TOMASELLA;S. MONFARDINI;C. CAROLLO;ALBA A. BRANDES;PELIZZO MR;LUCIA FRATINO;C. ASCHELE;STEFANO GUZZINATI;H. KOUSSIS;VANNA CHIARION‐SILENI;STEFANO MERIGLIANO;ALBERTO RUOL;ERMANNO ANCONA;STEFANO SANTI;MARZIA FRANZETTI;R SPOSETTI;LUIGI CHIECO‐BIANCHI","1.51;1.39;1.39;1;0.43;0.39;0.37;0.36;0.33;0.33;0.25;0.22;0.22;0.22;0.22;0.22;0.22;0.2;0.2;0.2","ALBERTO PERACCHIA;ALBERTO RUOL;ERMANNO ANCONA;GIOVANNI ZANINOTTO;H. KOUSSIS;LUIGI BONAVINA;STEFANO MERIGLIANO;STEFANO SANTI;VANNA CHIARION‐SILENI;ALBA A. BRANDES;CLAUDIO FRANCESCHI;GIOVANNELLA BAGGIO;MASSIMILIANO BONAFÉ;MARIO PLEBANI;FRANCO LUMACHI;DIEGO SERRAINO;A. ROTILIO;FRANCO BERTI;GIAN DOMENICO PINNA;MARINA GARDIMAN","336;336;336;336;336;336;336;336;336;194;132;132;132;109;103;93;91;91;91;91","ALBERTO RUOL;ERMANNO ANCONA;GIOVANNI ZANINOTTO;H. KOUSSIS;STEFANO MERIGLIANO;STEFANO SANTI;VANNA CHIARION‐SILENI;ALBA A. BRANDES;GIOVANNELLA BAGGIO;MARIO PLEBANI;A. ROTILIO;FRANCO BERTI;MARINA GARDIMAN;MARIO ERMANI;PIETRO AMISTÀ;RENATO SCIENZA;S. MONFARDINI;UMBERTO BASSO;FEDERICO ANGELINI;G. GIUST","336;336;336;336;336;336;336;194;132;109;91;91;91;91;91;91;91;91;80;75","MARIO PLEBANI;ALBA A. BRANDES;ALBERTO RUOL;ANNA MARIA CATTELAN;DOMENICO RUBELLO;ERMANNO ANCONA;GIOVANNELLA BAGGIO;GIOVANNI ZANINOTTO;H. KOUSSIS;STEFANO MERIGLIANO;STEFANO SANTI;VANNA CHIARION‐SILENI;A TORRISI;A. ROTILIO;ALESSANDRA ZAMPIERON;ANNAROSA DEL MISTRO;C. B. DE PALO;C. CAROLLO;C. SCHIRALDI;D MINUCCI","5;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","32;8;3;3;1;1;1;1","INTERNAL MEDICINE;RADIOLOGY;SURGERY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;IMMUNOLOGY;GENETICS;NUCLEAR MEDICINE;ONCOLOGY;ANESTHESIA;CANCER RESEARCH;GYNECOLOGY;OBSTETRICS;UROLOGY;CELL BIOLOGY;DATABASE;DEMOGRAPHY;EVOLUTIONARY BIOLOGY;FAMILY MEDICINE;FOOD SCIENCE;GERONTOLOGY;LAW;LIBRARY SCIENCE;MEDICAL EDUCATION;MEDICAL EMERGENCY;MEDICAL PHYSICS;OPERATING SYSTEM;OPERATIONS MANAGEMENT;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;PHYSICAL THERAPY;PSYCHIATRY;STATISTICS","29;10;10;9;7;6;5;5;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;GENE;HYPERPARATHYROIDISM;PRIMARY HYPERPARATHYROIDISM;SCINTIGRAPHY;THYROID;CARCINOMA;RADIATION THERAPY;ADENOMA;ANTIBODY;BIOPSY;CALCIUM;CYTOLOGY;DISEASE;EPIDEMIOLOGY;ESOPHAGUS;HUMAN PAPILLOMAVIRUS;IN VITRO;INGESTION;KIDNEY;OXIDATIVE STRESS;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;REGIMEN;SEX ORGAN;SURVIVAL RATE","12;5;5;5;5;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;COLORECTAL CANCER;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;CYCLOPHOSPHAMIDE;ESOPHAGEAL CANCER;ESOPHAGEAL DISEASE;FLUOROURACIL;LYMPHADENECTOMY;PARATHYROID CARCINOMA;PARATHYROID HORMONE;POLYMERASE CHAIN REACTION;THYROID CARCINOMA;ARGININE;ASTROCYTOMA;AUTOIMMUNE DISEASE;BASAL (MEDICINE);BASAL GANGLIA;CANCER REGISTRY;CHROMOSOME;COINFECTION;CYTOPATHOLOGY;DACARBAZINE;ECLAMPSIA;EPIDERMAL GROWTH FACTOR;FIBROBLAST;FINE-NEEDLE ASPIRATION;FOOD ALLERGY;GERIATRIC ONCOLOGY;GLUTATHIONE;GROWTH HORMONE;HEPATITIS C VIRUS;HODGKIN LYMPHOMA;IMMUNOGLOBULIN E;IMMUNOSENESCENCE;MALONDIALDEHYDE;METASTASIS;MULTIPLE ENDOCRINE NEOPLASIA;NEURORADIOLOGY;NEUTROPENIA;OCCULT;OLIGURIA;PARATHYROID ADENOMA;PARKINSON'S DISEASE;PERFORMANCE STATUS;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PLASMAPHERESIS;POPULATION STRUCTURE;PROGRAMMED CELL DEATH;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;PROTEINURIA;QUALITY ASSURANCE;REPERFUSION INJURY;SCLERODERMA (FUNGUS);STORAGE PROTEIN;TECHNETIUM (99MTC) SESTAMIBI;TECHNETIUM TC 99M SESTAMIBI;TEMOZOLOMIDE;THROMBOTIC THROMBOCYTOPENIC PURPURA;THYROIDECTOMY","3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ESOPHAGECTOMY;HPV INFECTION;PARATHYROIDECTOMY;ANAPLASTIC ASTROCYTOMA;BASAL GANGLIA DISEASE;BREAST CARCINOMA;CERVICAL INTRAEPITHELIAL NEOPLASIA;CONNECTIVE TISSUE DISEASE;EPIRUBICIN;HELLP SYNDROME;LEVODOPA;MAMMOGRAPHY;MASTECTOMY;MEDULLARY CARCINOMA;MICROANGIOPATHIC HEMOLYTIC ANEMIA;OLIGODENDROGLIOMA;ORAL ALLERGY SYNDROME;PAPILLOMAVIRIDAE;PARATHYROID GLAND;PARATHYROID NEOPLASM;PROLAMIN;RECTAL EXAMINATION;RELATIVE SURVIVAL;SENTINEL LYMPH NODE;VINCRISTINE;WHEAT ALLERGY","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;CARCINOMA;PARATHYROID NEOPLASMS;FEMALE;MALE;ADULT;HYPERPARATHYROIDISM;ADENOMA;MIDDLE AGED;AGED;ITALY;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;;BRAIN NEOPLASMS;GLIOMA;NEOPLASM RECURRENCE, LOCAL;NEOPLASMS;PARATHYROIDECTOMY;RADIOPHARMACEUTICALS","26;21;21;19;17;16;16;15;14;11;9;8;7;6;6;6;6;6;6;6","MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLIOMAS;HEPATITIS C INFECTION AND TREATMENT;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENOMIC ANALYSIS OF ANCIENT DNA;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;MOLECULAR MECHANISMS OF APOPTOSIS AND CELL DEATH;MOLECULAR MECHANISMS OF KIDNEY DEVELOPMENT AND DISEASE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;PROTEIN METABOLISM IN EXERCISE AND NUTRITION","5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","PARATHYROID HORMONE;CHEMOTHERAPY REGIMEN;HPV VACCINATION;METASTATIC COLORECTAL CANCER;NEOADJUVANT CHEMOTHERAPY;NEOADJUVANT THERAPY;PARATHYROID CARCINOMA;REGIMEN;SEX ORGAN;AGING;ANAPLASTIC ASTROCYTOMA;APOPTOSIS;APOPTOTIC CELLS;BASAL (MEDICINE);BASAL GANGLIA DISEASE;BREAST CARCINOMA;BREAST MRI;CANCER IN OLDER ADULTS;CHEMOTHERAPY;COMPLETE RESPONSE","5;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","PRIMARY HYPERPARATHYROIDISM;CELL CARCINOMA;CHEMOTHERAPY IMPROVES;COLORECTAL CANCER;COMPLETE RESPONSE;ESOPHAGEAL SQUAMOUS;GENITAL HUMAN;HUMAN PAPILLOMAVIRUS;IMMUNODEPRESSED WOMEN;IMPROVES SIGNIFICANTLY;NEOADJUVANT CHEMOTHERAPY;NORTHEAST ITALY;PAPILLOMAVIRUS TYPES;PATHOLOGIC COMPLETE;RESECTABLE ESOPHAGEAL;SQUAMOUS CELL;TERM SURVIVAL;THYROID CARCINOMA;ACUTE EXTRAPYRAMIDAL;ADRENAL MASSES;ADVANCED BREAST;ADVANCED STAGES;ASPIRATION CYTOLOGY;BASAL GANGLIA;BCAA SUPPLEMENTATION;BINARY MARKERS;BLOOD MONONUCLEAR;BREAST CANCER;BREAST CARCINOMA;CANCER CT","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","PREOPERATIVE CHEMOTHERAPY;PATHOLOGIC COMPLETE;RESECTABLE ESOPHAGEAL;FNA CYTOLOGY;RESPONSE RATE;COMPLETE RESPONSE;CURATIVE RESECTION;ESOPHAGEAL CARCINOMA;SIGNIFICANTLY IMPROVED;ADRENAL MASSES;AMERICAN CANCER;CANCER SOCIETY;HIGH-GRADE GLIOMA;PARTIAL RESPONSE;ADRENAL METASTASES;AIDS DIAGNOSIS;ANALYZED FORTY-EIGHT;ARM CHEMOTHERAPY;ARMS TRANSTHORACIC;BACKGROUND SURGERY;BENIGN LESIONS;CANCER AMERICAN;CHARACTERISTICS RESULTS;CHEMOTHERAPY ARM;CHEMOTHERAPY CONSISTED;CHEMOTHERAPY SUGGEST;CISPLATIN MGM;CLINICALLY RESECTABLE;COMPARED PATIENTS;COMPLETE RESECTION","8;6;6;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",5,0.15,5.09,8,1,1,0,0,9,0,1.75,9,0,0,5,2,0,0,0,4,1,0,0,54,54,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,4.67,263.25,7.27,0,0,60.25,0,0,1,0,2,0,1,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Belgium;Germany;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","4;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;BRAIN CANCER;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEART DISEASE;HIV/AIDS;INFECTIOUS DISEASES;NEUROSCIENCES;ORPHAN DRUG","4;3;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","4;1;1","BRAIN TUMOR","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2002,44,6.97727272727273,2.22727272727273,0.568181818181818,0.272727272727273,0.545454545454545,1.36111111111111,1.19047619047619,1.09090909090909,1.2,0.227272727272727,3,17,4,12,11,0.39,0.09,0.27,0.25,57.16,1.03607806624296,NA,0.136363636363636,0.681818181818182,0.511,0.416,0.364,0.416,"S. MONFARDINI;DOMENICO RUBELLO;MARIO PLEBANI;DARIO CASARA;CARLO RICCARDO ROSSI;GIOVANNI SCARZELLO;FRANCO LUMACHI;ALBA A. BRANDES;MARTINA ZANINOTTO;MARIA CRISTINA MARZOLA;ROMANO SCALERTA;LUCIA FRATINO;MICHELE MUSSAP;VANNA CHIARION‐SILENI;RENZO MAZZAROTTO;PIETRO ZUCCHETTA;PIERLUIGI PILATI;SARA LONARDI;C PAGETTA;S.M.M. BASSO","7;7;6;6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","S. MONFARDINI;MARIO PLEBANI;DOMENICO RUBELLO;DARIO CASARA;F COSTIGLIOLA;G BABIGHIAN;MARTINA ZANINOTTO;LUCIA FRATINO;MICHELE MUSSAP;JOHN R. BACH;ANDREA VIANELLO;MARIA ROSA PELIZZO;FRANCO LUMACHI;SARA LONARDI;C. ASCHELE;ALBA A. BRANDES;CARLO RICCARDO ROSSI;C PAGETTA;ANDREA PIOTTO;PIERGIORGIO GAMBA","2.29;1.54;1.17;1.06;1;1;0.74;0.67;0.59;0.5;0.5;0.45;0.41;0.41;0.41;0.38;0.37;0.37;0.37;0.33","S. MONFARDINI;DOMENICO RUBELLO;MARIO PLEBANI;DARIO CASARA;CARLO RICCARDO ROSSI;GIOVANNI SCARZELLO;ALBA A. BRANDES;MARTINA ZANINOTTO;LUCIA FRATINO;MICHELE MUSSAP;VANNA CHIARION‐SILENI;RENZO MAZZAROTTO;SARA LONARDI;GUIDO SOTTI;C. ASCHELE;CATERINA BOSO;MYRIAM PARIS;ILSE-MARIA RÄTSCH;PAOLA ZANOVELLO;PAOLO SERAFINI","7;7;6;6;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1","S. MONFARDINI;MARIO PLEBANI;DOMENICO RUBELLO;DARIO CASARA;F COSTIGLIOLA;G BABIGHIAN;MARTINA ZANINOTTO;LUCIA FRATINO;MICHELE MUSSAP;ANDREA VIANELLO;SARA LONARDI;C. ASCHELE;ALBA A. BRANDES;CARLO RICCARDO ROSSI;C. EDINI;ALBERTO BURLINA;NICOLA TOMMASONI;A.P. BURLINA;LUCIA SARTOR;MANUELA BEDA","2.29;1.54;1.17;1.06;1;1;0.74;0.67;0.59;0.5;0.41;0.41;0.38;0.37;0.33;0.33;0.33;0.33;0.33;0.33","MARIO PLEBANI;FERRUCCIO CERIOTTI;FRANCESCA RUBBOLI;PIERANGELO BONINI;ALBERTO VISINTIN;ALESSANDRA MAZZONI;DAVID M. SEGAL;ELISA APOLLONI;JESSICA H. SPITZER;PAOLA ZANOVELLO;PAOLO SERAFINI;VINCENZO BRONTE;DOMENICO RUBELLO;DARIO CASARA;S. MONFARDINI;ANGELO ROSOLEN;BRUNANGELO FALINI;PAOLO BONVINI;T. GASTALDI;MARIA ROSA PELIZZO","931;820;820;820;643;643;643;643;643;643;643;643;159;152;144;131;131;131;131;105","MARIO PLEBANI;ELISA APOLLONI;PAOLA ZANOVELLO;PAOLO SERAFINI;VINCENZO BRONTE;DOMENICO RUBELLO;S. MONFARDINI;DARIO CASARA;PAOLO BONVINI;MARTINA ZANINOTTO;VANNA CHIARION‐SILENI;ROBERTA REDELOTTI;C. CAUZZO;FABIOLA GUASTI;GIAN-MARIA BARBATO;GIOVANNELLA BAGGIO;ALESSANDRO P. BURLINA;ANITA AMMENTI;BARBARA ANDREETTA;GIANPAOLO AMICI","921;643;643;643;643;159;144;139;131;100;95;92;80;80;78;78;67;51;51;51","DOMENICO RUBELLO;S. MONFARDINI;DARIO CASARA;MARIO PLEBANI;ALBA A. BRANDES;GUIDO SOTTI;LUCIA FRATINO;MARTINA ZANINOTTO;MYRIAM PARIS;SARA LONARDI;VANNA CHIARION‐SILENI;A.P. BURLINA;ALBERTO BURLINA;ALESSANDRA DʼERI;ALESSANDRO P. BURLINA;ANITA AMMENTI;AZZAM ZIADE;BARBARA ANDREETTA;C. CAUZZO;C. EDINI","7;6;5;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;POLITICAL SCIENCE;BUSINESS;ENGINEERING;COMPUTER SCIENCE;ECONOMICS;ENVIRONMENTAL SCIENCE;PHILOSOPHY","42;9;5;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;ONCOLOGY;PATHOLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;GENETICS;BIOCHEMISTRY;CARDIOLOGY;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;LAW;ANESTHESIA;BIOMEDICAL ENGINEERING;BIOTECHNOLOGY;CANCER RESEARCH;CELL BIOLOGY;CHROMATOGRAPHY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;GYNECOLOGY;MEDICAL PHYSICS;PHYSICAL THERAPY;PSYCHIATRY;UROLOGY","33;13;11;9;8;7;6;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;RADIATION THERAPY;MYOCARDIAL INFARCTION;SCINTIGRAPHY;ADENOMA;BIOPSY;THYROID;ANTIBODY;CALCIUM;CONCOMITANT;DISEASE;HYPERPARATHYROIDISM;IMMUNE SYSTEM;IN VIVO;LYMPH;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MEDLINE;PERFUSION;PHARMACOKINETICS;PLEURAL EFFUSION;POPULATION;PREGNANCY;PRIMARY HYPERPARATHYROIDISM;SIGNAL TRANSDUCTION;TOXICITY","15;6;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;COLORECTAL CANCER;TROPONIN;BRACHYTHERAPY;CISPLATIN;OVARIAN CANCER;PARATHYROID ADENOMA;PARATHYROID HORMONE;T CELL;ACUTE CORONARY SYNDROME;ADRENAL ADENOMA;ALPHA INTERFERON;ANAPLASTIC LARGE-CELL LYMPHOMA;ANGINA;ANTIMETABOLITE;ARTERIAL DISEASE;ATTIC;AUTOANTIBODY;BIOMEDICAL WASTE;CERVICAL CANCER;COMPLETE RESPONSE;DIFFUSION MRI;DOXORUBICIN;EFFECTIVE DIFFUSION COEFFICIENT;ENDOCRINE SYSTEM;EX VIVO;FLUOROURACIL;GERIATRIC ONCOLOGY;GESTATION;GLUTAMATE DECARBOXYLASE;GOITER;HAEMATOPOIESIS;HEAT SHOCK PROTEIN;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATOCYTE;HYPERINTENSITY;ISLET;LEUCINE;LIMB PERFUSION;LYMPHANGIOMATOSIS;LYMPHOBLASTIC LEUKEMIA;MALIGNANT PLEURAL EFFUSION;MYCOSIS FUNGOIDES;NEONATAL SEPSIS;NEUROMUSCULAR DISEASE;PACLITAXEL;PARATHYROID CARCINOMA;PRECORDIAL EXAMINATION;PROTEIN KINASE B;PUVA THERAPY;RELATIVE RISK;REVASCULARIZATION;SEMINOMA;SEROCONVERSION;SEROLOGY;SOFT TISSUE SARCOMA;SUPPRESSOR;SYSTEMIC ADMINISTRATION;TECHNETIUM (99MTC) SESTAMIBI;TESTICULAR CANCER;THYROGLOBULIN;THYROID CARCINOMA;THYROID DISEASE;THYROID NODULES;THYROIDECTOMY;TOPOTECAN;TROPONIN I;TYPE 1 DIABETES;TYROSINE KINASE;UNIVARIATE ANALYSIS;UNSTABLE ANGINA;WHITE MATTER","8;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SENTINEL LYMPH NODE;PARATHYROID GLAND;PARATHYROIDECTOMY;ANAPLASTIC LYMPHOMA KINASE;BIOARTIFICIAL LIVER DEVICE;CLAUDICATION;COLPOSCOPY;CRITICAL LIMB ISCHEMIA;CUTANEOUS T-CELL LYMPHOMA;CYTOREDUCTIVE SURGERY;GESTATIONAL DIABETES;HEMATOPOIETIC CELL;HPV INFECTION;HSP90;IL-2 RECEPTOR;INTERFERON ALFA;INTERMITTENT CLAUDICATION;INTERNAL CAPSULE;MAMMOGRAPHY;MAPLE SYRUP URINE DISEASE;MYELOID-DERIVED SUPPRESSOR CELL;OVARIAN CARCINOMA;PARATHYROID NEOPLASM;PERIPHERAL T-CELL LYMPHOMA;PERITONEAL CARCINOMATOSIS;SAVIOR SIBLING;SENTINEL NODE;THYMIDYLATE SYNTHASE;VAGINAL CANCER","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;AGED;BREAST NEOPLASMS;MALE;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;HYPERPARATHYROIDISM;LYMPH NODES;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;ADENOCARCINOMA;AGED, 80 AND OVER;COLORECTAL NEOPLASMS;PERITONEAL NEOPLASMS;TREATMENT OUTCOME;VINBLASTINE;DOXORUBICIN;RADIONUCLIDE IMAGING","40;24;16;16;15;15;15;10;8;8;8;8;7;7;7;7;7;7;6;6","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;LYMPHOID NEOPLASMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;SARCOMA RESEARCH AND TREATMENT;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CHARACTERIZATION AND BEHAVIOR OF NUCLEAR GRAPHITE MATERIALS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND MANAGEMENT OF CHYLOTHORAX AND CHYLOUS ASCITES;DIAGNOSIS AND MANAGEMENT OF OTITIS MEDIA;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENETICS AND PATHOGENESIS OF TYPE 1 DIABETES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;GAMMA PROBE;BREAST CANCER SCREENING;BREAST TUMOURS;CANCER;CHEMOTHERAPY;CONCOMITANT;HYPOPARATHYROIDISM;PARATHYROID GLAND;PARATHYROID HORMONE;TREATMENT;TROPONIN ASSAYS;ACUTE LYMPHOBLASTIC LEUKEMIA;ADJUVANT CHEMOTHERAPY;ADRENAL ADENOMA;AGING;ANAPLASTIC LARGE-CELL LYMPHOMA;ANTIBODIES;ATHEROSCLEROTIC CARDIOVASCULAR RISK;ATTIC","4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","BREAST CANCER;RADIO-GUIDED SURGERY;SUPMSUPTC-MIBI RADIO-GUIDED;ACID DECARBOXYLASE;ACQUIRED CHYLOTHORAX;ACUTE CORONARY;ACUTE LYMPHOBLASTIC;ADJUVANT CHEMOTERAPY;ADRENAL IMAGING;ADVANCED OVARIAN;ADVANCED-STAGE NON-SEMINOMA;AGENTS CHEMOTHERAPY;ALEXSUPSUPARTIFICIAL LIVER;ALK CD;ANTAGONIST -ALLYLAMINO-DEMETHOXYGELDANAMYCIN;ANZIANI PROVA;ARTERIAL DISEASES;ATTIC WALL;AUTOLOGOUS BIOMATRIX;BIOMEDICAL ACTIVITIES;BOLUS -FLUOROURACIL;BREAST LESIONS;CANCER RISK;CANCER SINGLE;CARCINOMA TECHNICAL;CARDIAC TROPONIN;CARE PRACTICE;CASECONTROL STUDY;CAVAL INVOLVEMENT;CD LYMPHOMA","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE LYMPHOBLASTIC;CTNI ASSAY;LYMPHOBLASTIC LEUKAEMIA;DIMENSION CTNI;VERSUS MONTHS;ANURIC PATIENTS;CLINICAL RESPONSE;WEEKLY KTV;CARDIAC TROPONIN;CELL ACTIVATION;DADE BEHRING;GERMINAL CENTRES;HIV-INFECTED PATIENTS;LEUKAEMIA CELLS;LYMPH-NODE GERMINAL;MONTHS VERSUS;MSC LINES;TS LEVELS;ANTIBODY SYNTHESIS;APOPTOTIC ABILITIES;BEHRING DIMENSION;BOLUS -FU;C-MYC LEVELS;CARDIAC DAMAGE;CARE UNIT;CD-NEGATIVE ACUTE;CD-POSITIVE ACUTE;CD-POSITIVE CELLS;CHEST PAIN;CHILDHOOD ACUTE","7;7;7;6;6;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",6,0.14,10.96,5,0,1,0,1,5.5,0,1,5,0,0,0,0,2,0,0,0,0,0.75,0,210,210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7.75,1808.2,7.25,0,0,77.4,0,0,2,0,2,0,0,1,0,5,0,0,0,0,0,0,0,5,0,0,4,0,0,1,0,0,0,0,0,0,"Belgium","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","5;3;2;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ORPHAN DRUG;RARE DISEASES;HEMATOLOGY;BRAIN CANCER;BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;LYMPHOMA;NEUROSCIENCES;NUTRITION;PEDIATRIC","4;3;3;3;3;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","4;1","LEUKEMIA / LEUKAEMIA;BRAIN TUMOR;NERVOUS SYSTEM;NON-HODGKIN'S LYMPHOMA","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",2,1078475,39276.06,4.5,27,11,1,6,19422.9941565192,2.26535618789917,"AZIENDA OSPEDALIERA DI PADOVA;BAMBINO GESÙ CHILDREN'S HOSPITAL;BISPEBJERG HOSPITAL;CARDIFF UNIVERSITY;CENTRE FOR GENOMIC REGULATION;CHILDREN'S MEMORIAL HEALTH INSTITUTE;CUKUROVA UNIVERSITY;DÉLÉGATION PARIS 11;EGE UNIVERSITY;ESSEN UNIVERSITY HOSPITAL;HACETTEPE UNIVERSITY;HANNOVER MEDICAL SCHOOL;HOSPITAL DE SÃO JOÃO;HUMBOLDT-UNIVERSITÄT ZU BERLIN;HÔPITAUX UNIVERSITAIRES DE STRASBOURG;INSTITUT PASTEUR;INSTITUTO NACIONAL DE LA SALUD;ISTANBUL UNIVERSITY;ISTANBUL UNIVERSITY CERRAHPAŞA;ISTITUTI CLINICI DI PERFEZIONAMENTO","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);THN - THEMATIC NETWORK CONTRACTS (FUNDING SCHEME)","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES","2;2;1;1;1","GENETICS;BIOMEDICAL IMAGING;BRAIN DISORDERS;CARDIOVASCULAR;CLINICAL RESEARCH;HYPERTENSION;KIDNEY DISEASE;NEUROSCIENCES;PEDIATRIC;RARE DISEASES","2;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;EAR","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS","2;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","2",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2003,53,6.18867924528302,1.9622641509434,0.60377358490566,0.283018867924528,0.60377358490566,1.30769230769231,1.33333333333333,1.07142857142857,1.33333333333333,0.132075471698113,3,16,10,4,16,0.3,0.19,0.08,0.3,31.08,0.587128351815232,NA,0.113207547169811,0.660377358490566,0.391,0.314,0.267,0.314,"A BRUTTOCAO;ALBA A. BRANDES;O. TERRANOVA;GIOVANNELLA BAGGIO;LUCA DEIANA;LARA MARIA PASETTO;S. MONFARDINI;GIOVANNI MARIO PES;CIRIACO CARRU;CARMELO MILITELLO;DARIO CASARA;DE SANTIS L;DAVID SACERDOTI;DOMENICO RUBELLO;BRUNO MARTELLA;ANGELO GATTA;CALOGERO CARUSO;MARIO PLEBANI;PIETRO AMISTÀ;SURENDRA NARNE","5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ALBA A. BRANDES;DAVID SACERDOTI;A BRUTTOCAO;MARCO MONTAGNA;LARA MARIA PASETTO;O. TERRANOVA;S. MONFARDINI;CARMELO MILITELLO;DE SANTIS L;RENATO SCIENZA;PAOLO SIMIONI;GIORGIO PAVESI;PAOLO CARRARO;PIETRO AMISTÀ;DARIO CASARA;DOMENICO RUBELLO;GIOVANNELLA BAGGIO;UMBERTO BASSO;BRUNO MARTELLA;SURENDRA NARNE","1.74;1.31;1.1;1;0.92;0.9;0.68;0.65;0.65;0.6;0.5;0.5;0.5;0.45;0.43;0.43;0.43;0.43;0.4;0.33","A BRUTTOCAO;ALBA A. BRANDES;GIOVANNELLA BAGGIO;LARA MARIA PASETTO;S. MONFARDINI;DE SANTIS L;DAVID SACERDOTI;DOMENICO RUBELLO;ANGELO GATTA;MARIO PLEBANI;PIETRO AMISTÀ;SURENDRA NARNE;PAOLO RIGOTTI;DANIELE TREVISANUTO;STEFANO GUZZINATI;MARINA SILVESTRINI;F DEROSAS;FRANCESCA VASTOLA;ROBERTO SAETTI;UMBERTO BASSO","5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","ALBA A. BRANDES;DAVID SACERDOTI;A BRUTTOCAO;MARCO MONTAGNA;LARA MARIA PASETTO;S. MONFARDINI;DE SANTIS L;RENATO SCIENZA;PAOLO SIMIONI;GIORGIO PAVESI;PAOLO CARRARO;PIETRO AMISTÀ;DOMENICO RUBELLO;GIOVANNELLA BAGGIO;UMBERTO BASSO;SURENDRA NARNE;DANIELE TREVISANUTO;ELENA ROSSI;MARINA SILVESTRINI;F DEROSAS","1.74;1.31;1.1;1;0.92;0.68;0.65;0.6;0.5;0.5;0.5;0.45;0.43;0.43;0.43;0.33;0.33;0.33;0.33;0.33","ALBA A. BRANDES;MARCO MONTAGNA;S. MONFARDINI;MARIO ERMANI;FRANCESCA VASTOLA;UMBERTO BASSO;GIOVANNELLA BAGGIO;RENATO SCIENZA;ANTONINO ROTILIO;FRANCO BERTI;GIAMPIETRO PINNA;MARINA PAOLA GARDIMAN;AGNETE PARVING;FRANK DECLAU;GUY VAN CAMP;MANUELA MAZZOLI;N. GIARBINI;VALERIE NEWTON;CIRIACO CARRU;GIOVANNI MARIO PES","187;185;181;180;176;174;172;171;170;170;170;170;160;160;160;160;160;160;150;150","ALBA A. BRANDES;MARCO MONTAGNA;FRANCESCA VASTOLA;UMBERTO BASSO;MARINA PAOLA GARDIMAN;S. MONFARDINI;MANUELA MAZZOLI;GIOVANNELLA BAGGIO;CATERINA ZANETTI;STEFANO GUZZINATI;MARIO PLEBANI;FRANCESCO MARCHINI;PAOLO RIGOTTI;MARINO SCARIN;RICCARDO MANGANELLI;GRAZIELLA BUSATTO;DANIELE TREVISANUTO;MARTINA ZANINOTTO;DAVID SACERDOTI;MARIANGELA PITTON","187;185;176;174;170;170;160;150;141;139;105;95;95;78;78;70;56;56;45;45","ALBA A. BRANDES;DOMENICO RUBELLO;DAVID SACERDOTI;DE SANTIS L;GIOVANNELLA BAGGIO;LARA MARIA PASETTO;DANIELE TREVISANUTO;F DEROSAS;FRANCESCA VASTOLA;MARINA SILVESTRINI;MARIO PLEBANI;MARTINA ZANINOTTO;PIETRO AMISTÀ;ROBERTO SAETTI;STEFANO GUZZINATI;SURENDRA NARNE;UMBERTO BASSO;A BRUTTOCAO;ALICIA TOSONI;ANGELO GATTA","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;GEOGRAPHY;HISTORY;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY","48;12;9;6;5;4;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;IMMUNOLOGY;GENETICS;ENVIRONMENTAL HEALTH;RADIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ONCOLOGY;OPTICS;CARDIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;ANESTHESIA;ELECTRICAL ENGINEERING;GYNECOLOGY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;PSYCHIATRY","33;20;15;12;8;7;7;6;6;6;6;5;4;4;4;3;3;3;3;3;3","CANCER;POPULATION;GENE;DISEASE;INCIDENCE (GEOMETRY);SARCOMA;ANTIBODY;ASYMPTOMATIC;CHEMOTHERAPY;MYOCARDIAL INFARCTION;RADIATION THERAPY;THROMBOSIS;ABDOMEN;ADENOMA;ANGIOGENESIS;ARTERY;BACTERIA;BIOPSY;BONE MARROW;CARCINOMA;CAROTID ARTERIES;CLINICAL TRIAL;COMPLICATION;CONFIDENCE INTERVAL;CORD BLOOD;CREATINE KINASE;HEARING LOSS;HELICOBACTER PYLORI;HORMONE;INTERQUARTILE RANGE;LAPAROTOMY;LONGEVITY;LYMPHOMA;ODDS RATIO;PANCREAS;PERFUSION;REPRODUCIBILITY;RISK FACTOR;STOMACH;TRANSPLANTATION;UMBILICAL CORD;VEIN","11;7;6;5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;ALLELE;ADENOCARCINOMA;CANCER REGISTRY;COLORECTAL CANCER;ENDOCRINE SYSTEM;GASTRITIS;MUTATION;OVARIAN CANCER;PANCREATECTOMY;PARATHYROID ADENOMA;TROPONIN;TROPONIN I;TROPONIN T;ABDOMINAL AORTA;ABDOMINAL COMPARTMENT SYNDROME;ABDOMINAL HERNIA;ACUTE MEGAKARYOBLASTIC LEUKEMIA;ADJUVANT THERAPY;AIRWAY OBSTRUCTION;AMPULLA OF VATER;ANAL CANCER;ANGIOSTATIN;ANTIMICROBIAL PEPTIDES;ANTITHROMBIN;ANTRUM;AUDITORY BRAINSTEM RESPONSE;BACTERIOCIN;BOSWELLIA SERRATA;CANCER TREATMENT;CARDIOTOXICITY;CAUSE OF DEATH;CENTENARIAN;CEREBRAL HYPOPERFUSION;CERVICAL CANCER;CHEMOKINE;CHEMORADIOTHERAPY;CHOANAL ATRESIA;CHROMOSOMAL TRANSLOCATION;COAGULATION TESTING;CYCLOPHOSPHAMIDE;DEEP VEIN;DEMENTIA;EFFECTS OF SLEEP DEPRIVATION ON COGNITIVE PERFORMANCE;ENDOSTATIN;ETOPOSIDE;EXON;FLUORESCENCE SPECTROSCOPY;FOOD PRESERVATIVES;GASTRIC MUCOSA;GASTRIN;GENE REARRANGEMENT;GENOTYPE;GRAFT REJECTION;GREAT SAPHENOUS VEIN;GROWTH HORMONE;HEME;HEPATITIS B VIRUS;HEREDITARY HEMOCHROMATOSIS;HUMAN HERPESVIRUS;HUMAN LEUKOCYTE ANTIGEN;IMMUNIZATION;IMMUNOGLOBULIN HEAVY CHAIN;INCISIONAL HERNIA;INFARCTION;INJURY PREVENTION;INTERNAL ELASTIC LAMINA;INTESTINAL METAPLASIA;INTRINSIC FACTOR;KIDNEY CANCER;KIDNEY TRANSPLANTATION;LACTIC ACID;LASER SURGERY;LASER-INDUCED FLUORESCENCE;LONG SAPHENOUS VEIN;MAJOR HISTOCOMPATIBILITY COMPLEX;METASTASIS;MINIMAL RESIDUAL DISEASE;MTT ASSAY;NEOVASCULARIZATION;NISIN;OCCUPATIONAL MEDICINE;OCTREOTIDE;PANCREATIC CANCER;PANCREATIC DISEASE;PANCREATIC HEAD;PANCREATICODUODENECTOMY;PARATHYROID CARCINOMA;PARATHYROID HORMONE;PEGYLATION;PERNICIOUS ANEMIA;PHOSPHOLIPID;POLYMERASE CHAIN REACTION;PORTAL HYPERTENSION;RENAL ARTERY;SEPTIC SHOCK;SOFT TISSUE SARCOMA;SOMATOSTATIN RECEPTOR;SPINAL CORD STIMULATION;STAPHYLOCOCCUS AUREUS;STRIDOR;T-CELL LEUKEMIA;TEMOZOLOMIDE;THROMBOPHILIA;TITER;TOLERABILITY;TUNICA INTIMA;TUNICA MEDIA;VASCULAR ENDOTHELIAL GROWTH FACTOR;VASOSPASM;VENOUS THROMBOEMBOLISM;VIABILITY ASSAY;VIRAL LOAD;VIRULENCE;WEIGHT LOSS","5;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ATROPHIC GASTRITIS;HAPLOTYPE;TROPONIN COMPLEX;ACROMEGALY;ADULT T-CELL LEUKEMIA/LYMPHOMA;ALLELE FREQUENCY;ANTIRETROVIRAL THERAPY;AUTOIMMUNE GASTRITIS;BOOSTER DOSE;BREAST DISEASE;BREAST PAIN;CAGA;CARDIAC MARKER;CEREBRAL VASOSPASM;CXCR4;DEBULKING;FAILED BACK SURGERY;FIBROMUSCULAR DYSPLASIA;HBSAG;HEME OXYGENASE;IFOSFAMIDE;KAPOSI'S SARCOMA;LACTOCOCCUS LACTIS;LOSS OF HETEROZYGOSITY;MAMMOGRAPHY;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MORBID OBESITY;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NEOADJUVANT THERAPY;OCCUPATIONAL ACCIDENT;OCCUPATIONAL INJURY;PARATHYROID GLAND;PARATHYROIDECTOMY;PARIETAL CELL;PERIAMPULLARY CANCER;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;SPIRILLACEAE;VINCRISTINE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;ITALY;PANCREATIC NEOPLASMS;POSTOPERATIVE COMPLICATIONS;ADULT;;ADENOCARCINOMA;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;HELICOBACTER INFECTIONS;LIVER CIRRHOSIS;NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;GASTRIC MUCOSA;ADENOMA;GLIOBLASTOMA","39;23;21;17;17;15;13;13;11;10;8;8;8;8;8;8;7;7;6;6","GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;PANCREATIC CANCER RESEARCH AND TREATMENT;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCES IN METABOLOMICS RESEARCH;CHARGE SYNDROME AND RELATED GENETIC DISORDERS;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF CARPAL TUNNEL SYNDROME;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;GLIOMAS;HEME OXYGENASE AND CARBON MONOXIDE RESEARCH;HEPATITIS B INFECTION AND TREATMENT","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER INCIDENCE;CANCER SUSCEPTIBILITY;ATROPHIC GASTRITIS;CANCER RISK;CORD BLOOD;CREATINE KINASE;DEEP VEIN THROMBOSIS;GASTROENTEROPANCREATIC NEOPLASMS;INTERQUARTILE RANGE;KAPOSI'S SARCOMA;NEOADJUVANT THERAPY;PANCREATIC DISEASE;PANCREATIC NEUROENDOCRINE TUMORS;SURGICAL RISK CALCULATOR;TRANSPLANT RECIPIENTS;TROPONIN ASSAYS;TROPONIN COMPLEX;TROPONIN T;ABDOMINAL AORTA","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","CARDIAC TROPONIN;ANEURISMI CEREBRALI;BREAST CANCER;CORD BLOOD;CREATINE KINASE;DEGLI ANEURISMI;HEALTHY TERM;IHELICOBACTER PYLORII;KINASE MB;MB CONCENTRATIONS;SARDINIAN POPULATION;TERM NEONATES;UMBILICAL CORD;ABDOMINAL WALL;ACUTE MEGAKARYOBLASTIC;ACUTE REJECTION;ADJUSTABLE GASTRIC;ANATOMO-PATOLOGICI DEGLI;ANTIANGIOGENIC THERAPY;ANTIMICROBIAL PEPTIDE;ANTIRETROVIRAL THERAPY;ATRESIA ENDOSCOPIC;AUDIOLOGICAL DATA;AUDITORY BRAINSTEM;AUTOIMMUNE DISEASES;AXIAL-LOADED CT;BINIBMETHYLSCPDSCPGLUCAMINE IMPROVES;BIOLOGICAL RISK;BONE MARROW;BRAIN TUMORS","4;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREASTOVARIAN CANCER;TRANSPLANTED PATIENTS;ELDERLY PATIENTS;GENOMIC REARRANGEMENTS;PATIENTS DEVELOPED;PLASMA CELLS;VIRAL INFECTIONS;ACUTE REJECTION;ADJUVANT CHEMOTHERAPY;BRAIN TUMOURS;BRCA GENE;BRCA GENOMIC;CANCER DEVELOPMENT;CANCER FAMILIES;CD DEPOSITION;CHEMOTHERAPY REGIMEN;CONFIDENCE INTERVAL;DEVELOPED CANCER;GENOMIC DELETIONS;GRAFT SURVIVAL;II IPI;IMMUNOSUPPRESSIVE TREATMENT;INCREASED SIRS;KAPOSI SARCOMA;KIDNEY TRANSPLANTATION;LUNG CANCER;LYMPHOPROLIFERATIVE DISEASES;PATIENTS UNDERGOING;PERFORMANCE STATUS;TEMOZOLOMIDE CHEMOTHERAPY","4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",8,0.15,3.63,10,0,1,0,0,13.5,0,1,10,0,1,1,0,0,0,0,1,0,0,0,50.75,51.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,3.14,3367.86,12,1,0.11,144.44,0,0,0,1,4,0,2,2,0,9,0,0,0,0,0,0,0,8,0,1,8,0,0,1,0,0,0,0,0,0,"Germany;United Kingdom;Japan;Switzerland;United States","4;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","9;7;2;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BRAIN DISORDERS;DIABETES;NEUROSCIENCES;ORPHAN DRUG;RARE DISEASES;STROKE;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;CANCER;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH;KIDNEY DISEASE;LUNG;NUTRITION;ORGAN TRANSPLANTATION;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE","8;8;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","METABOLIC AND ENDOCRINE;STROKE;CANCER;RESPIRATORY","2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","7;1","LUNG CANCER;PROSTATE CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",2,1461949.5,145185.65,4,10.5,9,1,1.5,80188.7311262161,0.660940748851339,"AZIENDA OSPEDALIERA DI PADOVA;CARDIFF UNIVERSITY;RADBOUD UNIVERSITY NIJMEGEN;ANTWERP UNIVERSITY HOSPITAL;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;BISPEBJERG HOSPITAL;ILLUMINA (UNITED STATES);INSTITUTE OF MEDICAL ETHICS AND BIOETHICS, N. F;INSTITUTE OF ONCOLOGY LJUBLJANA;JAGIELLONIAN UNIVERSITY;PORTUGUESE ONCOLOGY INSTITUTE;TAMPERE UNIVERSITY;UNIVERSITY MEDICAL CENTER FREIBURG;UNIVERSITY OF ANTWERP;UNIVERSITY OF BONN;UNIVERSITY OF OULU;UNIVERSITY OF PADUA;VILNIUS UNIVERSITY","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);ACM - PREPARATORY, ACCOMPANYING AND SUPPORT MEASURES (FUNDING SCHEME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME)","2;1;1","42 HEALTH SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR","2;1;1;1;1","AGING;GENETICS;PREVENTION","1;1;1","EAR","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION","1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2004,56,7.89285714285714,2.625,0.517857142857143,0.339285714285714,0.571428571428571,1.19512195121951,1.03571428571429,1.11764705882353,1.03225806451613,0.232142857142857,2,25,10,5,10,0.45,0.18,0.09,0.18,33.39,0.709676791552843,NA,0.178571428571429,0.732142857142857,0.358,0.137,0.321,0.156,"S. MONFARDINI;LUIGI CHIECO‐BIANCHI;ALBA A. BRANDES;MARIO LISE;MARIO PLEBANI;GIAN LUCA DE SALVO;PAOLO RIGOTTI;DARIO CASARA;GUIDO SOTTI;DOMENICO RUBELLO;SAVINA AVERSA;G. ZAVAGNO;MICHELE RENI;ALESSANDRA SPITALE;AGNETE PARVING;VINCENZO CIMINALE;RITA MARCHI;LARA MARIA PASETTO;DANIELA SAGGIORO;RICCARDO CUSINATO","5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MARIO PLEBANI;ANGELO CHIARELLI;ALESSANDRA SPITALE;STEFANO GUZZINATI;AGNETE PARVING;ALBA A. BRANDES;S. MONFARDINI;M MAZZOLI;P ZAMBON;ILARIA DE BARBIERI;LA ROSA F;ALESSANDRA ZAMPIERON;LUIGI CHIECO‐BIANCHI;SARA LONARDI;MARIO LISE;DARIO CASARA;DOMENICO RUBELLO;GIAN LUCA DE SALVO;G. ZAVAGNO;LAURA BONALDI","1.4;1;0.7;0.7;0.64;0.61;0.53;0.5;0.5;0.5;0.5;0.5;0.49;0.45;0.45;0.4;0.4;0.34;0.34;0.33","S. MONFARDINI;LUIGI CHIECO‐BIANCHI;ALBA A. BRANDES;MARIO PLEBANI;PAOLO RIGOTTI;DARIO CASARA;GUIDO SOTTI;DOMENICO RUBELLO;SAVINA AVERSA;VINCENZO CIMINALE;RITA MARCHI;LARA MARIA PASETTO;DANIELA SAGGIORO;RICCARDO CUSINATO;SIMONE CESARO;LAURA BONALDI;L. LOREGGIAN;ANNA MARIA CATTELAN;LUIGI BORTOLOTTI;FEDERICO REA","5;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MARIO PLEBANI;ANGELO CHIARELLI;STEFANO GUZZINATI;ALBA A. BRANDES;S. MONFARDINI;M MAZZOLI;P ZAMBON;ILARIA DE BARBIERI;LUIGI CHIECO‐BIANCHI;DARIO CASARA;DOMENICO RUBELLO;LAURA BONALDI;ANGELO ROSOLEN;PAOLO RIGOTTI;LARA MARIA PASETTO;RICCARDO CUSINATO;GUIDO SOTTI;SAVINA AVERSA;NADIA VIGNES;SIMONE CESARO","1.4;1;0.7;0.61;0.53;0.5;0.5;0.5;0.49;0.4;0.4;0.33;0.33;0.33;0.31;0.31;0.3;0.3;0.25;0.25","ALBA A. BRANDES;MICHELE RENI;LUIGI CHIECO‐BIANCHI;MARIO LISE;VALENTINA RUSSO;LARA MARIA PASETTO;ALESSANDRO AMBROSI;EMANUELE DAMIANO LUCA URSO;FILIPPO MARINO;MARIA LUISA FRISO;PAOLA TOPPAN;SALVATORE PUCCIARELLI;ANGELO ROSOLEN;ANJA H. LOOS;CARLO LA VECCHIA;FREDDIE BRAY;SANDRO TOGNAZZO;A. AMBROSETTI;A. GUBKIN;A. V. PIVNIK","290;239;232;215;177;163;161;161;161;161;161;161;146;139;139;139;139;132;132;132","ALBA A. BRANDES;LARA MARIA PASETTO;MARIA LUISA FRISO;ANGELO ROSOLEN;LUIGI CHIECO‐BIANCHI;SANDRO TOGNAZZO;EMANUELE COZZI;FRANCESCA VASTOLA;UMBERTO BASSO;RICCARDO CUSINATO;HENRY DALLA ROSA;NADIA VIGNES;PAOLO BONVINI;DANIELA SAGGIORO;MARIO PLEBANI;DANIELE PIVA;DANIELE TREVISANUTO;MARIANGELA PITTON;MASSIMO MICAGLIO;MIRKO MAGAROTTO","290;163;161;146;144;139;108;107;107;96;93;93;93;90;88;82;82;82;82;82","ALBA A. BRANDES;MARIO PLEBANI;GUIDO SOTTI;S. MONFARDINI;ANGELO ROSOLEN;DANIELA SAGGIORO;DARIO CASARA;LARA MARIA PASETTO;LUIGI CHIECO‐BIANCHI;PAOLO RIGOTTI;RICCARDO CUSINATO;STEFANO GUZZINATI;A TORRISI;ALESSANDRA PIEROBON;ANDREA PULVIRENTI;ANDREA VIANELLO;ANGELO CHIARELLI;ANGELO GATTA;ANNA MARIA CATTELAN;ANNA PIAZZA","4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;SOCIOLOGY;GEOGRAPHY;PHILOSOPHY;ART;BUSINESS;MATHEMATICS;POLITICAL SCIENCE;PSYCHOLOGY","51;17;9;8;5;4;4;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;ONCOLOGY;RADIOLOGY;GASTROENTEROLOGY;GENETICS;OPTICS;VIROLOGY;MOLECULAR BIOLOGY;PALEONTOLOGY;ANATOMY;CANCER RESEARCH;DEMOGRAPHY;NUCLEAR MEDICINE;NURSING;PEDIATRICS;ANESTHESIA;CELL BIOLOGY;ENDOCRINOLOGY;PHARMACOLOGY;PSYCHIATRY;UROLOGY","34;17;12;9;8;8;8;7;7;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3","CANCER;CHEMOTHERAPY;GENE;INCIDENCE (GEOMETRY);RADIATION THERAPY;STAGE (STRATIGRAPHY);BIOPSY;DISEASE;VIRUS;ANTIBODY;KIDNEY;LUNG CANCER;POPULATION;THYROID;TRANSPLANTATION;AIRWAY;ALTERNATIVE MEDICINE;ANTIGEN;APOPTOSIS;ASYMPTOMATIC;CONCOMITANT;CREATININE;DIALYSIS;ENZYME;HEMODIALYSIS;HORMONE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IN VITRO;INTUBATION;LYMPH NODE;LYMPHOMA;MECHANICAL VENTILATION;PALLIATIVE CARE;PREGNANCY;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;REGIMEN;VENTILATION (ARCHITECTURE)","15;8;7;5;5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CISPLATIN;METASTASIS;VIRAL DISEASE;VIRAL LOAD;COLORECTAL CANCER;POLYMERASE CHAIN REACTION;T CELL;TRANSCRIPTION FACTOR;ACUTE TUBULAR NECROSIS;AIRWAY MANAGEMENT;AIRWAY OBSTRUCTION;ANAPLASTIC LARGE-CELL LYMPHOMA;ANTIMETABOLITE;ANTRUM;ASSAY SENSITIVITY;AUTOANTIBODY;BIRTH WEIGHT;CANCER INCIDENCE;CANCER REGISTRY;CARBON MONOXIDE;CD8;CERVICAL CANCER;CERVIX;CHEMORADIOTHERAPY;CONTINUOUS POSITIVE AIRWAY PRESSURE;CONTRAINDICATION;CYTOTOXIC T CELL;DEVELOPED COUNTRY;DRUG REACTION;END STAGE RENAL DISEASE;EPENDYMAL CELL;FETUS;FLUID-ATTENUATED INVERSION RECOVERY;FLUOROURACIL;GASTRITIS;GENE EXPRESSION;GENOTYPE;GESTATIONAL AGE;GRAVES' DISEASE;HEAT SHOCK PROTEIN;HEME;HEPATITIS C VIRUS;IMMUNOFLUORESCENCE;IMMUNOTHERAPY;INDIRECT IMMUNOFLUORESCENCE;IODINATED CONTRAST;KIDNEY TRANSPLANTATION;KYPHOSIS;LARYNGEAL MASK AIRWAY;LASER THERAPY;LEPTIN;LIPID PEROXIDATION;LIVER TRANSPLANTATION;MALIGNANT PLEURAL EFFUSION;MULTICENTER STUDY;NADPH OXIDASE;NEONATAL RESUSCITATION;NEURORADIOLOGY;NONINVASIVE VENTILATION;NUCLEIC ACID SEQUENCE;NUCLEOPHOSMIN;OCTREOTIDE;OPTIC NEUROPATHY;OVARIAN CANCER;PEDIATRIC ONCOLOGY;PERITUBULAR CAPILLARIES;PHENOTYPE;POSITIVE PRESSURE VENTILATION;PROTEASE;PROTEASOME INHIBITOR;REAL-TIME POLYMERASE CHAIN REACTION;RNA;SEROLOGY;SLEEP DISORDER;SOMATOSTATIN RECEPTOR;SPECTRAL ANALYSIS;SPLANCHNIC;TERMINAL CANCER;TERMINAL CARE;THYROID CARCINOMA;THYROID-STIMULATING HORMONE;THYROIDECTOMY;TOLERABILITY;TRACHEAL INTUBATION;TROPONIN;TROPONIN I;TYROSINE KINASE;UBIQUITIN;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS;VASCULAR RESISTANCE;VIASPAN;VIREMIA;VITAMIN E;WHITE MATTER","7;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SENTINEL NODE;CARBOPLATIN;SENTINEL LYMPH NODE;ANTIRETROVIRAL THERAPY;AXILLA;CREB;HERPESVIRIDAE;PRIMARY TUMOR;ANAPLASTIC LYMPHOMA KINASE;ANTI-NUCLEAR ANTIBODY;ANTIFOLATE;APGAR SCORE;AXILLARY NODES;CORPUS UTERI;DNA METHYLATION;ESTROGEN RECEPTOR;GENOTYPE-PHENOTYPE DISTINCTION;GRAVES' OPHTHALMOPATHY;HEME OXYGENASE;HIV-1 PROTEASE;HPV INFECTION;HSP90;IN UTERO;JURKAT CELLS;LACTACYSTIN;LOW LEVEL LASER THERAPY;LYMPHOVASCULAR INVASION;MAMMARY GLAND;METASTATIC BREAST CANCER;NASBA;OXALIPLATIN;P22PHOX;PANEL REACTIVE ANTIBODY;POUCHITIS;PROCTOCOLECTOMY;SEROPREVALENCE;SIDA;SPIRILLACEAE;TAQMAN;TUMOR ANTIGEN;UBIQUITIN LIGASE","4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MALE;MIDDLE AGED;AGED;ITALY;BREAST NEOPLASMS;RECTAL NEOPLASMS;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TREATMENT OUTCOME;APOPTOSIS;HIV INFECTIONS;NEOPLASMS;;HERPESVIRIDAE INFECTIONS;PHOSPHOPROTEINS;REGISTRIES;ADENOCARCINOMA","48;31;23;21;21;18;14;13;9;8;8;8;7;7;7;6;6;6;6;5","MOLECULAR RESEARCH ON BREAST CANCER;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 INFECTION;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;LYMPHOID NEOPLASMS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;TREATMENT AND MANAGEMENT OF ANAL CANCER;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLIOMAS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER","4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CARBOPLATIN;RADIOTHERAPY;AXILLA;CANCER INCIDENCE;CONCOMITANT;CT SCREENING;CYTOMEGALOVIRUS;GRAVES' OPHTHALMOPATHY;HEMODIALYSIS;HIV;HTLV-1;LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;PEDIATRIC INTUBATION;PRIMARY TUMOR;REGIMEN;STEREOTACTIC BODY RADIATION THERAPY;TRANSPLANT RECIPIENTS;TREATMENT","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;SENTINEL NODE;CANCER PATIENTS;CANCER REGISTRIES;CELL LUNG;CHEMO-RADIOTHERAPY CT-RT;CONCOMITANT CHEMO-RADIOTHERAPY;HUMAN T-LYMPHOTROPIC;INSTITUTION EXPERIENCE;LONG-TERM RESULTS;LUNG CANCER;NODE BIOPSY;POSITIVE PRESSURE;PREOPERATIVE CONCOMITANT;PRESSURE VENTILATION;QUALITY SPECIFICATIONS;SINGLE INSTITUTION;SULCUS TUMOR;SUPERIOR SULCUS;TUMOR SST;VIRUS TYPE;ABO BARRIER;ACTIVATE TYROSINASE-RELATED;ACUTE REJECTION;ADULT BRAIN;ADULT LUMBAR;ADVANCED-STAGE HODGKINS;ADVERSE REACTIONS;AFFECTING SENTINEL;AIEOP LNH","6;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CHEMORADIATION THERAPY;CONFIDENCE INTERVAL;PREOPERATIVE CHEMORADIATION;PYLORI ERADICATION;SLOW CLCREA;ANTIRETROVIRAL THERAPY;PATIENTS UNDERWENT;PREGNANT WOMEN;TRANSPLANTED PATIENTS;TUMOR RESPONSE;APVR BID;BIOPSY SAMPLES;BLOOD DONORS;CELL LINES;EUROPEAN COUNTRIES;HPV INFECTION;OHDG LEVELS;PLASMA CELLS;REGRESSION ANALYSIS;THERAPY REGIMEN;VIRAL INFECTIONS;ACUTE REJECTION;ANTICONVULSANT THERAPY;CANCER INCIDENCE;CD DEPOSITION;CEL SOLUTION;CELL GROWTH;CHEMOTHERAPY REGIMENS;CHILDHOOD B-NHL;CONTINUOUS VENOUS","12;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2",6,0.11,3,1.75,0,0,0,0,2,0,1.75,1.75,0,1,0,0,0,0,0,0,0,0,0,41.75,41.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,7.83,743.33,8.55,0,0,94.3,0,0,5,1,1,0,0,3,0,9,0,0,1,0,0,0,0,10,0,0,10,0,0,0,0,0,0,0,0,0,"Belgium;Germany","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","10;6;6;3;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;BRAIN CANCER;BRAIN DISORDERS;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;BIOTECHNOLOGY;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;CHRONIC PAIN;HEART DISEASE;HIV/AIDS","8;7;6;6;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;RESPIRATORY","6;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","9;1;1;1;1","NON-HODGKIN'S LYMPHOMA;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;HODGKIN'S DISEASE;LUNG CANCER;MELANOMA","3;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","7;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2005,32,9.125,2.5,0.40625,0.3125,0.46875,1.12676056338028,0.928571428571429,0.909090909090909,0.9375,0.46875,1,19,6,3,3,0.59,0.19,0.09,0.09,54.03,1.02054107998708,NA,0.1875,0.71875,0.334,0.205,0.312,0.203,"MARIO PLEBANI;SALVATORE PUCCIARELLI;S. MONFARDINI;UMBERTO CILLO;LARA MARIA PASETTO;GIACOMO ZANUS;ANDREA VIANELLO;ALBERTO BROLESE;PAOLO RIGOTTI;FRANCESCO ANTONIO CIARLEGLIO;GIOVANNI SARTORE;MARIA LUISA FRISO;ANTONIO JIRILLO;ALESSANDRO VITALE;MARTINA ZANINOTTO;SAVINA AVERSA;KIM OVERVAD;FABIO FARINATI;ROBERTO VENDRAMINELLI;PIERO CAPPELLETTI","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CATE SETON-JONES;SALVATORE PUCCIARELLI;MARIO PLEBANI;GIAN LUCA DE SALVO;S. CANTARO;EVANDRO PIVA;ANTONIO JIRILLO;S. MONFARDINI;PIERPAOLO DA PIAN;O. TERRANOVA;GIORGIA BOSCOLO;BARBARA BARBATO;SAVINA AVERSA;FABRIZIO CARDIN;MARTINA ZANINOTTO;ANDREA VIANELLO;UMBERTO CILLO;LARA MARIA PASETTO;GIOVANNI SARTORE;ROBERTO VENDRAMINELLI","1;0.69;0.56;0.5;0.5;0.5;0.5;0.34;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.28;0.28;0.27;0.26;0.25","MARIO PLEBANI;SALVATORE PUCCIARELLI;S. MONFARDINI;UMBERTO CILLO;LARA MARIA PASETTO;GIACOMO ZANUS;ANDREA VIANELLO;ALBERTO BROLESE;PAOLO RIGOTTI;FRANCESCO ANTONIO CIARLEGLIO;MARIA LUISA FRISO;ANTONIO JIRILLO;ALESSANDRO VITALE;MARTINA ZANINOTTO;SAVINA AVERSA;FABIO FARINATI;P. FERRARESE;MARIA LUISA CALABRÒ;GIOVANNI SCARZELLO;GIOVANNI CECCHETTO","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CATE SETON-JONES;SALVATORE PUCCIARELLI;MARIO PLEBANI;S. CANTARO;ANTONIO JIRILLO;S. MONFARDINI;PIERPAOLO DA PIAN;GIORGIA BOSCOLO;SAVINA AVERSA;FABRIZIO CARDIN;MARTINA ZANINOTTO;ANDREA VIANELLO;UMBERTO CILLO;LARA MARIA PASETTO;BRUNO GIROLAMI;MONICA MION;SERGIO SIRAGUSA;PAOLO PRANDONI;FABRIZIO FABRIS;STEFANO ROCCO","1;0.69;0.56;0.5;0.5;0.34;0.33;0.33;0.33;0.33;0.29;0.28;0.28;0.27;0.25;0.25;0.25;0.25;0.25;0.25","MARIO PLEBANI;ANJA OLSEN;ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;ANTONIO AGUDO;AURELIO BARRICARTE;CARLOS A. GONZÁLEZ;CARLOTTA SACERDOTE;CARMEN MARTÍNEZ;CARMEN NAVARRO;CORINNE CASAGRANDE;DIMITRIOS H ROUKOS;EILIV LUND;ELIO RÍBOLI;FRANCO BERRINO;FRANÇOISE CLAVEL‐CHAPELON;FREDERIKE L. BÜCHNER;FÁTIMA CARNEIRO;GABRIELE NAGEL;GIUSEPPE DEL GIUDICE","401;335;335;335;335;335;335;335;335;335;335;335;335;335;335;335;335;335;335;335","MARIO PLEBANI;BRUNO GIROLAMI;FABRIZIO FABRIS;PAOLO PRANDONI;SERGIO SIRAGUSA;ROBERTO MARENZI;PAOLO RIGOTTI;GUIDO SOTTI;LARA MARIA PASETTO;DAVID SACERDOTI;ANDREA VIANELLO;MARIA LUISA FRISO;SAVINA AVERSA;ANTONIO JIRILLO;C. LUZZATTO;GIANNI BISOGNO;GIOVANNI CECCHETTO;RITA ALAGGIO;S. MONFARDINI;ANGELO ROSOLEN","397;211;211;211;211;163;147;141;124;120;114;89;60;57;57;57;57;57;53;48","MARIO PLEBANI;ANDREA VIANELLO;ANTONIO JIRILLO;LARA MARIA PASETTO;MARTINA ZANINOTTO;SAVINA AVERSA;UMBERTO CILLO;ALBA A. BRANDES;ANGELO ROSOLEN;ANTONIO MURRONE;BRUNO GIROLAMI;C. LUZZATTO;CESARE CUTRONE;DANIELE TREVISANUTO;DAVID SACERDOTI;DAVIDE PASTORELLI;ELENA ROSSI;FABIO FARINATI;FABLE ZUSTOVICH;FABRIZIO CARDIN","4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHILOSOPHY;PHYSICS;CHEMISTRY;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY","29;10;3;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;ONCOLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;CARDIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;PALEONTOLOGY;RADIOLOGY;ARTIFICIAL INTELLIGENCE;CANCER RESEARCH;CELL BIOLOGY;ENVIRONMENTAL HEALTH;EPISTEMOLOGY;INTENSIVE CARE MEDICINE;OPTICS;PSYCHIATRY;STATISTICS;UROLOGY;VIROLOGY","26;13;9;6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;TRANSPLANTATION;IN VITRO;RADIATION THERAPY;CARCINOMA;COHORT;DIABETES MELLITUS;DISEASE;GENE;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);POPULATION;PROSPECTIVE COHORT STUDY;RECTUM;TOXICITY;VIRUS;ABDOMEN;ABLATION;ADVERSE EFFECT;ALIMENTARY TRACT;ANEMIA;ANGIOGENESIS;ANTIBODY;ANTICOAGULANT;APPENDIX;ARTERIOSCLEROSIS;ASYMPTOMATIC;BISECTION;BONE MARROW;BRIDGE (GRAPH THEORY);CARCINOID TUMORS;CELL CULTURE;CELL GROWTH;COGNITION;COHORT STUDY;COMPLICATION;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);CONTROL (MANAGEMENT);DIAGNOSTIC ACCURACY;DUCHENNE MUSCULAR DYSTROPHY;EMERGENCY DEPARTMENT;ENZYME;ERYTHROPOIETIN;FERRITIN;FISTULA;GOLD STANDARD (TEST);HEART FAILURE;HEMANGIOENDOTHELIOMA;HEMOGLOBIN;HEPARIN;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOSUPPRESSION;INTENSIVE CARE;INTERVAL (GRAPH THEORY);KIDNEY;LAPAROTOMY;LIVER FUNCTION;LYMPH NODE;LYMPHOMA;METHOTREXATE;MULTIVARIATE ANALYSIS;MULTIVARIATE STATISTICS;MUSCULAR DYSTROPHY;NEGLECT;NEOPLASM;NUCLEOSIDE;NUMBER LINE;ODDS RATIO;PERCENTILE;PERCUTANEOUS;PERIOPERATIVE;PLATELET;POLITICS;PREDICTIVE VALUE;PREDNISONE;PREGNANCY;QUALITY (PHILOSOPHY);RANDOMIZED CONTROLLED TRIAL;REGENERATION (BIOLOGY);REGIMEN;RESPIRATORY FAILURE;RESUSCITATION;SALIVA;SARCOMA;SIMPLE (PHILOSOPHY);SINGLE CENTER;STAGE (STRATIGRAPHY);STEM CELL;STENT;STOMACH;SURGICAL ONCOLOGY;TASK (PROJECT MANAGEMENT);TRANSFERRIN","10;8;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;ADENOCARCINOMA;BREAST CANCER;CISPLATIN;GEMCITABINE;LIVER TRANSPLANTATION;METASTASIS;NEUTROPENIA;PERIPHERAL BLOOD MONONUCLEAR CELL;VIRAL DISEASE;ABLATIVE CASE;ALPHA-FETOPROTEIN;AUTOANTIBODY;AZATHIOPRINE;BIRTH WEIGHT;BLEOMYCIN;BRAIN NATRIURETIC PEPTIDE;CANCER REGISTRY;CHEMORADIOTHERAPY;COMPLEMENTARY DNA;COMPLETE REMISSION;CYCLOPHOSPHAMIDE;CYTOPENIA;ENDOTHELIAL STEM CELL;ETOPOSIDE;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;FLUOROURACIL;FUSION GENE;GENE EXPRESSION;GLYCATION;GLYCEMIC;HEART TRANSPLANTATION;HEME;HEPARIN-INDUCED THROMBOCYTOPENIA;HERPES SIMPLEX VIRUS;IRON DEFICIENCY;LEUKOPENIA;LIVER REGENERATION;LOW BIRTH WEIGHT;LOW MOLECULAR WEIGHT HEPARIN;LYTIC CYCLE;MATRIGEL;MEAN CORPUSCULAR VOLUME;MENTAL REPRESENTATION;METABOLIC CONTROL ANALYSIS;MUTATION;NATRIURETIC PEPTIDE;NEONATAL RESUSCITATION;NEOVASCULARIZATION;NEPHRECTOMY;NEUROPSYCHOLOGY;NUCLEOSIDE ANALOGUE;PHASES OF CLINICAL RESEARCH;PLASMA GLUCOSE;POSITIVE PRESSURE VENTILATION;PRIMARY EFFUSION LYMPHOMA;RELATIVE RISK;REPRESENTATION (POLITICS);RHABDOMYOSARCOMA;SERUM FERRITIN;SERUM IRON;SQUAMOUS CARCINOMA;STOMACH CANCER;T-STAGE;TACROLIMUS;THYMIDINE;TOLERABILITY;TRANSCRIPTION FACTOR;TROPISM;TYPE 2 DIABETES;VIRAL LOAD;VIRAL REPLICATION","6;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OXALIPLATIN;ALVEOLAR RHABDOMYOSARCOMA;BRIDGE TO TRANSPLANTATION;CARBOPLATIN;COLONOSCOPY;DEOXYCYTIDINE;GENE EXPRESSION PROFILING;HEME OXYGENASE;HEMICOLECTOMY;HERPESVIRIDAE;IRINOTECAN;IRON STATUS;LENTIVIRUS;LIMB-GIRDLE MUSCULAR DYSTROPHY;MAMMOGRAPHY;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MISSENSE MUTATION;PAX3;PENTOSIDINE;PRIMARY TUMOR;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;SIDA;SYSTEMIC THERAPY;THIOTEPA;THYMIDINE KINASE;TOTAL BODY IRRADIATION;TOTAL IRON-BINDING CAPACITY;TOTAL MESORECTAL EXCISION;TRANSFERRIN SATURATION;VINORELBINE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;LIVER NEOPLASMS;AGED, 80 AND OVER;DIABETES MELLITUS, TYPE 2;ADOLESCENT;FLUOROURACIL;RECTAL NEOPLASMS;TREATMENT OUTCOME;;CHILD;DNA;HERPESVIRUS 8, HUMAN;PROGNOSIS;ADENOCARCINOMA","27;21;18;13;13;12;10;8;7;7;6;6;6;6;5;5;5;5;5;4","COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF HEART FAILURE;HEPATOCELLULAR CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DEVELOPMENT OF NUMERICAL COGNITION AND MATHEMATICS ABILITIES;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HEMATOPOIETIC STEM CELL BIOLOGY;HEME OXYGENASE AND CARBON MONOXIDE RESEARCH;HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS;HISTORY OF INTERNATIONAL HUMANITARIANISM AND HUMAN RIGHTS;IMMUNOLOGICAL MECHANISMS IN ATHEROSCLEROSIS DEVELOPMENT;KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;B-TYPE NATRIURETIC PEPTIDE;LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;;ABLATIVE CASE;ALIMENTARY TRACT;ALPHA-FETOPROTEIN;ALVEOLAR RHABDOMYOSARCOMA;ANAL CANCER;ANTIRETROVIRAL THERAPY;APPENDICEAL NEOPLASMS;ARTERIOSCLEROSIS;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;BISECTION;BRAIN NATRIURETIC PEPTIDE;BRIDGE (GRAPH THEORY);BRIDGE TO TRANSPLANTATION;CANCER IMAGING;CARBOPLATIN","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADVANCED RECTAL;LIVER TRANSPLANTATION;LOCALLY ADVANCED;MUSCULAR DYSTROPHY;NATRIURETIC PEPTIDES;RECTAL CANCER;ABLATION TREATMENTS;ALVEOLAR RHABDOMYOSARCOMA;ANTIRETROVIRAL-NAIVE HIV-INFECTED;AUTOMATED REGISTRATION;AUTOMATICALLY DEFINED;BIRTH WEIGHT;BJAB-DERIVED CELL;BONE MARROW;BREAST CANCER;CANCER METASTASES;CARBON MONOXIDE;CARCINOID TUMOR;CARCINOMA HCC;CARDIAC NATRIURETIC;CARDIOVASCULAR NATRIURETIC;CELL LINE;CELL LYMPHOMA;CLINICAL EFFECTIVENESS;CLINICAL MODEL;COHORT STUDY;COLLECTING DUCT;COLORECTAL CANCER;COLORECTAL OBSTRUCTION;COMPARE CLINICAL","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OXLDL AB;HEALTHY VOLUNTEERS;ACUTE REJECTION;DIABETIC PATIENTS;GROWTH FACTOR;HIV-INFECTED INDIVIDUALS;MGDL MMOLL;STEROID STOP;TRIPLE THERAPY;ADVANCED DIRECTIVE;ADVANCED DIRECTIVES;BBF CELLS;CALIBRATED HR;DCK ACTIVITIES;HIV-INFECTED PATIENTS;HR CI;IGG OXLDL;INSULIN-LIKE GROWTH;INTER-INDIVIDUAL VARIABILITY;PATIENTS TREATED;PHASE II;SIGNIFICANTLY LOWER;TYPE DIABETIC;VEGETABLE INTAKE;ACUTE-SEVERE DYSPNEA;ADJUNCTIVE AGENTS;ADVANCED ATHEROSCLEROSIS;BLOOD MONONUCLEAR;CARDIAC INVOLVEMENT;CARDIAC ORIGIN","6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2",4,0.12,9.02,2.75,0,1,0,1,2,0,3,3.75,0,0,1,0,2,0,0,1,0,0,0,133,133,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,6,632.2,17.46,3,0.27,31,0,1,2,1,3,0,3,1,0,9,1,0,0,0,0,0,0,11,0,0,10,1,0,0,0,0,0,0,0,0,"Italy;Belgium;United States","4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","11;7;3;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;CANCER;DIGESTIVE DISEASES;LIVER DISEASE;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC PAIN;PAIN RESEARCH;TRANSPLANTATION;ARTHRITIS;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOENGINEERING;BRAIN CANCER;BRAIN DISORDERS;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH","11;10;5;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;MUSCULOSKELETAL;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL","4;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","9;2;1;1","LIVER CANCER;BRAIN TUMOR;MELANOMA;NON-HODGKIN'S LYMPHOMA;STOMACH CANCER","2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","4;1;1",1,4,0.27,6,15,10,1,0,80188.7755706606,0.399058344166913,"AZIENDA OSPEDALIERA DI PADOVA;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE;ERASMUS MC;HOSPITAL UNIVERSITARIO LA PAZ;INSERM;INSTITUTE OF PHYSIOLOGY;ISTITUTO SUPERIORE DI SANITÀ;LEIDEN UNIVERSITY;LINKÖPING UNIVERSITY;MEDICAL RESEARCH COUNCIL;NATIONAL RESEARCH COUNCIL;TECHNION – ISRAEL INSTITUTE OF TECHNOLOGY;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF LIÈGE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2003-LIFESCIHEALTH-I (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","1;1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","1;1;1;1","GENETICS;HUMAN GENOME;PATIENT SAFETY;PEDIATRIC","1;1;1;1","GENERIC HEALTH RELEVANCE","1","5.1 PHARMACEUTICALS","1","NOT SITE-SPECIFIC CANCER","1","5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2006,62,10.2741935483871,3.06451612903226,0.290322580645161,0.274193548387097,0.306451612903226,1.13855421686747,1.05882352941176,0.944444444444444,1.05555555555556,0.370967741935484,1,29,14,6,12,0.47,0.23,0.1,0.19,49.73,0.973522940536358,NA,0.258064516129032,0.854838709677419,0.553,0.317,0.231,0.311,"LARA MARIA PASETTO;MARIO PLEBANI;DANIELE TREVISANUTO;VINCENZO ZANARDO;DONATO NITTI;S. MONFARDINI;GIAN LUCA DE SALVO;NICOLETTA DOGLIONI;DARIO CASARA;LISA DONOFRIO;KIM OVERVAD;MASSIMO RUGGE;GIUSEPPE DEL GIUDICE;FRANCO MANTERO;LUCIANO GIACOMELLI;DANNY VLEGGAAR;TINA S. ALSTER;CHERYL BURGESS;SALVATORE PUCCIARELLI;SARA ALTINIER","5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","LARA MARIA PASETTO;T. GASTALDI;S. MONFARDINI;DANIELE TREVISANUTO;VINCENZO ZANARDO;ALBERTO BURLINA;NICOLETTA DOGLIONI;MAURIZIO MURACA;GIOVANNI PUTOTO;RENZO PEGORARO;ANTONIO JIRILLO;MARIO PLEBANI;DAVIDE FIORE;P. C. MUZZIO;VITTORIO BAGGIO;DARIO CASARA;GUIDO SOTTI;L. RICCARDI;SIMONE CESARO;MARA CAVALIERE","1.11;1;0.95;0.73;0.73;0.64;0.56;0.5;0.5;0.5;0.45;0.4;0.39;0.39;0.39;0.39;0.36;0.33;0.33;0.33","LARA MARIA PASETTO;MARIO PLEBANI;DANIELE TREVISANUTO;VINCENZO ZANARDO;S. MONFARDINI;NICOLETTA DOGLIONI;DARIO CASARA;KIM OVERVAD;MASSIMO RUGGE;GIUSEPPE DEL GIUDICE;FRANCO MANTERO;LUCIANO GIACOMELLI;DANNY VLEGGAAR;SARA ALTINIER;SALVATORE PANICO;UTE BAUER;JAKOB LINSEISEN;PIETRO AMISTÀ;NICOLA BALDAN;FÁTIMA CARNEIRO","5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","LARA MARIA PASETTO;T. GASTALDI;S. MONFARDINI;DANIELE TREVISANUTO;VINCENZO ZANARDO;ALBERTO BURLINA;NICOLETTA DOGLIONI;GIOVANNI PUTOTO;RENZO PEGORARO;ANTONIO JIRILLO;MARIO PLEBANI;DARIO CASARA;GUIDO SOTTI;L. RICCARDI;MATTEO BERNARDI;SARA ALTINIER;MARTINA ZANINOTTO;LUCIANO GIACOMELLI;SILVIA CHIARELLI;LAURA BONALDI","1.11;1;0.95;0.73;0.73;0.64;0.56;0.5;0.5;0.45;0.4;0.39;0.36;0.33;0.33;0.31;0.31;0.25;0.25;0.25","MARIO PLEBANI;NICOLA BALDAN;PAOLO RIGOTTI;MASSIMO RUGGE;ANNALISA PERNA;BORISLAV D. DIMITROV;GIUSEPPE LOCATELLI;GIUSEPPE REMUZZI;M BEATINI;M. SCALAMOGNA;MARTA TURTURRO;PAOLO CRAVEDI;PIERO RUGGENENTI;UMBERTO VALENTE;LUCIANO GIACOMELLI;ANJA OLSEN;ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;AURELIO BARRICARTE;CARLOS A. GONZÁLEZ","708;516;516;475;474;474;474;474;474;474;474;474;474;474;465;463;463;463;463;463","MARIO PLEBANI;NICOLA BALDAN;PAOLO RIGOTTI;LUCIANO GIACOMELLI;ANJA OLSEN;ANNE TJØNNELAND;ANTONIA TRICHOPOULOU;ANTONIO AGUDO;AURELIO BARRICARTE;BERTRAND HÉMON;CARLOTTA SACERDOTE;CARMEN MARTÍNEZ;CARMEN NAVARRO;DIMITRIOS H ROUKOS;DOMENICO PALLI;EILIV LUND;ELIO RÍBOLI;FRANCO BERRINO;FRANÇOISE CLAVEL‐CHAPELON;FÁTIMA CARNEIRO","708;474;474;465;336;336;336;336;336;336;336;336;336;336;336;336;336;336;336;336","LARA MARIA PASETTO;MARIO PLEBANI;DARIO CASARA;ALBERTO BURLINA;ANTONIO JIRILLO;DANIELE TREVISANUTO;ELISABETTA VISCARDI;GUIDO SOTTI;LUCIANO GIACOMELLI;MARIA LUISA FRISO;MARTINA ZANINOTTO;PIETRO AMISTÀ;SARA ALTINIER;SARA LONARDI;UTE BAUER;VINCENZO ZANARDO;A AMBROSINI;A. AMADORI;A. TRIPEPI;ALBA A. BRANDES","5;5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;MATHEMATICS;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ART;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOLOGY;POLITICAL SCIENCE;PSYCHOLOGY","57;28;6;4;3;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;ONCOLOGY;RADIOLOGY;FAMILY MEDICINE;ANESTHESIA;CANCER RESEARCH;ENDOCRINOLOGY;IMMUNOLOGY;PALEONTOLOGY;PEDIATRICS;PSYCHIATRY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CARDIOLOGY;CELL BIOLOGY;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;NURSING;OBSTETRICS","39;21;15;14;12;8;8;6;5;5;5;5;5;5;5;4;4;3;3;3;3;3;3","CANCER;GENE;DISEASE;CHEMOTHERAPY;PROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;PREGNANCY;RADIATION THERAPY;BIOPSY;REGIMEN;POPULATION;RANDOMIZED CONTROLLED TRIAL;SARCOMA;STAGE (STRATIGRAPHY);AIRWAY;ALTERNATIVE MEDICINE;ANEURYSM;APOPTOSIS;BLOOD PRESSURE;CAROTID ARTERIES;CELL CULTURE;CHOLESTEROL;DIABETES MELLITUS;DRUG;GRADING SCALE;HEPATITIS C;HORMONE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IN VITRO;INFLAMMATION;INTUBATION;MULTIMODAL THERAPY;QUALITY OF LIFE (HEALTHCARE);STOMACH;THYROID;TRANSPLANTATION;UMBILICAL CORD","19;9;8;6;6;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;BIRTH WEIGHT;BREAST CANCER;FETUS;MUTATION;RHABDOMYOSARCOMA;CHEMORADIOTHERAPY;ESOPHAGEAL CANCER;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;FLUOROURACIL;GENE EXPRESSION;GESTATION;GESTATIONAL AGE;PROGRAMMED CELL DEATH;THYROID CANCER;TRACHEAL INTUBATION;VIRAL LOAD;ABDOMINAL AORTIC ANEURYSM;ACETYLATION;ADENOCARCINOMA;ADJUVANT THERAPY;AGE OF ONSET;ALIASING;ALLELE;ANDROGEN;ANTRUM;AORTIC ANEURYSM;ARGININE;AUTOANTIBODY;AUTOIMMUNE DISEASE;BACTEREMIA;BASAL (MEDICINE);BIOLOGICAL CLOCK;C-REACTIVE PROTEIN;CARCINOGENESIS;CATHETER ABLATION;CD8;CENTRAL VENOUS CATHETER;CERVICAL CANCER;CHEMOKINE;CHROMOSOME;CHRONIC HEPATITIS;CHRONOBIOLOGY;CIRCADIAN CLOCK;CISPLATIN;CLINICAL ENDPOINT;CLUBFOOT;COELIAC DISEASE;CONTINUOUS POSITIVE AIRWAY PRESSURE;CYTOTOXIC T CELL;DOCETAXEL;ENDOVASCULAR TREATMENT;EPIGENETICS;FATTY LIVER;GASTRITIS;GEMCITABINE;GENETIC ENHANCEMENT;GENOTYPE;GERIATRIC ONCOLOGY;GERMLINE;GLASGOW OUTCOME SCALE;GLUTAMINE;GLYCOGEN STORAGE DISEASE;GROWTH HORMONE;HAEMATOPOIESIS;HAZARD RATIO;HEART RATE;HEMISPATIAL NEGLECT;HEMOGLOBIN A;HISTONE;HUMAN GENETICS;IMAGE QUALITY;IMMUNOGLOBULIN G;INSULIN RESISTANCE;INTESTINAL RESECTION;INTIMA-MEDIA THICKNESS;KIDNEY TRANSPLANTATION;LARYNGEAL MASK AIRWAY;LEAN BODY MASS;LEUKODYSTROPHY;LIPID PROFILE;LIVER BIOPSY;LOW BIRTH WEIGHT;MEAN DIFFERENCE;METASTASIS;METHYLATION;MULTICENTER STUDY;NEONATAL RESUSCITATION;NEUROBLASTOMA;NEUTROPENIA;NOISE (VIDEO);NUMERICAL COGNITION;OBSTETRICS AND GYNAECOLOGY;OMENTECTOMY;OVARIAN CANCER;PANCREATIC CANCER;PARATHYROID ADENOMA;PARATHYROID CARCINOMA;PEDIATRIC ONCOLOGY;PERINATAL ASPHYXIA;PHENOTYPE;PHILOSOPHY OF MEDICINE;PHOSPHATASE;PLASMA GLUCOSE;POLYMERASE CHAIN REACTION;PROGENITOR CELL;PROGERIA;PROTEIN TYROSINE PHOSPHATASE;PSEUDOANEURYSM;QUALITY ASSURANCE;RADICAL SURGERY;RADIOFREQUENCY ABLATION;RECOMBINANT DNA;RELATIVE RISK;RETINOL;RNA;RYANODINE RECEPTOR;SADNESS;SALVAGE THERAPY;SELECTIVE IGA DEFICIENCY;SPIRAL COMPUTED TOMOGRAPHY;STOMACH CANCER;SUBLUXATION;TECHNETIUM (99MTC) SESTAMIBI;TECHNETIUM TC 99M SESTAMIBI;THERMAL ABLATION;THYROGLOBULIN;TISSUE TRANSGLUTAMINASE;TRANSCRIPTION FACTOR;TRANSFECTION;TRANSGENE;TRIGLYCERIDE;TROPONIN I;TUMOR PROGRESSION;ULTRADIAN RHYTHM;VERMIFORM;VIRAL DISEASE","6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OXALIPLATIN;ANTIRETROVIRAL THERAPY;APGAR SCORE;PAPILLARY THYROID CANCER;SENTINEL LYMPH NODE;UMBILICAL ARTERY;ALVEOLAR RHABDOMYOSARCOMA;AORTIC RUPTURE;ATROPHIC GASTRITIS;BACTERIAL CIRCADIAN RHYTHMS;CAPECITABINE;CERVICAL LYMPH NODES;COMPUTED RADIOGRAPHY;CREB;CTL*;CXCR4;DNA METHYLATION;ESOPHAGEAL ADENOCARCINOMA;FAS LIGAND;GERMLINE MUTATION;GLYCOGEN STORAGE DISEASE TYPE I;GRANZYME B;GROWTH HORMONE DEFICIENCY;HELICASE;HOUSEKEEPING GENE;HPV INFECTION;IMMUNOGLOBULIN A;INFRADIAN RHYTHM;INSULIN SENSITIVITY;KARYOTYPE;KRAS;LARYNGOSCOPES;MEAN BLOOD PRESSURE;MISSENSE MUTATION;ORNITHINE;PARATHYROID NEOPLASM;PERFORIN;PLACENTA;PRENATAL DIAGNOSIS;RIBAVIRIN;RYR1;SINGLE UMBILICAL ARTERY;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL FOR GESTATIONAL AGE;TOTAL MESORECTAL EXCISION;TROPONIN COMPLEX;UREA CYCLE;VIRAL VECTOR;VIRILIZATION","4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;AGED;MIDDLE AGED;STOMACH NEOPLASMS;ADENOCARCINOMA;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FLUOROURACIL;ORGANOPLATINUM COMPOUNDS;TREATMENT OUTCOME;;AGED, 80 AND OVER;CHILD;COLORECTAL NEOPLASMS;ESOPHAGEAL NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;RECTAL NEOPLASMS","51;31;30;22;22;20;15;12;11;10;9;9;9;8;8;8;8;8;8;8","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;COLORECTAL CANCER RESEARCH AND TREATMENT;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;NEUTROPHILIC DERMATOSES AND INFLAMMATORY BOWEL DISEASES;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;CONE-BEAM COMPUTED TOMOGRAPHY IN DENTISTRY;DEVELOPMENT OF NUMERICAL COGNITION AND MATHEMATICS ABILITIES;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DUAL-ENERGY COMPUTED TOMOGRAPHY;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;EVOLUTION OF CHILD HEALTH SERVICES IN EUROPE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","REGIMEN;METASTATIC COLORECTAL CANCER;APGAR SCORE;CHEMORADIOTHERAPY;CONTINUOUS GLUCOSE MONITORING;DIABETES;DIAGNOSIS;DIFFERENTIATED THYROID CANCER;EMERGENCY TRACHEAL INTUBATION;GAMMA PROBE;GRADING SCALE;HEPATITIS C;LIPOATROPHY;LIPODYSTROPHY;MULTIMODAL THERAPY;PEDIATRIC INTUBATION;POSITIVE END-EXPIRATORY PRESSURE;SKIN DEVELOPMENT;THYROID SURGERY;TRACHEAL INTUBATION","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;BLOOD PRESSURE;CANCER PATIENTS;CHRONIC HEPATITIS;EUROPEAN PROSPECTIVE;FACIAL LIPOATROPHY;GROWTH HORMONE;MULTICENTER STUDY;PATIENTS RESULTS;PROSPECTIVE INVESTIGATION;RECTAL CANCER;THYROID CANCER;UMBILICAL CORD;ABDOMINAL AORTIC;ACCEPTANCE TESTING;ACTIVATING PTPN;ACUTE ISCHEMIC;ACUTE RENAL-ALLOGRAFT;ADDISONS DISEASE;ADULT SOLID;ADVANCED COLORECTAL;ADVANCED RECTAL;AGENCY EMEA;ANEURYSM SCORE;ANTIAPOPTOTIC EFFECT;ANTIBIOTIC-LOCK THERAPY;AORTIC ANEURYSMS;ARTERY PSEUDOANEURYSM;ASPHYXIATED NEONATES;ATHEROSCLEROTIC MARKERS","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LSD PROTOCOL;DTC PATIENTS;PHPT PATIENTS;RADIOGUIDED SURGERY;CI PTREND;IGA DEFICIENCY;MEAT INTAKE;ANEURYSM SCORE;BONE MARROW;CANCER RISK;COLORECTAL CANCER;COMPLETE RESPONSE;GASTRIC CANCER;GASTRIC NONCARDIA;GDAY INCREASE;GLASGOW ANEURYSM;INCREASE CI;OPERATING THEATER;PROCESSED MEAT;RADIOFREQUENCY THERMAL;THERMAL ABLATION;THYROID CANCER;TISSUE TRANSGLUTAMINASE;TOTAL MEAT;UMBILICAL CORD;ARMS CELLS;CALIBRATED HR;CANNULA CONDITION;CHAIN REACTION;ESOPHAGEAL ADENOCARCINOMA","9;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3",12,0.19,6.25,2.25,1,1.75,0,6.25,2,0,1.5,2.25,0,1,10,2,2.75,2,1,6,1,0,0,107.25,107.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,3.75,578,7.41,2,0.17,42.75,0,0,4,0,5,0,3,0,0,10,0,0,0,0,0,0,0,12,0,0,10,2,0,0,0,0,0,0,0,0,"United Kingdom;United States","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","12;5;3;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;CARDIOVASCULAR;HEART DISEASE;RARE DISEASES;ATHEROSCLEROSIS;HEART DISEASE - CORONARY HEART DISEASE;ORPHAN DRUG;PATIENT SAFETY;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;DIABETES;DIGESTIVE DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;KIDNEY DISEASE;LIVER DISEASE;LUPUS;LYMPHOMA","9;8;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;EYE;INFLAMMATORY AND IMMUNE SYSTEM;SKIN","3;2;1;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES","9;2;1;1","NON-HODGKIN'S LYMPHOMA;SARCOMA","1;1","5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","1;1;1",2,5938273,381374.19,6,14.5,7,1,5.5,193508.250179434,0.320399775939834,"AZIENDA OSPEDALIERA DI PADOVA;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF PADUA;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AVANTEA;CALOUSTE GULBENKIAN FOUNDATION;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES;CORLINE SYSTEMS (SWEDEN);DÉLÉGATION PARIS 11;FEDERAL OFFICE FOR FOOD AND AGRICULTURE;FRIEDRICH-LOEFFLER-INSTITUT;GATC BIOTECH (GERMANY);GLASGOW CALEDONIAN UNIVERSITY;HANNOVER MEDICAL SCHOOL;INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT;INSTITUTE OF MOLECULAR GENETICS;ISTITUTO SPERIMENTALE ITALIANO LAZZARO SPALLANZANI;LEIDEN UNIVERSITY MEDICAL CENTER;MEDICAL RESEARCH COUNCIL","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);CA - COORDINATION ACTION (FUNDING SCHEME);FP6-2004-LIFESCIHEALTH-5 (CALL FOR PROPOSAL);FP6-2005-LIFESCIHEALTH-6 (CALL FOR PROPOSAL);IP - INTEGRATED PROJECT (FUNDING SCHEME)","2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","2;1;1","BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;HIV/AIDS;INFECTIOUS DISEASES;PEDIATRIC;PEDIATRIC AIDS;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;TRANSPLANTATION","1;1;1;1;1;1;1;1;1","INFECTION","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;6.1 PHARMACEUTICALS","1;1;1;1",NA,NA,NA,NA,"A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A06 AGRICULTURE, VETERINARY AND FOOD SCIENCE","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2007,53,9.49056603773585,2.86792452830189,0.339622641509434,0.339622641509434,0.339622641509434,1.43809523809524,1,1.2,1,0.339622641509434,1,17,14,7,9,0.32,0.26,0.13,0.17,51.17,0.969566092637667,NA,0.188679245283019,0.924528301886792,0.357,0.35,0.337,0.326,"DAVIDE D’AMICO;ENRICO GRINGERI;UMBERTO CILLO;AMEDEO CARRARO;F. D’AMICO;MICHELE VALMASONI;ALESSANDRO VITALE;GIACOMO ZANUS;ALBERTO BROLESE;PATRIZIA BOCCAGNI;MARIO PLEBANI;A. PAULETTO;FILIPPO BROCADELLO;JOKE HUYGHE;GUY VAN CAMP;EZIO ZANON;FABIO FARINATI;MASSIMO RUGGE;GIANCARLO CASTAMAN;AGNETE PARVING","5;5;5;5;5;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2","CHIOZZA ML;MARIO PLEBANI;FILIPPO BROCADELLO;PAOLO CARRARO;FRANCESCO FRANCINI‐PESENTI;DAVIDE D’AMICO;ENRICO GRINGERI;UMBERTO CILLO;AMEDEO CARRARO;F. D’AMICO;MICHELE VALMASONI;ALESSANDRO VITALE;ANGELO ROSOLEN;MANUEL ZORZI;O. TERRANOVA;GIANLUCA BISINELLA;COSIMO GIGANTE;S TURRA;FABRIZIO CARDIN;MARTA PILLON","1;0.89;0.65;0.62;0.45;0.4;0.4;0.4;0.4;0.4;0.4;0.4;0.35;0.33;0.33;0.33;0.33;0.33;0.33;0.32","DAVIDE D’AMICO;ENRICO GRINGERI;UMBERTO CILLO;AMEDEO CARRARO;F. D’AMICO;MICHELE VALMASONI;GIACOMO ZANUS;ALBERTO BROLESE;PATRIZIA BOCCAGNI;MARIO PLEBANI;A. PAULETTO;FILIPPO BROCADELLO;EZIO ZANON;RITA ALAGGIO;DANIELE NERI;LUISA MURER;VANIA QUAINO;M. POLACCO;PIETRO ZUCCHETTA;DANIELA BASSI","5;5;5;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2","CHIOZZA ML;MARIO PLEBANI;FILIPPO BROCADELLO;PAOLO CARRARO;FRANCESCO FRANCINI‐PESENTI;DAVIDE D’AMICO;ENRICO GRINGERI;UMBERTO CILLO;AMEDEO CARRARO;F. D’AMICO;MICHELE VALMASONI;ANGELO ROSOLEN;MANUEL ZORZI;GIANLUCA BISINELLA;COSIMO GIGANTE;S TURRA;MARTA PILLON;GIACOMO ZANUS;ALBERTO BROLESE;RACHELE PAJOLA","1;0.89;0.65;0.62;0.45;0.4;0.4;0.4;0.4;0.4;0.4;0.35;0.33;0.33;0.33;0.33;0.32;0.3;0.3;0.25","MARIO PLEBANI;PAOLO CARRARO;GIOVANNI MONTINI;LUISA MURER;MARIALUISA VALENTE;ANDREA ONETTI MUDA;ANNA PASTORE;ENRICO BERTINI;FILIPPO M. SANTORELLI;FIORELLA PIEMONTE;FRANCESCA DIOMEDI CAMASSEI;FRANCESCO EMMA;GIAN MARCO GHIGGERI;GIANLUCA CARIDI;LAURA BARISONI;SILVIA DI GIANDOMENICO;PIETRO ZUCCHETTA;ALESSANDRO CALDERAN;ANDREA CORSINI;ANTONELLA TOFFOLO","659;619;508;508;315;312;312;312;312;312;312;312;312;312;312;312;244;196;196;196","PAOLO CARRARO;LUISA MURER;MARIALUISA VALENTE;GIOVANNI MONTINI;F. D’AMICO;AMEDEO CARRARO;DAVIDE D’AMICO;ENRICO GRINGERI;MICHELE VALMASONI;UMBERTO CILLO;ALBERTO BROLESE;GIACOMO ZANUS;V. BLATT;M. SCANARINI;N. SRSEN;VANIA QUAINO;EZIO ZANON;STEFANO MASIERO;FILIPPO BROCADELLO;A NASO","608;312;312;196;168;164;164;164;164;164;154;154;136;115;111;108;107;93;84;79","AMEDEO CARRARO;DAVIDE D’AMICO;ENRICO GRINGERI;F. D’AMICO;MICHELE VALMASONI;UMBERTO CILLO;ALBERTO BROLESE;GIACOMO ZANUS;A. PAULETTO;FILIPPO BROCADELLO;PATRIZIA BOCCAGNI;AMANDA BONACONSA;ANGELO ROSOLEN;DANIELA BASSI;DANIELE NERI;EZIO ZANON;FRANCESCO ANTONIO CIARLEGLIO;FRANCESCO FRANCINI‐PESENTI;M. POLACCO;MANUELA MAZZOLI","5;5;5;5;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;PHYSICS;POLITICAL SCIENCE;SOCIOLOGY","53;19;6;4;4;4;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;BIOCHEMISTRY;PEDIATRICS;ENDOCRINOLOGY;GENETICS;INTENSIVE CARE MEDICINE;ONCOLOGY;ANESTHESIA;AUDIOLOGY;CANCER RESEARCH;CELL BIOLOGY;LINGUISTICS;MEDICAL PHYSICS;PALEONTOLOGY;PHYSICAL THERAPY;RADIOLOGY;STATISTICS;UROLOGY","38;16;15;11;7;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CANCER;GENE;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;ANTIGEN;CHEMOTHERAPY;ADVERSE EFFECT;DISEASE;IMMUNOHISTOCHEMISTRY;IN VITRO;LYMPHOMA;REPRODUCIBILITY;RETROSPECTIVE COHORT STUDY;VIRUS;ALTERNATIVE MEDICINE;ANALYSIS OF VARIANCE;ANTIBIOTICS;BIOPSY;BODY MASS INDEX;CLINICAL TRIAL;COHORT;DIABETES MELLITUS;DIALYSIS;ENCEPHALOPATHY;HEPATOCELLULAR CARCINOMA;HYPERPLASIA;INFLAMMATION;KIDNEY;LIVER DISEASE;LUNG;MALIGNANCY;MEDICAL DIAGNOSIS;MULTIVARIATE ANALYSIS;PLATELET;POPULATION;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;RECEPTOR;SCINTIGRAPHY;STAGE (STRATIGRAPHY);SURVIVAL ANALYSIS","6;5;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;CISPLATIN;COLORECTAL CANCER;CUMULATIVE INCIDENCE;IMMUNOPHENOTYPING;NEUTROPENIA;ADENOCARCINOMA;AIRWAY MANAGEMENT;ALLELE;ALZHEIMER'S DISEASE;ANAPLASTIC LARGE-CELL LYMPHOMA;ARTERIAL DISEASE;ASCOSPORE;BETHESDA SYSTEM;BREAST CANCER;CANE;CD8;CERVICAL CANCER;CHEST RADIOGRAPH;CHORIOALLANTOIC MEMBRANE;COBALAMIN;COMMUNITY-ACQUIRED PNEUMONIA;CONTINUOUS POSITIVE AIRWAY PRESSURE;CONTRAINDICATION;CYTOTOXIC T CELL;DESMOPLASTIC SMALL-ROUND-CELL TUMOR;END STAGE RENAL DISEASE;ENDOTHELIAL STEM CELL;ETANERCEPT;ETOPOSIDE;FIRST METATARSAL;FRESH FROZEN PLASMA;FRUCTOSAMINE;GEMCITABINE;GENE DUPLICATION;GENE EXPRESSION;GENE REARRANGEMENT;GENOTYPE;GERIATRIC ONCOLOGY;GLOMERULONEPHRITIS;GROWTH FACTOR;GROWTH HORMONE;HAEMOPHILIA A;HAZARD RATIO;HEMISPATIAL NEGLECT;HEPATIC ENCEPHALOPATHY;HEPATITIS C VIRUS;HODGKIN LYMPHOMA;HUMAN LEUKOCYTE ANTIGEN;INFLIXIMAB;INTESTINAL METAPLASIA;INTRON;KI-67;LIGAND (BIOCHEMISTRY);LIPID PROFILE;MAJOR HISTOCOMPATIBILITY COMPLEX;MALIGNANT PLEURAL EFFUSION;MATRIGEL;MUTATION;NEPHRECTOMY;NEPHROPATHY;NOISE EXPOSURE;NULL CELL;OVERWEIGHT;PACLITAXEL;PARAPLEGIA;PERIPHERAL BLOOD MONONUCLEAR CELL;PERTECHNETATE;PHASES OF CLINICAL RESEARCH;PHOTOCATALYSIS;PLACEBO;PROLIFERATION MARKER;PROSTATE;PROSTATE CANCER;QUALITY ASSURANCE;RANDOMIZATION;RENAL BIOPSY;RESTENOSIS;REVASCULARIZATION;SMOOTH MUSCLE TUMOR;SOMATOSTATIN RECEPTOR;STAPES;STREPTOCOCCUS PNEUMONIAE;SUBACUTE COMBINED DEGENERATION;T CELL;T-CELL LYMPHOMA;TEMOZOLOMIDE;THALIDOMIDE;THYROID CARCINOMA;THYROID NODULES;TOLERABILITY;TRACHEAL INTUBATION;TRIGLYCERIDE;TUBULOPATHY;TYPE 2 DIABETES;UNILATERAL NEGLECT;UNIVARIATE ANALYSIS;UNSTABLE ANGINA;URINATION;VASCULAR ENDOTHELIAL GROWTH FACTOR;VIMENTIN;VIRAL LOAD;VIRUS INACTIVATION;VISUAL PERCEPTION;VON WILLEBRAND FACTOR","5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARBOPLATIN;MILAN CRITERIA;MODEL FOR END-STAGE LIVER DISEASE;ACROMEGALY;ALLELE FREQUENCY;ANAPLASTIC LYMPHOMA KINASE;ANTIRETROVIRAL THERAPY;ASCUS (BRYOZOA);BASIC FIBROBLAST GROWTH FACTOR;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHILDHOOD OBESITY;CLAUDICATION;DESMIN;FILGRASTIM;GASTROINTESTINAL CANCER;GENE MUTATION;GLOMERULOPATHY;GLYCATED HEMOGLOBIN;HAPLOTYPE;HOMEOBOX;IFOSFAMIDE;INTERMITTENT CLAUDICATION;LIQUID-BASED CYTOLOGY;MAMMOGRAPHY;METHYLENE BLUE;MISSENSE MUTATION;NOISE-INDUCED HEARING LOSS;PCA3;PERCEPTUAL DISORDERS;PERFORIN;POINT MUTATION;PROSTATE-SPECIFIC ANTIGEN;SENILE PLAQUES;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATOSTATIN RECEPTOR 2;T-CELL RECEPTOR;VON WILLEBRAND DISEASE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;LIVER TRANSPLANTATION;TREATMENT OUTCOME;BIOMARKERS, TUMOR;FOLLOW-UP STUDIES;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;CHILD;STOMACH NEOPLASMS;;CARCINOMA, HEPATOCELLULAR;KIDNEY FAILURE, CHRONIC;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","46;33;27;23;19;17;14;11;9;9;9;9;8;8;7;6;6;6;5;5","GLIOMAS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEPATOCELLULAR CARCINOMA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICAL SIGNIFICANCE OF POLICOSANOL IN LIPID MANAGEMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND MANAGEMENT OF URTICARIA;DIAGNOSIS AND MANAGEMENT OF WERNICKE-KORSAKOFF SYNDROME;DISASTER RESPONSE AND PUBLIC HEALTH PREPAREDNESS;EFFECTS OF BLOOD TRANSFUSION IN CLINICAL PRACTICE;EFFECTS OF NOISE POLLUTION ON HEALTH AND WELL-BEING;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;GENETIC ADAPTATION OF LACTASE PERSISTENCE IN HUMANS;GENETIC AND DEVELOPMENTAL STUDIES OF LIMB MALFORMATIONS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;TREATMENT;CARBOPLATIN;CUMULATIVE INCIDENCE;IMMUNOPHENOTYPING;LIVER BIOPSY;LIVER CIRRHOSIS;LIVER DISEASE;MILAN CRITERIA;ACADEMIC YEAR;ACUTE-ON-CHRONIC LIVER FAILURE;ALCOHOLIC NEUROPATHY;AMYLOID HYPOTHESIS;ANAL CANCER;ANAPLASTIC LARGE-CELL LYMPHOMA;ANKLE-BRACHIAL INDEX;ANTACID;ANTIBIOTIC RESISTANCE;ANTIBODY-MEDIATED REJECTION","4;4;4;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","LIVER TRANSPLANTATION;CONTROLLED TRIAL;INTENTION-TO-TREAT ANALYSIS;PATIENTS UNDERGOING;RANDOMIZED CONTROLLED;A- CORRELATION;ADVANCED NSCLC;AGE-RELATED HEARING;AGGRESSIVELY TREATED;AMYLOID ANGIOGENIC;ANGIOGENIC ACTIVITY;ANTIBIOTIC TREATMENT;ANTIGEN COUPLED;ARTERY DISEASE;ASPETTI CLINICI;BABY EXPENSIVE;BENCH STUDY;BISECTION TASK;BRAIN TUMORS;C-CELL HYPERPLASIA;CANCER PATIENTS;CANE POLICOSANOL;CARBOPLATIN ETOPOSIDE;CARBOPLATIN PC;CARE UNIT;CELL LUNG;CELL LYMPHOMAS;CELL TUMOR;CELL VIABILITY;CELLULAR HIV","5;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","THERAPEUTIC EDUCATION;GLYCATED ALBUMIN;VEGF SECRETION;EDUCATION PROGRAM;CELL PROLIFERATION;CELL VIABILITY;DIABETIC PATIENTS;MILAN CRITERIA;SURVIVAL RATES;BEHAVIORAL THERAPY;CHILDREN TREATED;DROPOUT PROBABILITY;END-STAGE RENAL;FASTING PLASMA;GLYCEMIC CONTROL;HIGHRISK PATIENTS;HR CI;MEDIAN SURVIVAL;PLASMA GLUCOSE;RENAL DISEASE;RESPONSE RATE;VWD PATIENTS;ABETA PEPTIDES;ACUTE PYELONEPHRITIS;ASSOCIATION STUDIES;CAM ASSAY;CELL IMMORTALISATION;CHEST RADIOGRAPH;CLINICAL PYELONEPHRITIS;CO-AMOXICLAV MGKGDAY","8;7;7;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2",11,0.21,12,5,1,1,0,1,3,0,2,5,0,2,80,1,3.5,2,20,59,5,0,0,81,81.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4,958,12,0,0,53.5,0,0,2,1,4,0,2,3,0,5,3,0,0,0,0,0,0,12,0,0,8,4,0,0,0,0,0,0,0,0,"Italy","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS","12;9;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;LUNG;PEDIATRIC;ACUTE RESPIRATORY DISTRESS SYNDROME;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BRAIN DISORDERS;BREAST CANCER;CANCER;CARDIOVASCULAR;DIGESTIVE DISEASES;HYPERTENSION;KIDNEY DISEASE;NEUROSCIENCES;ORGAN TRANSPLANTATION;ORPHAN DRUG;PREVENTION","8;6;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;RENAL AND UROGENITAL;RESPIRATORY","1;1;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","6;1;1","BRAIN TUMOR;BREAST CANCER;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;MELANOMA;MYELOMA;NON-HODGKIN'S LYMPHOMA","1;1;1;1;1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","1",1,1813046,181304.6,4,10,7,1,14,227374.907322291,0.233095202211014,"AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AZIENDA OSPEDALIERA DI PADOVA;NATIONAL RESEARCH COUNCIL;OSLO UNIVERSITY HOSPITAL;POMPEU FABRA UNIVERSITY;UNIVERSITY OF GOTHENBURG;UNIVERSITY OF NAVARRA;UNIVERSITY OF SZEGED;UNIVERSITY OF TENNESSEE AT KNOXVILLE;VRIJE UNIVERSITEIT BRUSSEL","1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2005-NEST-PATH (CALL FOR PROPOSAL);FP6-POLICIES - POLICY SUPPORT: SPECIFIC ACTIVITIES COVERING WIDER FIELD OF RESEARCH UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);STREP - SPECIFIC TARGETED RESEARCH PROJECT (FUNDING SCHEME)","1;1;1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY","1;1","AUTOIMMUNE DISEASE","1",NA,NA,NA,NA,NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2008,72,9.52777777777778,2.26388888888889,0.263888888888889,0.222222222222222,0.25,1.22556390977444,1.05555555555556,1.14285714285714,1.05882352941176,0.333333333333333,3,39,15,4,11,0.54,0.21,0.06,0.15,55.89,1.01853441823984,NA,0.402777777777778,0.888888888888889,0.422,0.356,0.345,0.366,"GIOVANNI MONTINI;MARIO PLEBANI;IAN K. HEWITT;PIETRO ZUCCHETTA;GINO GEROSA;THOMAS BECKER;PATRIZIA BURRA;UMBERTO CILLO;JOSÉ M. ARIZÓN;H. LEHMKUHL;LUIGI PAVANELLO;M. COLLEDAN;PIER PAOLO MOLINARI;ITXARONE BILBAO;HELENA ISONIEMI;JACQUES PIRENNE;JOHAN VANHAECKE;FRANCESCA MASCHIO;A BERNARDOS;ERMANNO ANCONA","6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GIOVANNI MONTINI;MARIO PLEBANI;IAN K. HEWITT;PIERO MARSON;VALENTINA MEDICI;G STURNIOLO;RENZO ZANOTTI;G PASERO;ALESSANDRA ZAMPIERON;PIETRO ZUCCHETTA;GINO GEROSA;ERMANNO ANCONA;LORENZA CAREGARO;DANIELE TREVISANUTO;MASSIMO MICAGLIO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;FRANCESCO FRANCINI‐PESENTI;FILIPPO BROCADELLO;ANGELO ROSOLEN","2.73;1.27;0.73;0.67;0.5;0.5;0.5;0.5;0.5;0.43;0.4;0.38;0.37;0.37;0.37;0.37;0.37;0.37;0.37;0.37","GIOVANNI MONTINI;MARIO PLEBANI;IAN K. HEWITT;PIETRO ZUCCHETTA;GINO GEROSA;PATRIZIA BURRA;UMBERTO CILLO;H. LEHMKUHL;LUIGI PAVANELLO;PIER PAOLO MOLINARI;FRANCESCA MASCHIO;ERMANNO ANCONA;MASSIMO RUGGE;MARIA CHIARA CORTI;DAVIDE D’AMICO;GIACOMO ZANUS;ROBERTO RAGAZZI;ACHILLE C. PESSINA;LORENZA CAREGARO;ALBERTO BROLESE","6;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","GIOVANNI MONTINI;MARIO PLEBANI;IAN K. HEWITT;PIERO MARSON;G STURNIOLO;ALESSANDRA ZAMPIERON;PIETRO ZUCCHETTA;GINO GEROSA;ERMANNO ANCONA;LORENZA CAREGARO;MASSIMO MICAGLIO;FRANCESCO FRANCINI‐PESENTI;FILIPPO BROCADELLO;ANGELO ROSOLEN;UMBERTO CILLO;R. NARDACCHIONE;H. LEHMKUHL;ENZO GIRALDI;GIORGIO SPREAFICO;GIACOMO ZANUS","2.73;1.27;0.73;0.67;0.5;0.5;0.43;0.4;0.38;0.37;0.37;0.37;0.37;0.37;0.35;0.33;0.3;0.29;0.29;0.26","ROBERTO RAGAZZI;PIETRO ZUCCHETTA;GIOVANNI MONTINI;IAN K. HEWITT;ANTONELLA TOFFOLO;CARLO CRIVELLARO;FRANCESCA MASCHIO;LUCA RIGON;LUIGI PAVANELLO;PIER PAOLO MOLINARI;PATRIZIA BURRA;A. BALDAN;A. SÉRGIO;ANNA GIACOMIN;CHIARA CRISTOFORI;FABIO FARINATI;G PIVETTA;LISA GIRARDI;ROMILDA CARDIN;UMBERTO CILLO","556;518;500;498;495;495;495;495;495;495;471;469;469;469;469;469;469;469;469;469","ROBERTO RAGAZZI;G PIVETTA;LIVIANA DA DALT;D MINUCCI;CARLO GIAQUINTO;ALBERTO RUOL;EMANUELA GUIRROLI;ERMANNO ANCONA;GIUSEPPE PORTALE;LISA ZANATTA;LOREDANA NICOLETTI;MARIO COSTANTINI;C. CAROLLO;MARIO PLEBANI;ACHILLE C. PESSINA;GIAN PAOLO ROSSI;GIOVANNI MONTINI;LISANNA TOMASI;FILIPPO BROCADELLO;FRANCESCO FRANCINI‐PESENTI","556;469;349;298;253;247;247;247;247;247;247;247;244;223;193;174;151;146;108;108","GINO GEROSA;GIOVANNI MONTINI;MARIO PLEBANI;ACHILLE C. PESSINA;CARLO GIAQUINTO;ENZO GIRALDI;FILIPPO BROCADELLO;FRANCESCO FRANCINI‐PESENTI;GIORGIO SPREAFICO;GIOVANNELLA BAGGIO;LISANNA TOMASI;LORENZA CAREGARO;MARIA CHIARA CORTI;MASSIMO MICAGLIO;MASSIMO RUGGE;PIERO MARSON;PIETRO ZUCCHETTA;RENZO MANARA;ROBERTO RAGAZZI;A NASO","4;4;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","MEDICINE;BIOLOGY;POLITICAL SCIENCE;PHYSICS;CHEMISTRY;ENGINEERING;BUSINESS;COMPUTER SCIENCE;ECONOMICS;PHILOSOPHY;PSYCHOLOGY;GEOGRAPHY;SOCIOLOGY","70;21;7;5;4;3;2;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;PATHOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;GENETICS;IMMUNOLOGY;ONCOLOGY;ANESTHESIA;MICROBIOLOGY;PEDIATRICS;ENDOCRINOLOGY;LAW;UROLOGY;INTENSIVE CARE MEDICINE;NURSING;OPTICS;CARDIOLOGY;PALEONTOLOGY;PHARMACOLOGY","51;23;20;20;10;9;8;8;8;7;7;7;6;6;5;4;4;4;3;3;3","DISEASE;TRANSPLANTATION;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;CANCER;GENE;POPULATION;ANTIBIOTICS;CHEMOTHERAPY;EVEROLIMUS;ADVERSE EFFECT;CLINICAL TRIAL;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;REGIMEN;CIRRHOSIS;COHORT;ENCEPHALOPATHY;HEPATOCELLULAR CARCINOMA;MYOCARDIAL INFARCTION;URINARY SYSTEM","11;9;8;7;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3","LIVER TRANSPLANTATION;AZATHIOPRINE;GENOTYPE;HEART TRANSPLANTATION;PLACEBO;TACROLIMUS;ALLELE;DIMERCAPTOSUCCINIC ACID;HAZARD RATIO;METASTASIS;MUTATION;NEUTROPENIA;PERCUTANEOUS CORONARY INTERVENTION;THIAMINE DEFICIENCY;TOLERABILITY;VARICES;ACHALASIA;ACUTE STROKE;AGE OF ONSET;ANDROGEN;ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION;ANTIBACTERIAL AGENT;ANTIBIOTIC PROPHYLAXIS;AUTOANTIBODY;AUTOIMMUNE DISEASE;AUTOIMMUNITY;BREAST CANCER;CALCINOSIS;CAUSE OF DEATH;CD19;CD34;CEPHALOSPORIN;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;CHROMOGRANIN A;CHRONIC HEPATITIS;CHRONIC LIVER DISEASE;CISPLATIN;CLINICAL ENDPOINT;COLORECTAL CANCER;CONTENT VALIDITY;CONVENTIONAL PCI;CROHN'S DISEASE;CRONBACH'S ALPHA;DARBEPOETIN ALFA;DNA REPAIR;EJECTION FRACTION;ENDOMYOCARDIAL BIOPSY;EPOETIN ALFA;ESOPHAGEAL DISEASE;ESSENTIAL HYPERTENSION;ETOPOSIDE;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;EXHALED BREATH CONDENSATE;EXPIRATION;FIBRINOLYTIC AGENT;FOCAL NODULAR HYPERPLASIA;GERIATRIC ONCOLOGY;GESTATIONAL AGE;GONORRHEA;GRAFT REJECTION;GRAVES' DISEASE;GROWTH HORMONE;HAEMATOPOIESIS;HEALTH CARE DELIVERY;HEALTH POLICY;HEPATECTOMY;HEPATITIS B VIRUS;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);HYPERALDOSTERONISM;HYPEREMESIS GRAVIDARUM;INCLUSION AND EXCLUSION CRITERIA;INFLAMMATORY BOWEL DISEASE;INFORMED CONSENT;INTERIM ANALYSIS;INTERNAL CONSISTENCY;INTIMA-MEDIA THICKNESS;INTRACLASS CORRELATION;ISCHAEMIC STROKE;JANUS KINASE 2;KIDNEY TRANSPLANTATION;LARYNGEAL MASK AIRWAY;LIPID PROFILE;LOCUS (GENETICS);LYMPHOBLASTIC LEUKEMIA;METABOLIC SYNDROME;MULTICENTER STUDY;MULTIVITAMIN;MYCOBACTERIUM TUBERCULOSIS;MYCOPHENOLIC ACID;NAPROXEN;NUCLEOSIDE ANALOGUE;OCCULT;OCCUPATIONAL HYGIENE;OCCUPATIONAL MEDICINE;OVERWEIGHT;PANCREATECTOMY;PANCREATIC FISTULA;PANCREATIC PSEUDOCYST;PANCREATICODUODENECTOMY;PHARMACOEPIDEMIOLOGY;PHASES OF CLINICAL RESEARCH;PRIMARY ALDOSTERONISM;PROGRESSIVE DISEASE;PROTEOMICS;PROTOCOL (SCIENCE);QUALITY ASSURANCE;REFLUX;RELIABILITY (SEMICONDUCTOR);RENIN–ANGIOTENSIN SYSTEM;SALMONELLA;SOMATIC CELL;STIMULUS ONSET ASYNCHRONY;SYPHILIS;TEMOZOLOMIDE;THROMBOLYSIS;THYROID DISEASE;TITER;TRANSAMINASE;TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS;UNSTABLE ANGINA;VASCULAR ENDOTHELIAL GROWTH FACTOR;VIRAL LOAD;VIRULENCE;VON HIPPEL–LINDAU DISEASE;WERNICKE ENCEPHALOPATHY","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DACLIZUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;WERNICKE'S ENCEPHALOPATHY;ADJUVANT CHEMOTHERAPY;ANTIRETROVIRAL THERAPY;BIOMARKER DISCOVERY;CAGA;CALCINOSIS CUTIS;CARBOPLATIN;CARDIAC ALLOGRAFT VASCULOPATHY;CEFIXIME;CERVICAL INTRAEPITHELIAL NEOPLASIA;COLPOSCOPY;CROSSOVER STUDY;FILGRASTIM;GENOTYPING;GERMLINE MUTATION;GROWTH HORMONE DEFICIENCY;HBSAG;IFOSFAMIDE;KIDNEY DONATION;LARYNGEAL MASKS;MACE;MULTICENTER TRIAL;MYOTOMY;NAPROXEN SODIUM;NATIONAL CHOLESTEROL EDUCATION PROGRAM;NUCLEOTIDE EXCISION REPAIR;OCCUPATIONAL HEALTH NURSING;OXALIPLATIN;PAPILLOMAVIRIDAE;PLASMA RENIN ACTIVITY;PROTEIN SYNTHESIS INHIBITOR;SEXUALLY TRANSMITTED DISEASE;SHIGELLA","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;;ADOLESCENT;TREATMENT OUTCOME;CHILD;RETROSPECTIVE STUDIES;AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION;BIOMARKERS;CHILD, PRESCHOOL;MAGNETIC RESONANCE IMAGING;POSTOPERATIVE COMPLICATIONS;AGED, 80 AND OVER;LIVER NEOPLASMS;PROSPECTIVE STUDIES","55;45;44;30;27;26;21;16;11;11;9;9;8;8;8;8;8;7;7;7","PEDIATRIC URINARY TRACT INFECTIONS;ORGAN TRANSPLANTATION AND REJECTION;DIAGNOSIS AND MANAGEMENT OF WERNICKE-KORSAKOFF SYNDROME;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;KIDNEY TRANSPLANTATION;MANAGEMENT AND TREATMENT OF CHRONIC VENOUS DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ASTHMA;CANCER OF UNKNOWN PRIMARY SITE;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CLINICAL SIGNIFICANCE OF POLICOSANOL IN LIPID MANAGEMENT;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;COLORECTAL CANCER RESEARCH AND TREATMENT;COPPER AND ZINC IN HEALTH AND DISEASE;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD","5;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;EVEROLIMUS;REGIMEN;DACLIZUMAB;TACROLIMUS PHARMACOGENETICS;CANCER RISK;CONCOMITANT;DIMERCAPTOSUCCINIC ACID;FEBRILE INFANTS;HEART TRANSPLANT;IMMUNOSUPPRESSION;INTERLEUKIN-1 POLYMORPHISMS;LIVER TRANSPLANTATION;METABOLIC SYNDROME;POSTOPERATIVE PAIN;RENAL SCARRING;TOLERABILITY;URINARY TRACT INFECTIONS;VARICOSE VEINS;WERNICKE-KORSAKOFF SYNDROME","6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DE NOVO;MULTICENTER RANDOMIZED;RANDOMIZED TRIAL;DACLIZUMAB INDUCTION;LIVER TRANSPLANTATION;TACROLIMUS MONOTHERAPY;TRANSPLANT RECIPIENTS;VERSUS MMF;ACUTE PYELONEPHRITIS;ANTIBIOTIC TREATMENT;CARDIAC TRANSPLANT;CHILDREN FAILS;CONTROLLED TRIAL;CROHNS DISEASE;EVEROLIMUS VERSUS;HEART TRANSPLANT;INFECTION STUDY;ITALIAN PATIENTS;ITALIAN RENAL;METABOLIC SYNDROME;MONTH MULTICENTER;NATURAL HISTORY;NOVO CARDIAC;NOVO HEART;PATIENT OUTCOMES;RANDOMIZED CONTROLLED;RECENT ADVANCES;RECURRENT VARICES;REDUCE RENAL;RENAL INFECTION","4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EBC PH;HEALTHY SUBJECTS;SUBOPTIMAL LIVERS;CARDIOVASCULAR MORTALITY;HPV TESTING;INCREASED RISK;METABOLIC SYNDROME;RELATIVE SENSITIVITY;ALL-CAUSE MORTALITY;CONVENTIONAL CYTOLOGY;DNA REPAIR;HDL CHOLESTEROL;HPV DNA;INTRAVENOUS RT-PA;LOW HDL;NON-CARDIA GC;WOMEN AGED;ADVERSE EVENTS;AUTHOR INFORMATION;CONFIDENCE INTERVAL;DI CHIRURGIA;DOSE INTENSITY;GC RISK;HP NON-CARDIA;HYPERTENSIVE PATIENTS;IMAGING FINDINGS;INTERVAL CI;ISCHAEMIC STROKE;MACHINE PERFUSION;MAMILLARY BODIES","11;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3",14,0.19,9,2.75,1,1,0,3.5,2,0,1.25,3,0,1,1,0,1,0,0,1,0,1,0,81.75,81.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,5.24,376.24,14.75,5,0.28,34.44,0,0,5,3,5,0,3,2,0,16,1,0,0,0,0,0,0,17,1,0,17,1,0,0,0,0,0,0,0,0,"Italy;United States","5;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;4204 MIDWIFERY","18;11;6;3;3;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;DIGESTIVE DISEASES;PEDIATRIC;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;INFANT MORTALITY;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;PREVENTION;BIOMEDICAL IMAGING;HEMATOLOGY;KIDNEY DISEASE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;ANTIMICROBIAL RESISTANCE;BREAST CANCER","17;12;7;6;4;4;4;3;3;3;3;3;3;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;RENAL AND UROGENITAL;INFECTION;RESPIRATORY","6;3;3;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.3 MANAGEMENT AND DECISION MAKING;5.1 PHARMACEUTICALS;6.4 SURGERY;6.7 PHYSICAL","14;2;2;1;1;1","BREAST CANCER;CERVICAL CANCER;HEAD AND NECK CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SARCOMA","1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","4;1;1",2,1650000,205555.56,4.5,7,6,1,7,260560.089544513,0.276327814155512,"AZIENDA OSPEDALIERA DI PADOVA;CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE;ERASMUS MC;HOSPITAL DEL MAR MEDICAL RESEARCH INSTITUTE;LJUBLJANA UNIVERSITY MEDICAL CENTRE;MCGILL UNIVERSITY HEALTH CENTRE;RTI INTERNATIONAL;UNIVERSITY MEDICAL CENTER HAMBURG-EPPENDORF;UNIVERSITY OF BORDEAUX;UNIVERSITY OF BREMEN;UNIVERSITY OF GOTHENBURG;UNIVERSITY OF MILANO-BICOCCA;UNIVERSITY OF NOTTINGHAM","2;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);CSA-SA - SUPPORT ACTIONS (FUNDING SCHEME);FP7-HEALTH-2007-A (CALL FOR PROPOSAL);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","2;1;1;1;1","42 HEALTH SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;1;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;PATIENT SAFETY","1;1;1;1;1","CARDIOVASCULAR","1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,"A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2009,66,8.45454545454546,3.46969696969697,0.439393939393939,0.424242424242424,0.454545454545455,1.30857142857143,1.07407407407407,1.4,1.07142857142857,0.363636363636364,1,32,14,7,4,0.48,0.21,0.11,0.06,33.74,0.729452021142207,NA,0.272727272727273,0.863636363636364,0.391,0.349,0.319,0.346,"UMBERTO CILLO;PAOLO RIGOTTI;ALESSANDRO VITALE;FABIO FARINATI;ENRICO GRINGERI;PATRIZIA BURRA;F. D’AMICO;MICHELE VALMASONI;GIOVANNI MONTINI;LUCREZIA FURIAN;RICCARDO CUSINATO;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;ADRIANA CECI;OSCAR DELLA PASQUA;LUISA BARZON;F. DʼAMICO;GIORGIO PALÙ;PAOLO BERNANTE","6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","PAOLO RIGOTTI;GIOVANNI MONTINI;LUCIO PINELLO;UMBERTO CILLO;ALESSANDRO VITALE;LUCREZIA FURIAN;IAN K. HEWITT;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;CARLO MENGOLI;SILVIU ALBU;G BABIGHIAN;CRISTINA SILVESTRE;PAOLO BERNANTE;ADRIANA CECI;OSCAR DELLA PASQUA;PATRIZIA BURRA;STEFANO MASIERO;CLAUDIO FERRARO","1.32;1.04;1;0.98;0.84;0.75;0.56;0.51;0.51;0.51;0.5;0.5;0.5;0.5;0.45;0.44;0.44;0.4;0.39;0.39","UMBERTO CILLO;PAOLO RIGOTTI;ALESSANDRO VITALE;ENRICO GRINGERI;F. D’AMICO;MICHELE VALMASONI;GIOVANNI MONTINI;LUCREZIA FURIAN;RICCARDO CUSINATO;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;LUISA BARZON;F. DʼAMICO;GIORGIO PALÙ;PAOLO BERNANTE;LAURA SQUARZON;FRANCESCO MARCHINI;MATTEO MARTINATO;CARLO MENGOLI","6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2","PAOLO RIGOTTI;GIOVANNI MONTINI;LUCIO PINELLO;UMBERTO CILLO;ALESSANDRO VITALE;LUCREZIA FURIAN;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;CARLO MENGOLI;G BABIGHIAN;PAOLO BERNANTE;STEFANO MASIERO;CLAUDIO FERRARO;F. D’AMICO;LUCA BUSETTO;SILVIA GIROTTO;ENRICO GRINGERI;MICHELE VALMASONI;SARA BOZZETTO","1.32;1.04;1;0.98;0.84;0.75;0.51;0.51;0.51;0.5;0.5;0.45;0.39;0.39;0.37;0.35;0.34;0.34;0.34;0.33","ALICE FAVARETTO;FEDERICA AGOSTA;FRANCESCA RINALDI;I. MATTISI;L. BARACHINO;LUCIANO RINALDI;MASSIMILIANO CALABRESE;MASSIMO FILIPPI;MATTEO ATZORI;PAOLA GROSSI;PAOLA PERINI;PAOLO GALLO;VALENTINA BERNARDI;GIOVANNI MONTINI;PIETRO ZUCCHETTA;GIORGIO PALÙ;LUISA BARZON;JUAN PEDRO KUSANOVIC;MARIA TERESA GERVASI;OFFER EREZ","518;518;518;518;518;518;518;518;518;518;518;518;518;243;198;195;195;188;188;188","ALICE FAVARETTO;FRANCESCA RINALDI;I. MATTISI;LUCIANO RINALDI;MATTEO ATZORI;PAOLA GROSSI;PAOLA PERINI;PAOLO GALLO;VALENTINA BERNARDI;GIORGIO PALÙ;LUISA BARZON;MARIA TERESA GERVASI;RICCARDO CUSINATO;PAOLO RIGOTTI;WAIFRO RIGAMONTI;ELISA FRANCHIN;LAURA SQUARZON;MARGHERITA CATTAI;SILVANA PAGNI;GIOVANNELLA BAGGIO","518;518;518;518;518;518;518;518;518;195;195;188;183;122;122;119;119;119;119;102","UMBERTO CILLO;ENRICO GRINGERI;F. D’AMICO;MICHELE VALMASONI;F. DʼAMICO;GIORGIO PALÙ;LUISA BARZON;NICOLETTA DOGLIONI;RICCARDO CUSINATO;VINCENZO ZANARDO;ALESSANDRO VITALE;ANGELO ROSOLEN;CARLO GIAQUINTO;CARLO MENGOLI;DANIELA BASSI;DANIELE TREVISANUTO;ELISA FRANCHIN;FRANCESCO MARCHINI;GIOVANNELLA BAGGIO;GIOVANNI MONTINI","6;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;ECONOMICS;CHEMISTRY;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;COMPUTER SCIENCE;GEOGRAPHY;PSYCHOLOGY;HISTORY","64;18;7;4;3;3;3;3;3;2;2;2;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;GENETICS;PATHOLOGY;UROLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ONCOLOGY;OPTICS;VIROLOGY;FAMILY MEDICINE;PEDIATRICS;PHARMACOLOGY;CANCER RESEARCH;CARDIOLOGY;DEMOGRAPHY;LINGUISTICS;MICROBIOLOGY;MOLECULAR BIOLOGY;PALEONTOLOGY;PHYSICAL THERAPY;PSYCHIATRY;RADIOLOGY","44;21;15;12;10;10;8;7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3","TRANSPLANTATION;KIDNEY;ANTIBODY;CANCER;DISEASE;HEPATOCELLULAR CARCINOMA;PROSPECTIVE COHORT STUDY;GENE;INCIDENCE (GEOMETRY);POPULATION;PREGNANCY;CHEMOTHERAPY;CLINICAL TRIAL;REGIMEN;COMPLICATION;LYMPHOMA;NEPHROLOGY;OBESITY;RENAL FUNCTION;VIRUS","13;7;6;6;6;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3","LIVER TRANSPLANTATION;KIDNEY TRANSPLANTATION;FETUS;WEIGHT LOSS;WEST NILE VIRUS;BREAST CANCER;CALCINEURIN;CLINICAL ENDPOINT;CROHN'S DISEASE;DIMERCAPTOSUCCINIC ACID;IMMUNOPHENOTYPING;INFLAMMATORY BOWEL DISEASE;INFLIXIMAB;LIVER CANCER;MAINTENANCE THERAPY;NEPHRECTOMY;PLASMAPHERESIS;POLYMERASE CHAIN REACTION;TACROLIMUS;WAITING LIST","7;6;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CHORIOAMNIONITIS;KIDNEY TRANSPLANT;MILAN CRITERIA;AMNION;AMNIOTIC FLUID;AMPLICON;ANAPLASTIC LYMPHOMA KINASE;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;AXILLARY LYMPH NODES;BRAIN METASTASIS;BREAST CARCINOMA;CD99;CELL CYCLE CHECKPOINT;CETUXIMAB;CYCLIN-DEPENDENT KINASE;CYCLIN-DEPENDENT KINASE 2;ESOPHAGECTOMY;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GASTRIC BYPASS;GLOMERULOSCLEROSIS;HIV-1 PROTEASE;HYPERTRIGLYCERIDEMIA;INCUS;INFLAMMATORY BOWEL DISEASES;LDL APHERESIS;LIVING DONOR LIVER TRANSPLANTATION;LOW CALORIE DIET;MODEL FOR END-STAGE LIVER DISEASE;MORBID OBESITY;OVAL WINDOW;OXALIPLATIN;PHARMACOGENETICS;PROTEIN SYNTHESIS INHIBITOR;SENTINEL LYMPH NODE;SEROPREVALENCE;SMALL FOR GESTATIONAL AGE;SUICIDAL IDEATION;TAQMAN;TAXANE;TRAMP;VERY LOW CALORIE DIET;VESICOURETERAL REFLUX;VON WILLEBRAND DISEASE;WEIGHT CHANGE;WHOLE GENOME SEQUENCING;XANTHOGRANULOMATOUS PYELONEPHRITIS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;AGED;GRAFT REJECTION;IMMUNOSUPPRESSIVE AGENTS;ITALY;CHILD;YOUNG ADULT;ADOLESCENT;KIDNEY DISEASES;WEST NILE FEVER;BIOMARKERS;CHILD, PRESCHOOL;INFANT, NEWBORN;KIDNEY TRANSPLANTATION;TIME FACTORS","43;28;25;23;18;16;15;13;12;12;11;11;9;9;9;8;8;8;8;8","LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;GLOBAL IMPACT OF ARBOVIRAL DISEASES;KIDNEY TRANSPLANTATION;PEDIATRIC URINARY TRACT INFECTIONS;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;EPIDEMIOLOGY AND CAUSES OF PRETERM BIRTH;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;ROLE OF OSTEOPONTIN IN BIOMINERALIZATION AND INFLAMMATION;ANORECTAL SURGICAL PROCEDURES;ATRIAL FIBRILLATION;BODY COMPOSITION ASSESSMENT AND ANALYSIS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT;CHROMATIN REMODELING IN CANCER AND DEVELOPMENT;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DEVELOPMENTAL PERSPECTIVE ON MOTOR SKILL COMPETENCE;DIAGNOSIS AND MANAGEMENT OF OTITIS MEDIA;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS","4;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","LIVING DONOR LIVER TRANSPLANTATION;LIVER TRANSPLANTATION;REGIMEN;KIDNEY TRANSPLANTATION;LIVER CANCER;NEPHROLOGY;RENAL SCARRING;TREATMENT;WEST NILE VIRUS;CHORIOAMNIONITIS;CLINICAL ENDPOINT;DIMERCAPTOSUCCINIC ACID;IMMUNOPHENOTYPING;LIVER DISEASE;MAINTENANCE THERAPY;MILAN CRITERIA;ORGAN DONATION;OSTEOPONTIN;PEDIATRIC PHARMACOKINETICS;PLASMAPHERESIS","7;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;HEPATOCELLULAR CARCINOMA;NILE VIRUS;WEST NILE;DE NOVO;DUAL KIDNEY;KIDNEY TRANSPLANT;KIDNEY TRANSPLANTATION;PEDIATRIC PATIENTS;RENAL SCARRING;TRANSPLANT RECIPIENTS;ACUTE REJECTION;ADJUVANT TREATMENT;ADVANCED ESOPHAGEAL;ADVANCED HIV;AGE CORRELATION;ALLOCATION MODEL;ANGIOGENIC SWITCH;ANKYLOSING SPONDYLITIS;ANTIRETROVIRAL RESISTANCE;ANTITNFΑ THERAPY;ARTERIAL WALL;ARTHROSCOPY RECENT;ATRIAL FIBRILLATION;AUGUST SEPTEMBER;B-ALL MRD;BARIATRIC SURGERY;BIOELECTRICAL IMPEDANCE;BLEEDING SEVERITY;BLOOD PRESSURE","6;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TACROLIMUS BID;TACROLIMUS QD;REAL-TIME PCR;WEST NILE;ACUTE REJECTIONS;CD CD;COGNITIVE IMPAIRMENT;COGNITIVELY IMPAIRED;GRAY MATTER;INFLIXIMAB TREATMENT;LISTERIA MONOCYTOGENES;VENETO REGION;ACUTE CHORIOAMNIONITIS;ACUTE REJECTION;CELL LYMPHOMA;CHLAMYDIA TRACHOMATIS;CROHNS DISEASE;EXPERIMENTAL ARM;KIDNEY TRANSPLANT;LIVER CANCER;LYMPHOMA CELLS;MATTER VOLUME;MECHANICAL VENTILATION;NEOCORTICAL GRAY;NEUROINVASIVE DISEASE;NORMALIZED NEOCORTICAL;OXIDATIVE BURST;PATIENTS RECEIVED;PRIMARY LIVER;RENAL FUNCTION","6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",12,0.18,3.9,1.25,0,1,0,0,3,0,1,1.25,0,1,1,0,1,0,1,2,0,0,0,81.25,81.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,5.75,699.31,8.82,1,0.07,20.6,1,0,6,0,6,0,0,2,0,12,1,0,0,0,0,0,0,14,1,0,13,2,0,0,0,0,0,0,0,0,"Italy;United States;Switzerland;United Kingdom","4;4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3206 MEDICAL BIOTECHNOLOGY;3207 MEDICAL MICROBIOLOGY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","15;10;4;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PEDIATRIC;CANCER;DIGESTIVE DISEASES;INFECTIOUS DISEASES;PREVENTION;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;CARDIOVASCULAR;LIVER DISEASE;PATIENT SAFETY;STEM CELL RESEARCH;CHRONIC PAIN;COLO-RECTAL CANCER;CONGENITAL STRUCTURAL ANOMALIES;CROHN'S DISEASE;HEART DISEASE;HEMATOLOGY","13;9;6;5;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;INFECTION;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;BLOOD;MUSCULOSKELETAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","3;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;3.3 NUTRITION AND CHEMOPREVENTION;3.4 VACCINES;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES","10;2;2;1;1;1;1","BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;COLON AND RECTAL CANCER;LIVER CANCER;LUNG CANCER;NERVOUS SYSTEM;SARCOMA","2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","3;2;1;1",1,1997862,199786.2,5,10,5,1,5,300517.329544513,0.219621278080817,"AIX-MARSEILLE UNIVERSITY;AZIENDA OSPEDALIERA DI PADOVA;CANCER RESEARCH UK;FEDERACIÓN ESPAÑOLA DE PADRES DE NIÑOS CON CÁNCER;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;NEWCASTLE UNIVERSITY;ROYAL MARSDEN HOSPITAL;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF LEICESTER;UNIVERSITY OF MÜNSTER","1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","CANCER;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE","1;1;1;1","CANCER","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1","BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;NERVOUS SYSTEM;NEUROBLASTOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","1;1;1;1;1;1","5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2010,67,11.3432835820896,2.40298507462687,0.253731343283582,0.283582089552239,0.283582089552239,1.29032258064516,1,1.05555555555556,1,0.388059701492537,1,34,18,3,6,0.51,0.27,0.04,0.09,58.94,1.30426032901131,NA,0.388059701492537,0.895522388059702,0.366,0.272,0.325,0.261,"ROBERTO ROMERO;SHALI MAZAKI‐TOVI;JUAN PEDRO KUSANOVIC;EDI VAISBUCH;TINNAKORN CHAIWORAPONGSA;MATTEO FASSAN;MARIA TERESA GERVASI;MASSIMO RUGGE;LUCIANO GIACOMELLI;MARIO PLEBANI;PATRIZIA BURRA;UMBERTO CILLO;FABLE ZUSTOVICH;RENZO MANARA;SONIA S. HASSAN;CORRADO NEGRO;M BACIS;FRANCESCA TONELLI;LORRAYNE BELOTTI;DANIELE TREVISANUTO","7;7;6;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3","CARLO GIAQUINTO;MATTEO FASSAN;MARIO PLEBANI;ROBERTO ROMERO;SHALI MAZAKI‐TOVI;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;MASSIMO RUGGE;LUCIANO GIACOMELLI;A UDILANO;JUAN PEDRO KUSANOVIC;EDI VAISBUCH;RENZO MANARA;FABLE ZUSTOVICH;TINNAKORN CHAIWORAPONGSA;MARIA TERESA GERVASI;MARCO PIZZI;ALESSANDRO DELLA PUPPA;RENATO SCIENZA","1;0.66;0.58;0.57;0.57;0.5;0.5;0.5;0.49;0.49;0.48;0.47;0.47;0.47;0.42;0.4;0.4;0.38;0.37;0.37","MARIA TERESA GERVASI;LUCIANO GIACOMELLI;MARIO PLEBANI;PATRIZIA BURRA;UMBERTO CILLO;RENZO MANARA;DANIELE TREVISANUTO;A UDILANO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;ALESSANDRO DELLA PUPPA;RENATO SCIENZA;R POLATO;PAOLO ANGELI;A NASO;GIACOMO ZANUS;FRANCESCO PAOLO RUSSO;LUISA MURER;ALBERTO BROLESE;MARINA GARDIMAN","5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","CARLO GIAQUINTO;MARIO PLEBANI;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;LUCIANO GIACOMELLI;A UDILANO;RENZO MANARA;MARIA TERESA GERVASI;ALESSANDRO DELLA PUPPA;RENATO SCIENZA;MARCO CASTAGNETTI;BRUNO AZZENA;FRANCESCO CAVALLIN;ILARIA DE BARBIERI;EVISA ZHAPA;CRISTINA ZAGGIA;A. AMABILE;CESARE TIENGO;WAIFRO RIGAMONTI","1;0.58;0.5;0.5;0.5;0.49;0.48;0.47;0.4;0.37;0.37;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","GIANCARLO COMI;MARIA PIA SORMANI;MASSIMILIANO CALABRESE;MASSIMO FILIPPI;ROBERTO ROMERO;SHALI MAZAKI‐TOVI;MATTEO FASSAN;MARIO PLEBANI;ARTHUR S. SLUTSKY;CLAUDIA FILIPPINI;DANIELA PASERO;ELISABETH ZAVALA;ERICA L. MARTIN;FRANÇESCO DELLA CORTE;G. CORNARA;ILARIA MASTROMAURO;LUCIANA MASCIA;M.J. ARGUÍS;MARINA MUNARI;MAURIZIO BERARDINO","482;482;482;482;452;452;372;354;321;321;321;321;321;321;321;321;321;321;321;321","MASSIMILIANO CALABRESE;MARINA MUNARI;LUCIANO GIACOMELLI;UMBERTO CILLO;MARIA TERESA GERVASI;LUISA MURER;MARIA-TERESA GERVASI;ALBERTO BURLINA;FRANCESCA RINALDI;P. PERINI;PAOLO GALLO;PAOLO RIGOTTI;FLAVIA BORTOLOTTI;LUCIA ZANCAN;MARINA GARDIMAN;MARIO PLEBANI;RENATO SCIENZA;ALBERTO BROLESE;F. D’AMICO;GIACOMO ZANUS","482;321;298;293;237;228;215;206;167;167;167;164;145;145;145;124;113;112;112;112","MARIA TERESA GERVASI;LUCIANO GIACOMELLI;UMBERTO CILLO;A UDILANO;MARIO PLEBANI;R POLATO;RENATO SCIENZA;RENZO MANARA;A NASO;ALBERTO BROLESE;ALESSANDRO DELLA PUPPA;DANIELE TREVISANUTO;F. D’AMICO;GIACOMO ZANUS;LUISA MURER;MARIA-TERESA GERVASI;MARINA GARDIMAN;MARTINA ZANINOTTO;MASSIMILIANO CALABRESE;MAURO BUTTARELLO","5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;POLITICAL SCIENCE;PHYSICS;BUSINESS;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;ENGINEERING;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","64;23;9;7;6;5;5;5;5;4;3;1;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;PATHOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PSYCHIATRY;LAW;RADIOLOGY;QUANTUM MECHANICS;CANCER RESEARCH;FAMILY MEDICINE;MEDICAL EMERGENCY;AUDIOLOGY;CARDIOLOGY;GYNECOLOGY;NUCLEAR MEDICINE;OBSTETRICS;UROLOGY","38;17;16;12;10;10;9;9;8;7;7;6;6;5;4;4;4;3;3;3;3;3;3","PREGNANCY;TRANSPLANTATION;GENE;CANCER;POPULATION;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;CONFIDENCE INTERVAL;HEALTH CARE;HEPATOCELLULAR CARCINOMA;INFLAMMATION;INTERQUARTILE RANGE;LESION;LUNG;MAGNETIC RESONANCE IMAGING;ALTERNATIVE MEDICINE;ANTIGEN;APOPTOSIS;CREATININE;DISEASE;DYSPLASIA;ENZYME;FOCUS GROUP;GRADING (ENGINEERING);HEARING LOSS;HEART FAILURE;HEMODIALYSIS;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;MALIGNANCY;MEMBRANE;MULTIPLE SCLEROSIS;OBESITY;OBSERVATIONAL STUDY;OCCUPATIONAL SAFETY AND HEALTH;PHARMACOKINETICS;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;PULMONARY SURFACTANT;QUALITY (PHILOSOPHY);RECEIVER OPERATING CHARACTERISTIC;RENAL FUNCTION;RISK ASSESSMENT;SPINAL CORD;SURGICAL ONCOLOGY;TEMPORAL BONE;THROMBOSIS;TINNITUS;TOXICITY;VIRUS","11;9;8;7;5;5;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;FETUS;GESTATION;GESTATIONAL AGE;KIDNEY TRANSPLANTATION;ADENOCARCINOMA;AUDIOGRAM;CARCINOGENESIS;CHROMOSOME;CLINICAL ENDPOINT;ESCHERICHIA COLI;FACIAL CANAL;HAZARD RATIO;IMMUNOSTAINING;INFERTILITY;INSULIN RESISTANCE;INTESTINAL METAPLASIA;PREECLAMPSIA;TACROLIMUS;WHITE MATTER","5;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADIPOKINE;AMNIOTIC FLUID;ALCOHOL INTOXICATION;ANEUPLOIDY;ATROPHIC GASTRITIS;BARRETT'S ESOPHAGUS;BLOOD ALCOHOL;CHROMOSOME 17 (HUMAN);COMPARATIVE GENOMIC HYBRIDIZATION;CONGENITAL DIAPHRAGMATIC HERNIA;CYTOGENETICS;DACLIZUMAB;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA MICROARRAY;ENTEROBACTERIACEAE;FERTILITY PRESERVATION;FLUORESCENCE IN SITU HYBRIDIZATION;GENE EXPRESSION PROFILING;GESTATIONAL HYPERTENSION;GLYCATED HEMOGLOBIN;HBSAG;HEME OXYGENASE;HFR CELL;HOMOVANILLIC ACID;HYDROSALPINX;INJURY SEVERITY SCORE;INTEGRON;INTRAEPITHELIAL NEOPLASIA;IRINOTECAN;ISCHEMIA-MODIFIED ALBUMIN;KIDNEY DEVELOPMENT;KLEBSIELLA PNEUMONIAE;LYMPHOBLASTIC LYMPHOMA;MAMMOGRAPHY;MICROARRAY;MILAN CRITERIA;MULTICENTER TRIAL;OLIGODENDROGLIOMA;PANCREAS TRANSPLANTATION;PHOSPHATIDYLCHOLINE;PLACENTAL GROWTH FACTOR;PLASMA RENIN ACTIVITY;POST-THROMBOTIC SYNDROME;PREMATURE RUPTURE OF MEMBRANES;PRENATAL DIAGNOSIS;PRETERM LABOR;RETICULOCYTE;RETINOL BINDING PROTEIN;RIBAVIRIN;SMALL FOR GESTATIONAL AGE;SOMATOSTATIN RECEPTOR 2;TAQMAN;TRANSFERRIN SATURATION;TRANSPOSABLE ELEMENT;UTERINE ARTERY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MALE;MIDDLE AGED;AGED;RETROSPECTIVE STUDIES;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;YOUNG ADULT;ADOLESCENT;ITALY;MAGNETIC RESONANCE IMAGING;PREGNANCY;TREATMENT OUTCOME;;IMMUNOSUPPRESSIVE AGENTS;LIVER TRANSPLANTATION;PROSPECTIVE STUDIES;ADENOCARCINOMA","57;40;31;28;24;17;13;11;11;11;10;10;9;9;9;8;8;8;8;7","PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;GLIOMAS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;ADVANCES IN ULTRASOUND ELASTOGRAPHY IMAGING TECHNIQUES;AMINO ACID TRANSPORT AND METABOLISM IN HEALTH AND DISEASE;CARDIOTOXICITY OF CANCER TREATMENTS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EBOLA VIRUS RESEARCH AND OUTBREAKS;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EPIDEMIOLOGY AND CAUSES OF PRETERM BIRTH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTERQUARTILE RANGE;LIVER TRANSPLANTATION;TREATMENT;AUDIOGRAM;CLINICAL ENDPOINT;FACIAL CANAL;GRADING (ENGINEERING);HEPATOCELLULAR CARCINOMA;IMMUNOSTAINING;INTESTINAL METAPLASIA;LIVING DONOR LIVER TRANSPLANTATION;MATERNAL-FETAL TOLERANCE;PREECLAMPSIA;PRETERM INFANTS;SURGICAL ONCOLOGY;TACROLIMUS PHARMACOGENETICS;ABBREVIATED INJURY SCALE;ADRENAL VEIN SAMPLING;ALCOHOL INTOXICATION;ALDOSTERONE","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","LIVER TRANSPLANTATION;HEPATOCELLULAR CARCINOMA;AMNIOTIC CAVITY;BARRETTS CARCINOGENESIS;CLINICAL OUTCOME;DE NOVO;HEALTH WORKERS;MICROBIAL INVASION;PATIENTS UNDERGOING;RENAL TRANSPLANTATION;RISK ASSESSMENT;UNIVERSITY HOSPITAL;ACELLULAR DERMAL;ACID DECARBOXYLASE;ACUTE PYELONEPHRITIS;ADVAGRAF VERSUS;AFFECT CLINICAL;AGENTS RESULTS;ALCOHOL CONSUMPTION;ALDOSTERONE-PRODUCING ADENOMA;ALDOSTERONERENIN RATIO;ANTI INFLUENZA;ANTI-ANGIOGENIC FACTORS;AROMATIC L-AMINO;ARTERY NOTCHING;ARTICLE HYPERRESISTINEMIA;ASC-US RESULTS;ASPIRATION CYTOLOGY;ASSESSING BRAIN;ATROPHY RATES","4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FETAL DEATH;MATERNAL PLASMA;CRITICAL VALUES;BILATERAL UTERINE;VENTILATORY STRATEGY;ARTERY NOTCHING;B-CELL LYMPHOMA;GESTATIONAL HYPERTENSION;GRAY ZONE;MEDIASTINAL GRAY;NORMAL PREGNANCY;PATIENTS UNDERGOING;PLASMA CONCENTRATIONS;PREGNANT WOMEN;PRIMARY MEDIASTINAL;PROTECTIVE STRATEGY;UTERINE ARTERY;VIRAL INFECTION;EARLY-ONSET PREECLAMPSIA;FRESH CYCLES;MG KG;OOCYTE CRYOPRESERVATION;PLASMA RESISTIN;PRE-TERM LABOR;PUBERTAL CHILDREN;RESISTIN CONCENTRATION;SIGNIFICANTLY LOWER;STEROID WITHDRAWAL;TACROLIMUS MMF;BAC SAMPLES","12;8;7;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3",12,0.18,7,2.25,1,1.75,0,1,1.75,0,1.25,3.25,0,0,3.25,1,0,1,1,2.5,1,0,0,67.5,67.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3.95,606.32,21.55,2,0.08,28.44,0,0,8,0,4,0,5,8,0,17,5,0,0,0,0,0,0,23,0,2,21,3,0,0,0,1,0,0,0,0,"Italy;United States;Belgium;Netherlands","4;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3213 PAEDIATRICS;39 EDUCATION;3904 SPECIALIST STUDIES IN EDUCATION;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","24;15;3;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;BIOMEDICAL IMAGING;DIGESTIVE DISEASES;GENETICS;LUNG;PEDIATRIC;PREVENTION;RARE DISEASES;AGING;ASSISTIVE TECHNOLOGY;BIOENGINEERING;CHRONIC PAIN;DIABETES;EMERGING INFECTIOUS DISEASES;HEART DISEASE;LIVER DISEASE;NEUROSCIENCES;PAIN RESEARCH","18;11;6;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CARDIOVASCULAR;METABOLIC AND ENDOCRINE;RESPIRATORY;ORAL AND GASTROINTESTINAL;BLOOD;CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;NEUROLOGICAL;RENAL AND UROGENITAL","4;3;3;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.7 PHYSICAL","8;3;1;1;1;1","LIVER CANCER;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER;THYROID CANCER","3;1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2011,86,9.48837209302326,2.40697674418605,0.290697674418605,0.313953488372093,0.383720930232558,1.19883040935673,1.38888888888889,1.22727272727273,1.83333333333333,0.569767441860465,5,33,20,28,3,0.38,0.23,0.33,0.03,32.71,0.769010242072521,NA,0.255813953488372,0.837209302325581,0.557,0.49,0.451,0.49,"PIERO MARSON;G PASERO;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;GIORGIO PALÙ;MARIO PLEBANI;LEONARDO PUNZI;R. D’INCÀ;MARCO GERVASI;V A POTAPOV;PRADEEP SAMBAREY;L. MAZHEIKA;MASSIMO RUGGE;GIOVANNI CECCHETTO;MARIA CHIARA CORTI;HARISH M. SEHDEV;JAYA VIJAYARAGHAVAN;ESTELLA MUSACCHIO;A NASO","17;11;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PIERO MARSON;G PASERO;MARIO PLEBANI;LUCA GUARDA‐NARDINI;G BABIGHIAN;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;GIORGIO PALÙ;SILVIU ALBU;LEONARDO PUNZI;RITA ALAGGIO;ANDREA FERRARI;ALESSANDRA BUJA;ANTONIETTA CAVALLARO;CRISTINA BERGO;SARA N. RICHTER;ILARIA FRASSON;GIOVANNI PUTOTO;R RONDINONE","9.08;5.17;1.32;1;0.75;0.62;0.62;0.62;0.57;0.5;0.46;0.4;0.4;0.38;0.37;0.37;0.37;0.37;0.33;0.33","PIERO MARSON;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;GIORGIO PALÙ;MARIO PLEBANI;LEONARDO PUNZI;R. D’INCÀ;MARCO GERVASI;V A POTAPOV;PRADEEP SAMBAREY;L. MAZHEIKA;MASSIMO RUGGE;GIOVANNI CECCHETTO;MARIA CHIARA CORTI;HARISH M. SEHDEV;JAYA VIJAYARAGHAVAN;A NASO;JONATHAN A. PHILLIPS;SHALINI FUSEY","17;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","PIERO MARSON;MARIO PLEBANI;LUCA GUARDA‐NARDINI;G BABIGHIAN;DANIELE TREVISANUTO;NICOLETTA DOGLIONI;VINCENZO ZANARDO;GIORGIO PALÙ;LEONARDO PUNZI;RITA ALAGGIO;ANTONIETTA CAVALLARO;CRISTINA BERGO;SARA N. RICHTER;GIOVANNI PUTOTO;MATTEO PAROTTO;ELISA ROSSATO;ALBERTO CARRARO;PIERANTONIO OSTUNI;ROMEO BARDINI;FILIPPO MARZOT","9.08;1.32;1;0.75;0.62;0.62;0.62;0.57;0.46;0.4;0.37;0.37;0.37;0.33;0.33;0.33;0.33;0.32;0.28;0.25","MARCO GERVASI;A. CONDE‐AGUDELO;ASHLESHA K. DAYAL;BONNIE J. DATTEL;D. MANCHULENKO;D. VIDYADHARI;GEORGE W. CREASY;HARISH M. SEHDEV;JASON K. BAXTER;JAYA VIJAYARAGHAVAN;JOHN O’BRIEN;JONATHAN A. PHILLIPS;L. MAZHEIKA;LISA SULLIVAN;MEENA KHANDELWAL;PRADEEP SAMBAREY;PRIYA SOMA‐PILLAY;ROBERTO ROMERO;SHALINI FUSEY;SONIA S. HASSAN","866;865;865;865;865;865;865;865;865;865;865;865;865;865;865;865;865;865;865;865","MARCO GERVASI;ALESSANDRO VITALE;FABIO FARINATI;GIACOMO ZANUS;LUISA BENVEGNÙ;PAOLO ANGELI;PATRIZIA BURRA;UMBERTO CILLO;GIUSEPPINA BONACCORSO;DEMETRIO PITTARELLO;M. P. ALBERGONI;R. D’INCÀ;LUCIANO GIACOMELLI;MASSIMO RUGGE;ANTONIETTA CAVALLARO;CRISTINA BERGO;PAOLO GALLO;CECILIA DAOLIO;PIERO MARSON;RITA ALAGGIO","866;146;146;146;146;146;146;146;122;106;99;81;77;77;70;70;68;67;64;58","PIERO MARSON;DANIELE TREVISANUTO;MARCO GERVASI;MARIO PLEBANI;NICOLETTA DOGLIONI;VINCENZO ZANARDO;ANTONIETTA CAVALLARO;CHIARA MESSINA;CRISTINA BERGO;G BABIGHIAN;MATTEO PAROTTO;PIERANTONIO OSTUNI;R. D’INCÀ;RAFFAELLA COLOMBATTI;RITA ALAGGIO;A MATTAREI;A NASO;ALBERTO BOSI;ALESSANDRA ZAMPIERON;ALESSANDRO VITALE","16;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;ART;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;ECONOMICS;SOCIOLOGY;GEOGRAPHY;HISTORY;MATERIALS SCIENCE","81;23;9;8;6;5;5;4;4;4;4;3;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;PEDIATRICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;ANESTHESIA;DERMATOLOGY;MICROBIOLOGY;PHARMACOLOGY;PHYSICAL THERAPY;RADIOLOGY;ANATOMY;CARDIOLOGY;LAW;NURSING;OBSTETRICS;OPTICS;VIROLOGY","48;26;21;13;13;13;8;7;7;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","DISEASE;ALTERNATIVE MEDICINE;CANCER;GENE;POPULATION;PSYCHOLOGICAL INTERVENTION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ANTIBODY;ARTHRITIS;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);PREGNANCY;RHEUMATOID ARTHRITIS;RHEUMATOLOGY;TRANSPLANTATION;ANALGESIC;ASPIRIN;ASYMPTOMATIC;COMPLICATION;METHOTREXATE;RADIATION THERAPY;RHEUMATISM","20;8;7;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","PLACEBO;CROHN'S DISEASE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFLAMMATORY BOWEL DISEASE;ULCERATIVE COLITIS;ANAKINRA;ANTIPYRETIC;AUTOANTIBODY;AUTOIMMUNE DISEASE;AZATHIOPRINE;CERVIX;COLORECTAL CANCER;CUMULATIVE INCIDENCE;ESCHERICHIA COLI;ETANERCEPT;GENE EXPRESSION;GESTATION;HAZARD RATIO;INFLIXIMAB;PLASMID;PRIMARY SCLEROSING CHOLANGITIS;STAPES","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);ENTEROBACTERIACEAE;ABATACEPT;ACUTE CHEST SYNDROME;AMNIOTIC FLUID;ANTI-NUCLEAR ANTIBODY;ANTIRHEUMATIC DRUGS;BINGE DRINKING;CETUXIMAB;CHONDROCALCINOSIS;CLADE;COLONOSCOPY;CONNECTIVE TISSUE DISEASE;DANDER;DOUBLE BLIND;DYSCRASIA;ELLAGIC ACID;HAPLOINSUFFICIENCY;HYPERPHENYLALANINEMIA;ILEITIS;IN SITU HYBRIDIZATION;INCUS;INTRAEPITHELIAL NEOPLASIA;INTRAUTERINE GROWTH RESTRICTION;KLEBSIELLA;KLEBSIELLA PNEUMONIAE;KNEE PAIN;LEUKAPHERESIS;MALLEUS;MEROPENEM;METATARSALGIA;MODEL FOR END-STAGE LIVER DISEASE;MOLECULAR EPIDEMIOLOGY;MULTILOCUS SEQUENCE TYPING;MYCOBACTERIUM TUBERCULOSIS COMPLEX;OXALIPLATIN;PHENYLKETONURIAS;PIOGLITAZONE;PLACENTA;PROMOTER;PULSED-FIELD GEL ELECTROPHORESIS;SECONDARY HYPERPARATHYROIDISM;SULFASALAZINE;SYSTEMIC THERAPY;THIOPURINE METHYLTRANSFERASE;VANCOMYCIN","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ITALY;AGED;;ADULT;ANTIRHEUMATIC AGENTS;ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;ADOLESCENT;HISTORY, 20TH CENTURY;CHILD;HISTORY, 19TH CENTURY;RHEUMATIC DISEASES;YOUNG ADULT;AGED, 80 AND OVER;IMMUNOSUPPRESSIVE AGENTS;CHILD, PRESCHOOL;CROSS INFECTION","61;34;34;25;24;21;20;20;19;14;13;12;11;11;11;11;10;9;8;8","CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND MANAGEMENT OF ADRENAL INSUFFICIENCY;DIAGNOSIS AND MANAGEMENT OF OTITIS MEDIA;EPIDEMIOLOGY AND CAUSES OF PRETERM BIRTH;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;RHEUMATOID ARTHRITIS;ACUTE MYELOID LEUKEMIA;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ATOPIC DERMATITIS AND SKIN MICROBIOME;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;COMPLICATIONS OF GALLSTONE DISEASE;CONE-BEAM COMPUTED TOMOGRAPHY IN DENTISTRY;CONTRIBUTIONS OF PAUL EHRLICH TO TRANSLATIONAL MEDICINE;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND MANAGEMENT OF CARPAL TUNNEL SYNDROME","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","RHEUMATISM;ANTIPYRETIC;CERVICAL LENGTH;CROSS-SECTIONAL STUDY;CUMULATIVE INCIDENCE;DISCONTINUATION;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS;PRIMARY SCLEROSING CHOLANGITIS;TYMPANOSTOMY TUBES;;ABATACEPT;ACROMION;ACUTE CHEST SYNDROME;ACUTE MEDICINE;ACUTE MYELOID LEUKEMIA;ADAPTIVE THERMOGENESIS;ADOLESCENT DRUG USE;ADRENOCORTICAL CARCINOMA;AGGRESSIVE FIBROMATOSIS;ALBUMINURIA","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","ANTI-RHEUMATIC THERAPY;SHORT HISTORY;BOWEL DISEASE;CLINICAL PRACTICE;DIAGNOSTIC CRITERIA;INFLAMMATORY BOWEL;INTENSIVE CARE;MAIN STAGES;MULTICENTER RANDOMIZED;PRETERM BIRTH;PRIMARY SCLEROSING;PROGESTERONE REDUCES;PROVA STUDY;RHEUMATOID ARTHRITIS;RISK FACTORS;SCLEROSING CHOLANGITIS;SHORT CERVIX;SONOGRAPHIC SHORT;SURGICAL TREATMENT;VAGINAL PROGESTERONE;AAC-IB-CR PLASMID-MEDIATED;ABSENT MALLEUS;ACCOUNT CONJECTURAL;ACETABULAR MORPHOLOGY;ACUTE CHEST;ACUTE COCAINE;ACUTE MEDICAL;ACUTE MYELOID;ADDISONS DISEASE;ADRENOCORTICAL TUMORS","6;6;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","PSC PATIENTS;RHEUMATOID ARTHRITIS;RR CI;BTT SDS;GUINEA-BISSAU FAMILY;PRETERM BIRTH;ROTATOR CUFF;VAGINAL PROGESTERONE;ACR RESPONSE;ANALYTICAL QUALITY;RHEUMATIC DISEASES;RISK FACTORS;AD-SOS SDS;CUFF TEARS;FAMILY DYSFUNCTION;MINUTE IR;PATIENTS WOMEN;POPLITEAL CYSTS;PROGESTERONE GEL;SHORT CERVIX;SIGNIFICANTLY LOWER;SONOGRAPHIC SHORT;XIX CENTURY;ALCOHOL CONSUMPTION;ATOPIC DERMATITIS;BIRTH WEIGHT;BLOOD PHENYLALANINE;DIALYSIS PATIENTS;FUNGAL INFECTIONS;HIP FRACTURE","8;7;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3",15,0.17,3.5,3,1,1,1,0,5.5,0,1,3.5,0,1,3,0,2,0,0,2.5,1,0,0,58.5,65.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5.09,564.48,18.71,10,0.38,60.23,0,0,5,0,8,0,1,12,0,19,6,0,0,0,0,0,0,25,1,0,25,1,0,0,0,0,0,0,0,0,"Italy;United States;Belgium;Netherlands;Japan","5;5;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4208 TRADITIONAL, COMPLEMENTARY AND INTEGRATIVE MEDICINE","23;13;7;4;3;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;CANCER;DIGESTIVE DISEASES;LIVER DISEASE;LIVER CANCER;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;PEDIATRIC;BRAIN DISORDERS;CHRONIC LIVER DISEASE AND CIRRHOSIS;COST EFFECTIVENESS RESEARCH;HEALTH SERVICES;INFLAMMATORY BOWEL DISEASE;LUNG;NEUROSCIENCES;PEDIATRIC RESEARCH INITIATIVE","24;15;9;8;7;7;5;4;3;3;3;3;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","4;3;2;2;1;1;1","6.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","13;3;2;2;1;1;1;1","LIVER CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;NEUROBLASTOMA;NOT SITE-SPECIFIC CANCER;SARCOMA","5;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","7;1",2,7631481.5,465579.55,6.5,16,9,1,37,331186.322973599,0.259672559023084,"AZIENDA OSPEDALIERA DI PADOVA;CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE;LEIDEN UNIVERSITY;UNIVERSITY COLLEGE LONDON;ACADEMIC MEDICAL CENTER;APOTEX (CANADA);AZIENDA UNIVERSITARIA OSPEDALIERA CONSORZIALE - POLICLINICO BARI;BAMBINO GESÙ CHILDREN'S HOSPITAL;BASQUE FOUNDATION FOR HEALTH INNOVATION AND RESEARCH;CAIRO UNIVERSITY;CHILDREN'S MEMORIAL HEALTH INSTITUTE;DÉLÉGATION PARIS 11;ERASMUS MC;EUROPEAN MEDICINES AGENCY;GIANNI BENZI PHARMACOLOGICAL RESEARCH FOUNDATION;HOSPITAL FOR SICK CHILDREN;MINISTRY OF HEALTH;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT;OSPEDALE ANTONIO CARDARELLI","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2010-SINGLE-STAGE (CALL FOR PROPOSAL);CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","HEMATOLOGY;ORPHAN DRUG;RARE DISEASES","1;1;1","BLOOD","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","2;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","49 MATHEMATICAL SCIENCES;31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;4901 APPLIED MATHEMATICS","2;1;1;1;1","RARE DISEASES;TUBERCULOSIS","1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2012,62,8.75806451612903,1.85483870967742,0.387096774193548,0.209677419354839,0.580645161290323,1.21276595744681,1.14285714285714,1.18181818181818,1.09090909090909,0.483870967741935,3,29,17,2,11,0.47,0.27,0.03,0.18,25.55,0.611668796538219,5.78987341772152,0.32258064516129,0.903225806451613,0.413,0.22,0.278,0.228,"GIORGIO PALÙ;LAURA SAINATI;ANTONIETTA CAVALLARO;VITTORINA ZAGONEL;NORBERTO CONFALONIERI;ALFONSO MANZOTTI;GIUSEPPE BASSO;ELISA FRANCHIN;PASQUALE FIDUCCIA;SARA N. RICHTER;PIETRO CERVERI;RAFFAELLA COLOMBATTI;LUISA BARZON;ILARIA FRASSON;CESARE CHEMELLO;AGOSTINO STEFFAN;DONATO NITTI;R MARCOLONGO;SALVATORE PUCCIARELLI;BO HYUN YOON","4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MARIO PLEBANI;FILIBERTO ZATTONI;NORBERTO CONFALONIERI;ALFONSO MANZOTTI;PIETRO CERVERI;CESARE CHEMELLO;R MARCOLONGO;FEDERICA STELLA;FRANCO TOSATO;ANNE-MARIE ANÉ;DINO SGARABOTTO;SERENA MARINELLO;GIORGIO PALÙ;GIANNI BISOGNO;ANDREA FERRARI;ANTONIETTA CAVALLARO;SARA N. RICHTER;ILARIA FRASSON;CHRIS PULLEN;LAURA SAINATI","2;1;0.65;0.65;0.65;0.65;0.57;0.53;0.53;0.5;0.5;0.5;0.49;0.48;0.48;0.42;0.42;0.42;0.4;0.36","GIORGIO PALÙ;LAURA SAINATI;ANTONIETTA CAVALLARO;GIUSEPPE BASSO;ELISA FRANCHIN;SARA N. RICHTER;RAFFAELLA COLOMBATTI;LUISA BARZON;CESARE CHEMELLO;DONATO NITTI;R MARCOLONGO;SALVATORE PUCCIARELLI;EMANUELE COZZI;MARIO PLEBANI;FEDERICA STELLA;PAOLA LAGO;GIOVANNA BOCCUZZO;GIOVANNELLA BAGGIO;M SEVESO;PIERO MARSON","4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MARIO PLEBANI;FILIBERTO ZATTONI;CESARE CHEMELLO;R MARCOLONGO;FEDERICA STELLA;FRANCO TOSATO;DINO SGARABOTTO;GIORGIO PALÙ;GIANNI BISOGNO;ANTONIETTA CAVALLARO;SARA N. RICHTER;LAURA SAINATI;ENRICO ORVIETO;RAFFAELLA COLOMBATTI;GIOVANNI CECCHETTO;MARCO TONELLO;MARICA PERON;ROMEO BARDINI;PAOLO BONVINI;ILARIA DE BARBIERI","2;1;0.65;0.57;0.53;0.53;0.5;0.49;0.48;0.42;0.42;0.36;0.36;0.36;0.33;0.33;0.33;0.33;0.33;0.33","GIORGIO PALÙ;BO HYUN YOON;GABRIELLA BRACALENTE;LAMI YEO;MARIA-TERESA GERVASI;OFFER EREZ;ROBERTO ROMERO;SONIA S. HASSAN;TINNAKORN CHAIWORAPONGSA;ZHONG DONG;ELISA FRANCHIN;LUISA BARZON;ALBERTO EDEFONTI;ALBERTO MAGNASCO;CORRADO MURTAS;ELISA BENETTI;FRANCESCO SCOLARI;GIAN MARCO GHIGGERI;GIOVANNI MESSINA;LAURA MASSELLA","220;208;208;208;208;208;208;208;208;208;189;189;157;157;157;157;157;157;157;157","MARIA-TERESA GERVASI;ELISA BENETTI;LUISA MURER;GIOVANNI PITTONI;ANTONIETTA CAVALLARO;GIOVANNELLA BAGGIO;CRISTINA BERGO;MARIA LUISA DE GIORGI;CESARE CHEMELLO;GIORGIO PALÙ;SARA N. RICHTER;PAOLA LAGO;PATRIZIA BURRA;PAOLO FELTRACCO;GIANNI BISOGNO;ELISA FRANCHIN;LUISA BARZON;ALBERTO BURLINA;FABIOLA GUASTI;GIORGIO MENEGHETTI","208;157;157;148;145;139;74;74;72;71;71;61;52;51;48;40;40;39;36;36","ANTONIETTA CAVALLARO;CESARE CHEMELLO;ALBERTO BURLINA;DONATO NITTI;ENRICO ORVIETO;FRANCO TOSATO;GIANNI BISOGNO;GIORGIO PALÙ;GIOVANNELLA BAGGIO;LAURA SAINATI;MARCO AGOSTINI;MARIA-TERESA GERVASI;MARIO PLEBANI;PAOLA LAGO;R MARCOLONGO;RAFFAELLA COLOMBATTI;SALVATORE PUCCIARELLI;SARA N. RICHTER;A. LLA DE PUPPA;ALESSANDRO MARTINI","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;POLITICAL SCIENCE;ENGINEERING;ECONOMICS;PSYCHOLOGY;CHEMISTRY;PHILOSOPHY;BUSINESS;GEOGRAPHY;HISTORY;MATERIALS SCIENCE;MATHEMATICS;SOCIOLOGY","54;16;6;6;5;4;3;3;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PATHOLOGY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;ONCOLOGY;PSYCHIATRY;RADIOLOGY;GASTROENTEROLOGY;VIROLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;LAW;NURSING;PEDIATRICS;ANESTHESIA;BIOCHEMISTRY;ENDOCRINOLOGY;PHYSICAL THERAPY","37;16;11;9;8;7;7;7;7;6;6;5;5;5;5;5;4;4;4;4","GENE;CANCER;TRANSPLANTATION;DISEASE;EMERGENCY DEPARTMENT;HEALTH CARE;POPULATION;VIRUS;ALTERNATIVE MEDICINE;ANTIBODY;ARTHROPLASTY;INCIDENCE (GEOMETRY);INTENSIVE CARE;MULTIVARIATE ANALYSIS;PSYCHOLOGICAL INTERVENTION;AMPUTATION;ANTIBIOTICS;CHEMOTHERAPY;CONFIDENCE INTERVAL;HEMODYNAMICS;HEPATITIS B;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;ISCHEMIA;KIDNEY;LUMBAR;MECHANICAL VENTILATION;MYOCARDIAL INFARCTION;PERCEPTION;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;RENAL FUNCTION;RETROSPECTIVE COHORT STUDY;SURVIVAL RATE;TOTAL KNEE REPLACEMENT","11;9;7;6;5;5;5;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENOTYPE;MUTATION;COLORECTAL CANCER;KIDNEY TRANSPLANTATION;RITUXIMAB;UNIVARIATE ANALYSIS;ALLELE;CHRONIC HEPATITIS;COMPLEMENT SYSTEM;ESCHERICHIA COLI;HUMAN CYTOMEGALOVIRUS;KNEE REPLACEMENT;LIVER TRANSPLANTATION;MULTICENTER STUDY;OSTEOARTHRITIS;OVARIAN CANCER;PATIENT SAFETY;PLASMAPHERESIS;PLASMID;TACROLIMUS;VIRAL DISEASE","5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ECULIZUMAB;FAMILIAL ADENOMATOUS POLYPOSIS;GERMLINE MUTATION;HERPESVIRIDAE;KLEBSIELLA PNEUMONIAE;ADENOMATOUS POLYPOSIS COLI;AMNIOTIC FLUID;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;CHILDHOOD OBESITY;CHORIOAMNIONITIS;COLECTOMY;COLONOSCOPY;COMPOUND HETEROZYGOSITY;CRITICAL LIMB ISCHEMIA;CYTOMEGALOVIRUS INFECTIONS;ECHOVIRUS;ELISPOT;FRAMESHIFT MUTATION;GANCICLOVIR;GENOTYPING;GLYCATED HAEMOGLOBIN;GLYCATED HEMOGLOBIN;GONADOTROPIN-RELEASING HORMONE;HORMONAL THERAPY;HYPERINSULINISM;INTEGRON;IRINOTECAN;KNEE ARTHRITIS;MEDIASTINAL EMPHYSEMA;MILAN CRITERIA;MISSENSE MUTATION;MOLECULAR EPIDEMIOLOGY;MULTILOCUS SEQUENCE TYPING;NEOADJUVANT THERAPY;PRENATAL DIAGNOSIS;PROBAND;PROPIDIUM IODIDE;PROSTATE-SPECIFIC ANTIGEN;PULMONARY ARTERY CATHETER;PULSED-FIELD GEL ELECTROPHORESIS;RELATIVE SURVIVAL;SULFONYLUREA RECEPTOR;THYMOGLOBULIN;TRASTUZUMAB;UNICOMPARTMENTAL KNEE ARTHROPLASTY;VASO-OCCLUSIVE CRISIS;VENLAFAXINE","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;ITALY;ADULT;MIDDLE AGED;ADOLESCENT;AGED;CHILD;CHILD, PRESCHOOL;PAIN MANAGEMENT;AGED, 80 AND OVER;ANALGESIA;ANEMIA, SICKLE CELL;BETA-LACTAMASES;ARTHROPLASTY, REPLACEMENT, KNEE;HEPATITIS B VIRUS;HEPATITIS B, CHRONIC;INFANT","42;26;25;20;17;12;12;11;11;9;8;8;6;6;6;6;5;5;5;5","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GLIOMAS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;KIDNEY TRANSPLANTATION;PROJECTIONS AND OUTCOMES OF ARTHROPLASTY SURGERY IN THE US;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATITIS B INFECTION AND TREATMENT;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;PEDIATRIC PAIN ASSESSMENT AND MANAGEMENT;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;EPIDEMIOLOGY AND CAUSES OF PRETERM BIRTH;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;GLOBAL IMPACT OF ARBOVIRAL DISEASES","3;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","SICKLE-CELL DISEASE;UNIVARIATE ANALYSIS;ANTIBODY-MEDIATED REJECTION;BREAST CANCER;CYTOMEGALOVIRUS;DIAGNOSIS;ECULIZUMAB;HEPATITIS B;MUTYH;NEONATAL PAIN;PAIN MANAGEMENT;PLASMAPHERESIS;TOTAL KNEE REPLACEMENT;TREATMENT;ABDOMINAL MASS;ADENOMATOUS POLYPOSIS COLI;ADOLESCENTS;AGGRESSIVE FIBROMATOSIS;AMNIOCENTESIS;AMPUTATION","3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","KIDNEY TRANSPLANT;SICKLE CELL;ABCC MUTATIONS;CELL DISEASE;ELDERLY PATIENTS;GLYCATED HEMOGLOBIN;IBLAI SUBKPC-SUB;INVASIVE PROCEDURES;ITALIAN NICUS;KLEBSIELLA PNEUMONIAE;KNEE REPLACEMENT;LIVER TRANSPLANTATION;MULTICENTER STUDY;PAIN MANAGEMENT;PATIENT SAFETY;PATIENTS PTS;PRE-ANALYTICAL ERRORS;RARE TUMOURS;TOTAL KNEE;AC DELEGATES;ADDITIONAL DISABILITIES;ADENOMATOUS POLYPOSIS;ADVANCED BREAST;ADVANCED SONOLOGICAL;ALGORITHM COMBINING;ALSTRÖM SYNDROME;AMNIOTIC CAVITY;AMNIOTIC FLUID;AMPUTATION RATE;ANTIANGIOGENIC DRUG","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","AMNIOTIC FLUID;PRETERM DELIVERY;SPONTANEOUS PRETERM;MATERNAL BLOOD;NEPHROGENIC ADENOMA;COMPREHENSIVE CARE;OHD LEVELS;FLUID IL-;INTRA-AMNIOTIC INFLAMMATION;RMS CELLS;STATISTICALLY SIGNIFICANT;ACUTE REJECTION;BLA KPC-;EMBRYONAL CANCERS;GAIT SPEED;HANDGRIP STRENGTH;IDH MUTATED;IQR PGML;KLEBSIELLA PNEUMONIAE;MEDIAN PGML;NUCLEIC ACIDS;PAEDIATRIC AGE;RENAL FUNCTION;SIGNIFICANT DIFFERENCE;VIRAL DNA;ADVANCED PROTOCOL;ANTIBODY-MEDIATED REJECTION;CALCINEURIN INHIBITORS;FLUID IP-;IDIOPATHIC NEPHROTIC","15;13;10;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3",18,0.29,5.38,2.75,1,1,0,0,4,0,1,3.75,0,1,3,0,1,1,1.25,2,2,0,0,80.75,80.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,3.89,913.55,34.12,7,0.24,81.14,0,0,4,1,10,0,3,11,0,24,5,0,0,0,0,0,0,28,1,0,28,0,0,1,0,0,0,0,0,0,"Italy;United States;Belgium;Germany","7;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","27;15;5;4;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;CARDIOVASCULAR;CANCER;PATIENT SAFETY;HEART DISEASE;LIVER DISEASE;RARE DISEASES;CHRONIC LIVER DISEASE AND CIRRHOSIS;BIOENGINEERING;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;PREVENTION;STEM CELL RESEARCH;BREAST CANCER;DIABETES;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES","26;16;8;7;6;6;5;5;5;4;3;3;3;3;3;2;2;2;2;2","CARDIOVASCULAR;CANCER;ORAL AND GASTROINTESTINAL;INFECTION;RENAL AND UROGENITAL;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;NEUROLOGICAL","5;4;4;2;2;1;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;3.3 NUTRITION AND CHEMOPREVENTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS","16;6;2;2;1;1;1;1;1","LIVER CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NOT SITE-SPECIFIC CANCER","3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","5;2;1;1",1,5200000,433333.33,5,12,8,1,8,392852.989640266,0.157819850261985,"AZIENDA OSPEDALIERA DI PADOVA;CLINIQUE SAINT JEAN;CORLIFE (GERMANY);GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST;HANNOVER MEDICAL SCHOOL;KU LEUVEN;LEIBNIZ UNIVERSITY HANNOVER;LEIDEN UNIVERSITY MEDICAL CENTER;NICOLAE TESTEMIȚANU STATE UNIVERSITY OF MEDICINE AND PHARMACY;UNIVERSITY OF PADUA;UNIVERSITY OF ZURICH;UNIVERSITÉ PARIS-CITÉ","1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2011-TWO-STAGE (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","1;1","BIOENGINEERING;CARDIOVASCULAR;HEART DISEASE;PEDIATRIC;REGENERATIVE MEDICINE","1;1;1;1;1","CARDIOVASCULAR","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PADOVA",2013,58,11.4655172413793,2.1551724137931,0.344827586206897,0.241379310344828,0.413793103448276,1.26262626262626,1.17647058823529,1.07692307692308,1.26315789473684,0.431034482758621,0,30,13,2,4,0.52,0.22,0.03,0.07,32.4,0.928465763738706,5.09438202247191,0.327586206896552,0.913793103448276,0.392,0.312,0.354,0.33,"PÉTER L. LAKATOS;LAURA SAINATI;RAFFAELLA COLOMBATTI;DANIELE TREVISANUTO;FABIO FARINATI;DANIELA LAZĂR;LIMAS KUPČINSKAS;SØREN AVNSTRØM;JOHAN BURISCH;K. KATSANOS;EBBE LANGHOLZ;DANA ĎURICOVÁ;JONAS HALFVARSON;PAOLA LAGO;S. ČUKOVIĆ-ČAVKA;NIELS THORSGAARD;GIOVANNI BATTISTA BARTOLUCCI;KÁRI RUBEK NIELSEN;SHAJI SEBASTIAN;GIUSEPPE BASSO","6;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GIUSTINA DE SILVESTRO;DANIELE TREVISANUTO;GIOVANNI BATTISTA BARTOLUCCI;PAOLA LAGO;LUCA MARCHETTO;LAURA SAINATI;RAFFAELLA COLOMBATTI;CORRADO BETTERLE;MARIA LUISA SCAPELLATO;ETTORE DE CANALE;LUCÍA ROSSI;FABIO FARINATI;D. PETRICCA;ANTONELLA ALLEGRO;CATERINA MIAN;NATASCHA HEUN;PIERO MARSON;STEFANO MICHELASSI;MARCO LOMBARDI;S. PASSALACQUA","0.87;0.83;0.62;0.61;0.5;0.48;0.48;0.39;0.37;0.36;0.36;0.34;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","LAURA SAINATI;RAFFAELLA COLOMBATTI;DANIELE TREVISANUTO;FABIO FARINATI;PAOLA LAGO;GIUSEPPE BASSO;GIUSTINA DE SILVESTRO;P. PERINI;ETTORE DE CANALE;ANDREA BARTOLINI;LORENZO A. CALÒ;MATTEO MARTINATO;UMBERTO CILLO;ANTONIETTA CAVALLARO;GIORGIO MENEGHETTI;LARA MUSSOLIN;RENZO MANARA;LUCÍA ROSSI;ALESSANDRO DELLA PUPPA;MARIA LUISA SCAPELLATO","5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","GIUSTINA DE SILVESTRO;DANIELE TREVISANUTO;PAOLA LAGO;LAURA SAINATI;RAFFAELLA COLOMBATTI;CORRADO BETTERLE;MARIA LUISA SCAPELLATO;ETTORE DE CANALE;LUCÍA ROSSI;FABIO FARINATI;ANTONELLA ALLEGRO;NATASCHA HEUN;PIERO MARSON;TIZIANA TISON;DAVIDE NACAMULLI;SERENA DE PELLEGRIN;ANDREA BARTOLINI;LORENZO A. CALÒ;ANTONIETTA CAVALLARO;SARA N. RICHTER","0.87;0.83;0.61;0.48;0.48;0.39;0.37;0.36;0.36;0.34;0.33;0.33;0.33;0.33;0.33;0.31;0.28;0.28;0.28;0.28","PÉTER L. LAKATOS;ADRIAN GOLDIS;DANA ĎURICOVÁ;DANIELA LAZĂR;E. А. BELOUSOVA;EBBE LANGHOLZ;FERNANDO MAGRO;IDA VIND;IOANNIS KAIMAKLIOTIS;JOHAN BURISCH;JONAS HALFVARSON;K. KATSANOS;KÁRI RUBEK NIELSEN;LIMAS KUPČINSKAS;NIELS THORSGAARD;OLGA SHONOVÁ;PEKKA COLLIN;PIA MANNINEN;PIA MUNKHOLM;RIINA SALUPERE","1138;569;569;569;569;569;569;569;569;569;569;569;569;569;569;569;569;569;569;569","MATTEO MARTINATO;R. D’INCÀ;GIUSEPPE BASSO;GEERTRUY TE KRONNIE;GIANNI BISOGNO;GIOVANNI CECCHETTO;PATRIZIA DALL’IGNA;PIETRO ZUCCHETTA;RAFFAELLA COLOMBATTI;LAURA SAINATI;GIULIA GIRARDIN;LUIGI GALLIMBERTI;MARIA PAOLA ALBERGONI;ROBERTA FAVERO;LARA MUSSOLIN;MARTA PILLON;GIORGIO MENEGHETTI;PAOLA LAGO;PATRIZIA RAMPAZZO;RENZO MANARA","470;393;216;146;135;135;135;117;108;105;99;82;77;77;76;76;70;70;70;70","RAFFAELLA COLOMBATTI;LAURA SAINATI;GIUSEPPE BASSO;PAOLA LAGO;DANIELE TREVISANUTO;ALESSANDRO DELLA PUPPA;ANDREA BARTOLINI;GIORGIO MENEGHETTI;LARA MUSSOLIN;MARIA LUISA SCAPELLATO;MARTA PILLON;MATTEO MARTINATO;P. PERINI;PATRIZIA RAMPAZZO;RENZO MANARA;SERENA DE PELLEGRIN;A. ALBERTÍ;A. MEMMO;A.M. GRION;ALESSANDRA CASONATO","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ECONOMICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;ENVIRONMENTAL SCIENCE;BUSINESS;GEOLOGY;HISTORY;MATHEMATICS;POLITICAL SCIENCE","54;15;11;7;5;4;4;3;3;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PEDIATRICS;GENETICS;ENVIRONMENTAL HEALTH;PATHOLOGY;ANESTHESIA;PSYCHIATRY;CARDIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;NURSING;ONCOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ECONOMIC GROWTH;FAMILY MEDICINE;OPTICS;RADIOLOGY","41;14;12;11;9;9;7;7;5;5;5;5;5;5;4;4;4;4;4;4","DISEASE;COHORT;POPULATION;GENE;PREGNANCY;COHORT STUDY;HEALTH CARE;ADVERSE EFFECT;CANCER;LYMPHOMA;PLATELET;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;ABLATION;ANTIBIOTICS;ASYMPTOMATIC;BLOOD PRESSURE;CONFIDENCE INTERVAL;HORMONE;INCIDENCE (GEOMETRY);INTENSIVE CARE;INTUBATION;KIDNEY;KIDNEY DISEASE;MECHANICAL VENTILATION;MULTIPLE SCLEROSIS;OBSERVATIONAL STUDY;ODDS RATIO;PSYCHOLOGICAL INTERVENTION;QUALITY OF LIFE (HEALTHCARE);RESPIRATORY DISTRESS;STROKE (ENGINE);THROMBOSIS;URINARY SYSTEM;VEIN","12;7;7;6;6;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INFLAMMATORY BOWEL DISEASE;CROHN'S DISEASE;MUTATION;ULCERATIVE COLITIS;ANAPLASTIC LARGE-CELL LYMPHOMA;APHERESIS;CYSTOGRAPHY;FETUS;GENE EXPRESSION;GERMLINE;GESTATIONAL AGE;VENOUS THROMBOSIS;ADDISON'S DISEASE;ADRENAL CRISIS;ADRENOCORTICOTROPIC HORMONE;ALCOHOL CONSUMPTION;ALKALOSIS;ALLELE;AUTOIMMUNE DISEASE;AUTOIMMUNE HEPATITIS;BIRTH WEIGHT;BORDERLINE INTELLECTUAL FUNCTIONING;CARBAPENEM;CARCINOGENESIS;CARDIOPULMONARY RESUSCITATION;CASCADE IMPACTOR;CD8;CHRONIC HEPATITIS;CLINICAL ENDPOINT;COLORECTAL CANCER;CONTINUOUS POSITIVE AIRWAY PRESSURE;CORONARY FLOW RESERVE;CRONBACH'S ALPHA;CYCLOPHOSPHAMIDE;DEEP VEIN;DNA DAMAGE;DOBUTAMINE;DOWNREGULATION AND UPREGULATION;ECTOPIC URETER;ENDOTRACHEAL INTUBATION;ENDOVASCULAR TREATMENT;ESCHERICHIA COLI;ETEST;ETOPOSIDE;FRACTION OF INSPIRED OXYGEN;GENOTYPE;GESTATION;GRAM STAINING;GREAT SAPHENOUS VEIN;HEALTH PROFESSIONALS;HEART RATE;HEMOGLOBINOPATHY;HOSPICE CARE;HYDRONEPHROSIS;INFLIXIMAB;INTELLIGENCE QUOTIENT;INTERIM ANALYSIS;INTRAPARIETAL SULCUS;LASER ABLATION;LIVER TRANSPLANTATION;LOW BIRTH WEIGHT;LUMBAR PUNCTURE;LYMPHOBLASTIC LEUKEMIA;MALIGNANT PLEURAL EFFUSION;METRONIDAZOLE;MICROALBUMINURIA;MICROANGIOPATHY;MICROWAVE ABLATION;MITOXANTRONE;MOTOR CORTEX;NEONATAL INFECTION;NEPHRECTOMY;NEURORADIOLOGY;OCCUPATIONAL EXPOSURE LIMIT;OVERWEIGHT;OXIDATIVE DAMAGE;OXYGEN DELIVERY;PAIN ASSESSMENT;PARTICLE COUNTER;PERFORMANCE STATUS;PLACEBO;POLYMERASE CHAIN REACTION;PROGRESSION-FREE SURVIVAL;PROTEINURIA;RADIOFREQUENCY ABLATION;REFLUX;RITUXIMAB;SCINTILLATOR;SICKLE CELL ANEMIA;STATUS EPILEPTICUS;SUPERIOR PARIETAL LOBULE;TEMOZOLOMIDE;THROMBOTIC MICROANGIOPATHY;THROMBOTIC THROMBOCYTOPENIC PURPURA;THYROID DISEASE;THYROID HORMONES;THYROIDITIS;TOLERABILITY;TRACHEAL INTUBATION;URINALYSIS;VERBAL REASONING;VIRULENCE;WECHSLER ADULT INTELLIGENCE SCALE","4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GERMLINE MUTATION;ACUTE CHEST SYNDROME;ACUTE LYMPHOCYTIC LEUKEMIA;ANAPLASTIC LYMPHOMA KINASE;AUTOIMMUNE THYROIDITIS;BRONCHOPULMONARY DYSPLASIA;CENTRAL SULCUS;CHILDHOOD OBESITY;CHOLESTASIS OF PREGNANCY;ENTEROBACTERIACEAE;FACTOR V LEIDEN;IDH1;INFLAMMATORY BOWEL DISEASES;INTERNATIONAL PROGNOSTIC INDEX;KLEBSIELLA PNEUMONIAE;LYSO-;MICROANGIOPATHIC HEMOLYTIC ANEMIA;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MISSENSE MUTATION;MULTIPLEX POLYMERASE CHAIN REACTION;OXALIPLATIN;PERFORIN;PRENATAL DIAGNOSIS;RESPIRATORY RATE;RETINOPATHY OF PREMATURITY;RIBAVIRIN;SCHISTOCYTE;SDHA;VESICOURETERAL REFLUX;WECHSLER INTELLIGENCE SCALE FOR CHILDREN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;ADOLESCENT;ANEMIA, SICKLE CELL;AGED;ITALY;YOUNG ADULT;CHILD;INFANT, NEWBORN;COLITIS, ULCERATIVE;CROHN DISEASE;PROSPECTIVE STUDIES;ADRENAL GLAND NEOPLASMS;INFLAMMATORY BOWEL DISEASES;RESPIRATORY DISTRESS SYNDROME, NEWBORN;ADDISON DISEASE","35;27;27;23;17;16;13;12;11;11;10;9;9;8;8;8;7;7;7;6","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;DIAGNOSIS AND MANAGEMENT OF ADRENAL INSUFFICIENCY;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PEDIATRIC PAIN ASSESSMENT AND MANAGEMENT;PEDIATRIC URINARY TRACT INFECTIONS;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;COMPLICATIONS AND MANAGEMENT OF STOMA-RELATED ISSUES;DEVELOPMENT OF NUMERICAL COGNITION AND MATHEMATICS ABILITIES;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND TREATMENT OF PATENT DUCTUS ARTERIOSUS;EFFECTS OF CAFFEINE ON HUMAN HEALTH;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND MOLECULAR CHARACTERIZATION OF PARASITIC DISEASES;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;EPIDEMIOLOGY AND TREATMENT OF URINARY TRACT INFECTIONS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;GENOTOXICITY AND CARCINOGENESIS MECHANISMS;GLIOMAS","6;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","SICKLE-CELL DISEASE;PAIN ASSESSMENT TOOLS;PAIN MANAGEMENT;PAIN MEASUREMENT;ANAPLASTIC LARGE-CELL LYMPHOMA;CYSTOGRAPHY;ENDOVASCULAR THERAPY;INFLAMMATORY BOWEL DISEASE;NEONATAL PAIN;PEDIATRIC PAIN;STROKE (ENGINE);ACUTE CHEST SYNDROME;ACUTE LYMPHOBLASTIC LEUKEMIA;ACUTE LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;ADRENAL CRISIS;AIR QUALITY MONITORING;ALKALOSIS;ANTIMICROBIAL SUSCEPTIBILITY TESTING;APHASIA","5;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CELL DISEASE;SICKLE CELL;BOWEL DISEASE;INCEPTION COHORT;INFLAMMATORY BOWEL;ENDOVASCULAR TREATMENT;MULTIPLE SCLEROSIS;ACUTE LYMPHOBLASTIC;ADACOLUMN RISPETTO;ADDISON DISEASE;ADDISONS DISEASE;ADVERSE EVENTS;AGE COHORTS;ALISPORIVIR ALV;AUTOIMMUNE POLYENDOCRINE;AUTOIMMUNE THYROIDITIS;BAG EFFECT;BIOLOGICO NEL;BIRTH WEIGHT;BLAKPC ALLELES;BLOOD DISORDERS;BLOOD PRESSURE;BLOOD SPOTS;BRAIN TUMOR;BUS DRIVERS;CALCULATION PROCESSING;CARBAPENEM RESISTANCE;CASCADE IMPACTOR;CELL LYMPHOMA;CELL-FREE DNA","5;5;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION PREVENTION;ACUTE LYMPHOBLASTIC;ENVIRONMENTAL FACTORS;HEREDITARY DISEASE;INCREASED LEVELS;INTELLECTUAL FUNCTION;LYMPHOBLASTIC LEUKEMIA;NGML NA;SSC PATIENTS;THERAPEUTIC EDUCATION;WESTERN EUROPEAN;ADRENAL CORTEX;ADRENAL IMAGING;CELL DISEASE;CEREBRAL SILENT;CLINICAL COMPLICATIONS;DISEASE SCD;EASTERN EUROPEAN;EPICOM COHORT;EUROPEAN PATIENTS;GENE EXPRESSION;HCC PATIENTS;HEALTHCARE PROVIDERS;IBD PATIENTS;INCEPTION COHORT;LAPAROSCOPIC ABLATION;LOW LEVELS;LYMPHOMA PATIENTS;NEONATAL INFECTION;PARAGANGLIAL TUMORS","5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",13,0.22,3.75,7,2,1,1,0,7,0,1,7,0,0,4.25,1,0,1,1.5,4,1.5,0,0,97,97,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,6.39,2582.35,24.21,10,0.43,110.91,2,1,0,2,6,0,1,11,0,16,7,0,0,0,0,0,0,23,0,0,22,0,0,1,0,0,0,0,0,0,"Italy;United States;France;Belgium;Switzerland;United Kingdom","5;5;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4205 NURSING","23;9;5;3;3;3;3;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;PATIENT SAFETY;HEART DISEASE;CANCER;HEART DISEASE - CORONARY HEART DISEASE;RARE DISEASES;NEUROSCIENCES;AUTOIMMUNE DISEASE;PEDIATRIC;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;ARTHRITIS;BRAIN DISORDERS;DIGESTIVE DISEASES;EYE DISEASE AND DISORDERS OF VISION;NUTRITION;ORPHAN DRUG;PREVENTION","21;12;8;8;7;5;5;5;4;3;3;3;3;2;2;2;2;2;2;2","CARDIOVASCULAR;CANCER;EYE;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;RENAL AND UROGENITAL","5;4;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL","11;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;BRAIN TUMOR;COLON AND RECTAL CANCER;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;THYROID CANCER","2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1",1,5996971,461305.46,6,13,8,1,25,346170.004796607,0.1675477343396,"AVANTEA;AZIENDA OSPEDALIERA DI PADOVA;CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES;DÉLÉGATION PARIS 11;INSTITUT CATALÀ DE LA SALUT;INSTITUT D'INVESTIGACIÓ BIOMÉDICA DE BELLVITGE;INSTITUT UNIVERSITARI DE CIENCIA I TECNOLOGIA (SPAIN);TEL AVIV UNIVERSITY;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF CALIFORNIA SYSTEM;UNIVERSITY OF GOTHENBURG;UNIVERSITY OF MANITOBA;UNIVERSITY OF PADUA","1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2013-INNOVATION-1 (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","1;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;PREVENTION","1;1;1;1","CARDIOVASCULAR","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",30,"PUBLIC LIBRARY OF SCIENCE","30","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3210 NUTRITION AND DIETETICS;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4206 PUBLIC HEALTH;52 PSYCHOLOGY;3105 GENETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;37 EARTH SCIENCES;3701 ATMOSPHERIC SCIENCES;38 ECONOMICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES","33;9;5;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;HEMATOLOGY;RARE DISEASES;CANCER;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;INFECTIOUS DISEASES;LIVER CANCER;LIVER DISEASE;LUNG;PREVENTION;ASSISTIVE TECHNOLOGY;BIOENGINEERING;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - B;HEPATITIS - C","7;4;4;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;ORAL AND GASTROINTESTINAL;CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","4;4;3;2;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY","1;1","CLINICAL","9","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","7;3;2","LIVER CANCER;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER","4;1;1",NA,NA
"AOU_PADOVA",2014,72,11.1944444444444,2.33333333333333,0.291666666666667,0.236111111111111,0.277777777777778,1.28682170542636,1.16666666666667,1.0625,1.17647058823529,0.472222222222222,2,35,18,9,5,0.49,0.25,0.12,0.07,28.65,0.758176450487293,4.98336798336798,0.277777777777778,0.958333333333333,0.435,0.382,0.329,0.39,"SABINA ZAMBON;NICOLA VERONESE;GIUSEPPE SERGI;GIOVANNELLA BAGGIO;ENZO MANZATO;EGLE PERISSINOTTO;ALESSANDRO DELLA PUPPA;GAETANO CREPALDI;MARINA DE RUI;ELENA DEBORA TOFFANELLO;FRANCESCO BOLZETTA;ESTELLA MUSACCHIO;MARIO PLEBANI;DANIELE TREVISANUTO;GIUSEPPE LOMBARDI;GIUSEPPE TARANTINI;MARTINA PERAZZOLO MARRA;MARCO SCHIAVON;UMBERTO CILLO;VITTORINA ZAGONEL","6;6;6;6;6;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3","MARIO PLEBANI;MAURO CANCIAN;ALESSANDRO DELLA PUPPA;DANIELE TREVISANUTO;GIUSEPPE LOMBARDI;SABINA ZAMBON;NICOLA VERONESE;GIUSEPPE SERGI;GIOVANNELLA BAGGIO;ENZO MANZATO;EGLE PERISSINOTTO;GAETANO CREPALDI;R DESTRO;AURORA STRANO;DANIELA BOVO;M. V. GAZZOLA;LARA MUSSOLIN;NICOLETTA DOGLIONI;MARINA DE RUI;FRANCESCO BOLZETTA","1.23;1;0.85;0.53;0.51;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.44;0.43;0.42;0.42","SABINA ZAMBON;NICOLA VERONESE;GIUSEPPE SERGI;GIOVANNELLA BAGGIO;ENZO MANZATO;EGLE PERISSINOTTO;ALESSANDRO DELLA PUPPA;GAETANO CREPALDI;MARINA DE RUI;FRANCESCO BOLZETTA;ESTELLA MUSACCHIO;MARIO PLEBANI;DANIELE TREVISANUTO;GIUSEPPE TARANTINI;MARTINA PERAZZOLO MARRA;MARCO SCHIAVON;UMBERTO CILLO;FEDERICO REA;LEONARDO SARTORI;NICOLETTA DOGLIONI","6;6;6;6;6;6;6;6;5;5;4;4;4;3;3;3;3;3;3;3","MARIO PLEBANI;MAURO CANCIAN;ALESSANDRO DELLA PUPPA;DANIELE TREVISANUTO;SABINA ZAMBON;NICOLA VERONESE;GIUSEPPE SERGI;GIOVANNELLA BAGGIO;ENZO MANZATO;EGLE PERISSINOTTO;GAETANO CREPALDI;R DESTRO;AURORA STRANO;DANIELA BOVO;M. V. GAZZOLA;LARA MUSSOLIN;NICOLETTA DOGLIONI;MARINA DE RUI;FRANCESCO BOLZETTA;FRANCESCO CAUSIN","1.23;1;0.85;0.53;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.44;0.43;0.42;0.42;0.4","GIUSEPPE TARANTINI;ALAIDE CHIEFFO;ALBERTO MENOZZI;ANTONIO COLOMBO;ARIAN FRASHERI;BRUNO MARIO CESANA;EDOARDO PUCCI;GENNARO GIUSTINO;GENNARO SARDELLA;J. DOMÍNGUEZ;JOSEPA MAURI;LUIGI STEFFANON;MÓNICA MASOTTI-CENTOL;NEUS SALVATELLA;PATRIZIA PRESBITERO;ROBERTO GARBO;EGLE PERISSINOTTO;ENZO MANZATO;GAETANO CREPALDI;GIOVANNELLA BAGGIO","422;402;402;402;402;402;402;402;402;402;402;402;402;402;402;402;325;325;325;325","GIUSEPPE TARANTINI;GIOVANNELLA BAGGIO;MARIO PLEBANI;UMBERTO CILLO;MARTINA ZANINOTTO;LAURA SCIACOVELLI;AMELIA RUFFATTI;ELISA SALVAN;TERESA DEL ROSS;ANGELO ROSOLEN;LARA MUSSOLIN;FRANCESCO BARBARO;FULVIA CHIECO‐BIANCHI;MARIANGIOLA CRIVELLARO;DANIELE TREVISANUTO;LUISA MENEGHINI;NICOLA ZADRA;SERENA DE PELLEGRIN;SILVIA BENAVIDES‐VARELA;CRISTINA BASSO","422;325;274;142;130;129;122;103;103;86;86;84;68;68;51;49;49;49;49;43","GIOVANNELLA BAGGIO;ALESSANDRO DELLA PUPPA;DANIELE TREVISANUTO;MARIO PLEBANI;UMBERTO CILLO;AMELIA RUFFATTI;CHIARA INFANTOLINO;CRISTINA BASSO;ELISA CARTURAN;FRANCESCO CAUSIN;GIUSEPPE TARANTINI;LARA MUSSOLIN;LUISA MENEGHINI;MARTINA ZANINOTTO;NICOLA ZADRA;NICOLETTA DOGLIONI;VERONICA MARDEGAN;ALIDA L.P. CAFORIO;ANDREA DORIA;ANGELA AMIGONI","6;5;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;ECONOMICS;PSYCHOLOGY;COMPUTER SCIENCE;SOCIOLOGY;BUSINESS;POLITICAL SCIENCE;GEOGRAPHY;PHILOSOPHY;CHEMISTRY","71;18;15;6;5;5;4;4;3;3;2;2;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;INTENSIVE CARE MEDICINE;GENETICS;GASTROENTEROLOGY;PEDIATRICS;CARDIOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;RADIOLOGY;OPTICS;CANCER RESEARCH;IMMUNOLOGY;PSYCHIATRY;PHYSICAL THERAPY;DEMOGRAPHY;EMERGENCY MEDICINE;ENDOCRINOLOGY;OBSTETRICS","48;24;14;12;11;10;9;8;8;8;8;7;6;6;6;5;4;4;4;4","INCIDENCE (GEOMETRY);CONFIDENCE INTERVAL;POPULATION;PREGNANCY;TRANSPLANTATION;CHEMOTHERAPY;DISEASE;MAGNETIC RESONANCE IMAGING;ODDS RATIO;COHORT;DIABETES MELLITUS;GENE;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ALTERNATIVE MEDICINE;BONE MARROW;COHORT STUDY;CONFOUNDING;HORMONE;INTENSIVE CARE;KIDNEY;LUNG;LYMPHOMA;NEUROLOGY;PROPORTIONAL HAZARDS MODEL;RADIATION THERAPY;VITAMIN D AND NEUROLOGY","7;6;6;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","GESTATION;HAZARD RATIO;NEURORADIOLOGY;CARDIAC MAGNETIC RESONANCE;CISPLATIN;CLINICAL ENDPOINT;DEPRESSIVE SYMPTOMS;DIFFUSION MRI;GESTATIONAL AGE;KIDNEY TRANSPLANTATION;LUNG TRANSPLANTATION;MUTATION;NEURONAVIGATION;QUALITY ASSURANCE;QUALITY MANAGEMENT;VITAMIN D DEFICIENCY;A549 CELL;ACINETOBACTER;AEROBIOLOGY;ALLERGEN;ANDROGEN;ANTIPHOSPHOLIPID SYNDROME;ANTITHROMBIN;APHERESIS;ATELECTASIS;AUDIOMETRY;B CELL;BREAST CANCER;C1-INHIBITOR;CAESAREAN SECTION;CARDIAC MAGNETIC RESONANCE IMAGING;CARDIOMYOPATHY;CARDIOTOXICITY;CAROTID ENDARTERECTOMY;CDKN2A;CELL CYCLE;CEREBRAL ANGIOGRAPHY;CHILDBIRTH;COMPRESSION STOCKINGS;CONSUMPTIVE COAGULOPATHY;CONTRAINDICATION;CROHN'S DISEASE;CRYOPRESERVATION;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;CYTARABINE;DEEP VEIN;DIASTOLE;DIGITAL SUBTRACTION ANGIOGRAPHY;DILATED CARDIOMYOPATHY;DOXORUBICIN;EJECTION FRACTION;ENDOMYOCARDIAL BIOPSY;ENOPHTHALMOS;ETHMOIDECTOMY;ETOPOSIDE;EVIDENCE-BASED MEDICINE;FERTILITY;FLACC SCALE;FLUCONAZOLE;FUNCTIONAL ENDOSCOPIC SINUS SURGERY;GEMCITABINE;GENOTYPE;GROWTH HORMONE;HEART TRANSPLANTATION;HODGKIN LYMPHOMA;HOME HEMODIALYSIS;INDUCTION CHEMOTHERAPY;INTERVENTRICULAR SEPTUM;ISOCITRATE DEHYDROGENASE;LARYNGEAL MASK AIRWAY;LEISURE TIME;LEUKOPENIA;LIFE EXPECTANCY;LIVER TRANSPLANTATION;LUNG FUNCTION;LUPUS ANTICOAGULANT;LYMPHOBLASTIC LEUKEMIA;MEDICAL MALPRACTICE;MICRORNA;MINIMAL RESIDUAL DISEASE;MYCOBACTERIUM TUBERCULOSIS;NEONATAL RESUSCITATION;NEPHRECTOMY;NEUTROPENIA;NOISE (VIDEO);ORGAN TRANSPLANTATION;ORTHOSTATIC VITAL SIGNS;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;PRECENTRAL GYRUS;PROCALCITONIN;PROTEINURIA;PSEUDOMONAS AERUGINOSA;RANDOMIZATION;RITUXIMAB;SENSORINEURAL HEARING LOSS;SINUS (BOTANY);TELEMEDICINE;TEMOZOLOMIDE;THERAPEUTIC TOUCH;THROMBOELASTOMETRY;THYMIC CARCINOMA;TITER;TYPE 2 DIABETES;ULCERATIVE COLITIS;VENOUS THROMBOSIS;VENTILATOR-ASSOCIATED PNEUMONIA;WAIST;WHITE MATTER","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GERIATRIC DEPRESSION SCALE;QUALITY MANAGEMENT SYSTEM;ACINETOBACTER BAUMANNII;ACROMEGALY;AEROALLERGEN;ANTHRACYCLINE;ASPARAGINASE;BASILIXIMAB;CARBOPLATIN;CARMUSTINE;CASPOFUNGIN;CELL CYCLE CHECKPOINT;CHORIOAMNIONITIS;CROHN DISEASE;DEFENSIVE MEDICINE;DEHYDROEPIANDROSTERONE SULFATE;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;DRUG-ELUTING STENT;ECHINOCANDIN;EXOME SEQUENCING;FEBRILE NEUTROPENIA;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;FRACTIONAL ANISOTROPY;GENOTYPING;GERMINAL CENTER;GLOMERULOSCLEROSIS;IDH1;LARYNGEAL MASKS;MICAFUNGIN;MILAN CRITERIA;MISSENSE MUTATION;MOLECULAR EPIDEMIOLOGY;MYCOBACTERIUM TUBERCULOSIS COMPLEX;NON-SMALL CELL LUNG CANCER (NSCLC);ONCOGENE;PEMETREXED;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TELEREHABILITATION;THIOTEPA;TYMPANOMETRY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;VITAMIN D;RETROSPECTIVE STUDIES;VITAMIN D DEFICIENCY;AGED, 80 AND OVER;FOLLOW-UP STUDIES;RISK FACTORS;TREATMENT OUTCOME;YOUNG ADULT;ADOLESCENT;CHILD;INFANT, NEWBORN;PROSPECTIVE STUDIES","45;39;35;27;24;21;19;19;12;11;11;9;8;8;8;8;7;7;7;7","GLIOMAS;VITAMIN D AND HEALTH OUTCOMES;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;HEMATOPOIETIC STEM CELL BIOLOGY;KIDNEY TRANSPLANTATION;LABORATORY MEDICINE AND TESTING PROCEDURES;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ORGAN TRANSPLANTATION AND REJECTION;PEDIATRIC PAIN ASSESSMENT AND MANAGEMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ASTHMA;BIOGENESIS AND FUNCTIONS OF CIRCULAR RNAS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CARDIOTOXICITY OF CANCER TREATMENTS;CHOLANGIOCARCINOMA;CHROMATIN REMODELING IN CANCER AND DEVELOPMENT;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CHRONIC RHINOSINUSITIS AND NASAL POLYPS","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;NEURORADIOLOGY;PAIN ASSESSMENT TOOLS;PAIN MEASUREMENT;PEDIATRIC PAIN;B-CELL RECEPTOR SIGNALING;BUFFY COAT;CARDIAC MAGNETIC RESONANCE;CARDIAC SCREENING;EVEROLIMUS;GERIATRIC DEPRESSION SCALE;GLIOBLASTOMA;HARMONIZATION;IMMUNOSUPPRESSION;INDOCYANINE GREEN;LABORATORY QUALITY MANAGEMENT;LUNG TRANSPLANT;MEDICAL LABORATORY;NEONATAL PAIN;NEURONAVIGATION","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MAGNETIC RESONANCE;PROVA STUDY;SERUM -HYDROXYVITAMIN;BILIARY CIRRHOSIS;BIRTH WEIGHT;BONE MARROW;CARDIAC MAGNETIC;CELL LUNG;INDOCYANINE GREEN;INTENSIVE CARE;LABORATORY MEDICINE;LOW BIRTH;LUNG CANCER;NON-SMALL CELL;PLASMA LEVELS;PRIMARY BILIARY;RANDOMIZED TRIAL;WEIGHT INFANTS;ABO INCOMPATIBLE;ABSTRACT AGE;ABSTRACT JUNCTIONAL;ACID FLUORESCENCE;ACQUIRED TRACHEAL;ACUTE LYMPHOBLASTIC;ADAPTATON DUE;AGE DEPENDENCE;AMINOLEVULINIC ACID;ANATOMICAL SUBSTRATES;ANDOR RADIOTHERAPY;ANEURYSMS ASSISTED","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","PADUA ITALY;OHD LEVELS;ONLINE PUBLICATION;PUBLICATION DATE;CARDIAC THORACIC;SCIENCES UNIVERSITY;VASCULAR SCIENCES;AZIENDA OSPEDALIERA;BB MPM;CB DEPARTMENT;EC BB;EL EC;IR EL;ITALY BG;ITALY KP;ITALY MM;KP IR;LA SAPIENZA;MM GDA;MPM CB;OSPEDALIERA PADUA;PADUA PADUA;PATHOLOGY LA;RADIOLOGY AZIENDA;RADIOLOGY ONCOLOGY;ROME ITALY;SAPIENZA UNIVERSITY;UNIVERSITY ROME;ODDS RATIO;ONLINE NA","21;16;12;12;11;11;11;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;10;9;9",22,0.31,6.24,4.75,1,1,2,4.5,3,0,1,4.75,0,0,5,1,1,1.75,3,3,1.75,0,0,70.75,70.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,5.16,1463.92,24.11,17,0.63,88.96,0,0,4,1,10,1,4,7,0,19,6,0,0,0,0,0,0,26,0,1,24,2,0,1,0,0,0,0,0,0,"United States;Italy;Belgium;United Kingdom;Germany;Netherlands;Sweden","8;4;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3213 PAEDIATRICS;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","25;20;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;AUTOIMMUNE DISEASE;CARDIOVASCULAR;DIGESTIVE DISEASES;HEMATOLOGY;CANCER;INFLAMMATORY BOWEL DISEASE;PEDIATRIC;HEART DISEASE;BRAIN DISORDERS;DIABETES;KIDNEY DISEASE;NEUROSCIENCES;NUTRITION;PSORIASIS;BIOENGINEERING;BIOMEDICAL IMAGING","24;14;9;6;5;5;5;5;4;4;4;3;2;2;2;2;2;2;1;1","CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;METABOLIC AND ENDOCRINE;BLOOD;CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;SKIN;STROKE","3;3;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES","17;2;2;2;2;1;1","LIVER CANCER;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA","2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.2 SURVEILLANCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","4;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,"PUBLIC LIBRARY OF SCIENCE","13","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;4202 EPIDEMIOLOGY;4206 PUBLIC HEALTH;3103 ECOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE","17;7;6;5;3;2;2;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;REGENERATIVE MEDICINE;TRANSPLANTATION","3;3;1;1;1;1","RESPIRATORY;CANCER","2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","9","THYROID CANCER;HEAD AND NECK CANCER;NOT SITE-SPECIFIC CANCER;PITUITARY TUMOR","4;1;1;1",NA,NA
"AOU_PADOVA",2015,80,14.9125,2.1125,0.275,0.175,0.4125,1.35772357723577,1.1,1.16666666666667,1.13793103448276,0.4875,1,47,17,7,6,0.59,0.21,0.09,0.07,44.62,1.19740128501582,5.05544147843943,0.5125,0.9625,0.322,0.274,0.278,0.314,"DANIELE TREVISANUTO;GAYA SPOLVERATO;ALESSANDRO VITALE;SABINA ZAMBON;TIMOTHY M. PAWLIK;A. ALBERTÍ;UMBERTO CILLO;NICOLA VERONESE;GIUSEPPE SERGI;ENZO MANZATO;LEONARDO PUNZI;FRANCESCO CAVALLIN;EGLE PERISSINOTTO;GIOVANNA SCROCCARO;ALESSANDRO DELLA PUPPA;GIUSEPPE LOMBARDI;ASLAM EJAZ;R. D’INCÀ;MARINA DE RUI;GAETANO CREPALDI","5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","ELISA PIVA;DANIELE TREVISANUTO;GAYA SPOLVERATO;ALESSANDRO VITALE;TIMOTHY M. PAWLIK;ASLAM EJAZ;MARIO PLEBANI;UMBERTO CILLO;FRANCESCO CAVALLIN;GIUSEPPE BASSO;ROBERTO BOVO;BERNDT URLESBERGER;ARMANDO TRIPODI;MARIO RÜDIGER;ALESSANDRO MARTINI;JONATHAN WYLLIE;CHARLES CHRISTOPH ROEHR;GIUSEPPE LIPPI;MARIA ROSARIA BARILLARI;JOS BRUINENBERG","1;0.63;0.62;0.62;0.55;0.55;0.5;0.44;0.4;0.34;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33","DANIELE TREVISANUTO;ALESSANDRO VITALE;A. ALBERTÍ;UMBERTO CILLO;LEONARDO PUNZI;ALESSANDRO DELLA PUPPA;R. D’INCÀ;MARIA CATERINA PUTTI;BRUNO GIOMETTO;GIOVANNELLA BAGGIO;GIUSEPPE BASSO;ALBERTO BURLINA;FRANCESCA SIMONETTI;LAURA SAINATI;EMANUELE BERTAGLIA;GIUSEPPE TARANTINI;S BELLIA;MARIO PLEBANI;STEFANO PIASERICO;LUISA MURER","5;5;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2","ELISA PIVA;DANIELE TREVISANUTO;ALESSANDRO VITALE;MARIO PLEBANI;UMBERTO CILLO;GIUSEPPE BASSO;LEONARDO PUNZI;ALESSANDRO DELLA PUPPA;R. D’INCÀ;BRUNO GIOMETTO;PAOLO BONVINI;FEDERICA LOVISA;MARIA CATERINA PUTTI;STEFANO PIASERICO;R MARCOLONGO;GIOVANNELLA BAGGIO;A. ALBERTÍ;COSTANTINO BOTSIOS;MARICA PERON;FRANCESCO CAUSIN","1;0.63;0.62;0.5;0.44;0.34;0.32;0.31;0.31;0.3;0.29;0.29;0.26;0.25;0.25;0.23;0.23;0.22;0.2;0.2","DANIELE TREVISANUTO;ALBERTO BURLINA;EMANUELE BERTAGLIA;SABINO ILICETO;ALBERTO CIPRIANI;ANNA CHIARA FRIGO;BARBARA BAUCE;BENEDETTA GIORGI;CRISTINA BASSO;DOMENICO CORRADO;FEDERICO MIGLIORE;GAETANO THIENE;ILARIA RIGATO;KALLIOPI PILICHOU;LUISA CACCIAVILLANI;MANUEL DE LAZZARI;MARTINA PERAZZOLO MARRA;STEFANIA RIZZO;ALLAN M. LUND;B. CHABROL","591;540;511;499;494;494;494;494;494;494;494;494;494;494;494;494;494;494;493;493","DANIELE TREVISANUTO;ALBERTO BURLINA;EMANUELE BERTAGLIA;CRISTINA BASSO;DOMENICO CORRADO;MANUEL DE LAZZARI;FRANCESCA FURLAN;GIOVANNELLA BAGGIO;CARLA CREMONESE;PAOLO SANTONASTASO;CESARE CUTRONE;ALESSANDRO VITALE;GIOVANELLA BAGGIO;MARTA PILLON;NICOLETTA DOGLIONI;SIMONE STEVANIN;GIAN LUCA BABBO;LAURA SAINATI;LUISA MURER;ALESSANDRO DELLA PUPPA","591;540;511;494;494;494;419;292;103;103;98;95;77;76;68;68;62;62;62;61","ALESSANDRO VITALE;DANIELE TREVISANUTO;ALESSANDRO DELLA PUPPA;ALBERTO BURLINA;GIOVANNELLA BAGGIO;R. D’INCÀ;UMBERTO CILLO;A. ALBERTÍ;ALESSANDRA RIGO;ANDREA VIANELLO;EMANUELE BERTAGLIA;EUGENI DOMÈNECH;FEDERICA LOVISA;FRANCESCA FURLAN;FRANCESCA SIMONETTI;GIORGIO BROGIATO;GIUSEPPE BASSO;GIUSEPPE TARANTINI;JULIÀN PANÉS;LUDOVICA FRIZZIERO","5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;BUSINESS;MATHEMATICS;CHEMISTRY;GEOGRAPHY;SOCIOLOGY;ENVIRONMENTAL SCIENCE;PHILOSOPHY","78;17;10;9;7;6;4;4;3;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;PEDIATRICS;IMMUNOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;GENETICS;RISK ANALYSIS (ENGINEERING);BIOCHEMISTRY;CARDIOLOGY;PHYSICAL THERAPY;CANCER RESEARCH;ENDOCRINOLOGY;OPTICS;PHARMACOLOGY;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;NURSING;ANESTHESIA;ECONOMIC GROWTH;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;GENERAL SURGERY;LAW;NUCLEAR MEDICINE;PSYCHIATRY;RADIOLOGY;UROLOGY","61;29;13;12;11;10;10;8;8;7;7;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","DISEASE;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;CANCER;GENE;HEART FAILURE;INCIDENCE (GEOMETRY);TRANSPLANTATION;COHORT;CONFIDENCE INTERVAL;ANEMIA;ASYMPTOMATIC;COST EFFECTIVENESS;HEALTH CARE;NEWBORN SCREENING;PSYCHOLOGICAL INTERVENTION;RETROSPECTIVE COHORT STUDY;VIRUS;ALTERNATIVE MEDICINE;BLOOD PRESSURE;CLINICAL TRIAL;CONCOMITANT;CONFOUNDING;DRUG;ENCEPHALOPATHY;EPIDEMIOLOGY;GLIOBLASTOMA;KINASE;ODDS RATIO;POPULATION;PREGNANCY;RADIATION THERAPY;RESUSCITATION;SIGNAL TRANSDUCTION;VENTILATION (ARCHITECTURE);VITAMIN B12","14;12;7;7;7;6;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;LIVER TRANSPLANTATION;METHYLMALONIC ACID;TEMOZOLOMIDE;ARGININE;BIRTH WEIGHT;CARDIOMYOPATHY;CARDIOPULMONARY RESUSCITATION;EJECTION FRACTION;ERYTHROPOIESIS;ESOPHAGEAL CANCER;HAZARD RATIO;HEALTH MANAGEMENT SYSTEM;HEART RATE;HEPATITIS C VIRUS;INFLAMMATORY BOWEL DISEASE;INFLIXIMAB;LEFT BUNDLE BRANCH BLOCK;MALIGNANT PLEURAL EFFUSION;METASTASIS;MULTICENTER STUDY;MUTATION;NEONATAL RESUSCITATION;NEURORADIOLOGY;PROSTATE CANCER;PROTEOMICS;QUALITY-ADJUSTED LIFE YEAR;TYROSINE KINASE;ULCERATIVE COLITIS","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","METHYLMALONIC ACIDURIA;CRIZOTINIB;DISEASE MANAGEMENT;INEFFECTIVE ERYTHROPOIESIS;PROSTATECTOMY;RETICULOCYTE;RIBAVIRIN;UREA CYCLE;ACROMEGALY;ACUTE CHEST SYNDROME;ANAPLASTIC LYMPHOMA KINASE;ANEMIA OF CHRONIC DISEASE;ANNEXIN A5;APGAR SCORE;BRAIN METASTASIS;CARDIAC RESYNCHRONIZATION THERAPY;CERVICAL INTRAEPITHELIAL NEOPLASIA;CIRCULATING TUMOR CELL;COLECTOMY;COLPOSCOPY;COMPOUND HETEROZYGOSITY;CUTANEOUS LARVA MIGRANS;DACLIZUMAB;DIFFUSE ALVEOLAR DAMAGE;EPOXYGENASE;ESOPHAGECTOMY;EXOME SEQUENCING;FETAL HEMOGLOBIN;IMMATURE TERATOMA;LUNG FIBROSIS;MEAN ARTERIAL PRESSURE;MILAN CRITERIA;MITOCHONDRIAL DISEASE;OCCUPATIONAL INJURY;OSTEOPOROTIC FRACTURE;POINT MUTATION;PROTEIN KINASE DOMAIN;PROTHROMBIN COMPLEX CONCENTRATE;RECEPTOR PROTEIN-TYROSINE KINASES;SPECKLE TRACKING ECHOCARDIOGRAPHY;VISCERAL LARVA MIGRANS","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;ADULT;AGED;MIDDLE AGED;ITALY;YOUNG ADULT;LIVER NEOPLASMS;CHILD;IMMUNOSUPPRESSIVE AGENTS;TREATMENT OUTCOME;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;ADOLESCENT;INFANT, NEWBORN;ADRENAL CORTEX HORMONES;CARCINOMA, HEPATOCELLULAR;HEPATECTOMY","50;37;35;28;26;20;19;17;15;14;11;11;11;10;10;9;9;8;8;8","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GLIOMAS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;CHOLANGIOCARCINOMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;ESOPHAGEAL INTERVENTION TECHNIQUES;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HEPATOCELLULAR CARCINOMA;KIDNEY TRANSPLANTATION;MANAGEMENT AND TREATMENT OF HEMOPHILIA;METABOLISM AND FUNCTION OF ARACHIDONIC ACID DERIVATIVES;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;RHEUMATOID ARTHRITIS;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ARISTOLOCHIC ACID NEPHROPATHY AND UROTHELIAL CANCER;BRAIN LATERALIZATION AND HANDEDNESS IN HUMANS AND ANIMALS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE","5;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CLINICAL ENDPOINT;CONCOMITANT;GLIOBLASTOMA;METHYLMALONIC ACIDURIA;NEONATAL RESUSCITATION;RADIOTHERAPY;TEMOZOLOMIDE;ALK INHIBITORS;BOCEPREVIR;CARDIOTHORACIC SURGERY;COMPARABILITY;COST-EFFECTIVENESS ANALYSIS;CROSS-SECTIONAL STUDY;DISEASE MANAGEMENT;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS;DRUG DEVELOPMENT COSTS;ETIOLOGY;HYPERTENSION;INEFFECTIVE ERYTHROPOIESIS;INTRAHEPATIC CHOLANGIOCARCINOMA","3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ITALIAN ASSOCIATION;AINO ITALIAN;HEPATIC RESECTION;ORGANIC ACIDURIAS;VENETO REGION;CHRONIC HEPATITIS;CONCOMITANT TEMOZOLOMIDE;COST-UTILITY ANALYSIS;CYCLE DISORDERS;ELDERLY PATIENTS;HEALTH BENEFIT;HEPATOCELLULAR CARCINOMA;INEFFECTIVE ERYTHROPOIESIS;INFLAMMATORY BOWEL;INTEGRATED MANAGEMENT;INTRAHEPATIC CHOLANGIOCARCINOMA;ITALIAN PEDIATRIC;LIVER RESECTION;MULTICENTER RETROSPECTIVE;MULTIDISCIPLINARY EXPERIENCE;NEONATAL RESUSCITATION;NET HEALTH;PATIENTS TREATED;PHENOTYPIC SPECTRUM;PROVA STUDY;REAL WORLD;RETROSPECTIVE STUDY;RHEUMATIC DISEASE;SICKLE CELL;UREA CYCLE","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IU ML;ML PLT;LEFT VENTRICULAR;ORTHOSTATIC HYPERTENSION;ALK KINASE;HR CI;IRON OVERLOAD;REAL WORLD;WORLD DATA;CLINICAL TRIALS;CRISIS COMPARED;ELBW INFANTS;IRON CHELATORS;MEDICAL THERAPY;MP CD;PATIENTS MALES;SIGNIFICANTLY LOWER;SSC PATIENTS;TIME HORIZON;VENTRICULAR ARRHYTHMIAS;VENTRICULAR GLOBAL;ADVERSE EVENTS;AGE YRS;ALLOGENIC SKIN;CARDIAC MORBIDITY;CD PATIENTS;CHEST CRISIS;CHRONIC DISEASE;CHRONIC ULCERS;CLINICAL PRACTICE","13;10;9;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4",33,0.41,7.05,8,1,1.75,0,1,10,0,1,8,0,0,7,1,2,1.5,2.5,5,3,0,0,97,97,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,4.06,687.89,31.67,14,0.37,53.11,2,3,6,0,6,0,6,15,0,26,9,0,0,0,0,0,0,37,0,1,34,3,0,1,0,0,0,0,0,0,"Italy;Germany;United States;Japan;Belgium;Netherlands","9;7;5;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","36;20;5;4;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;PATIENT SAFETY;PREVENTION;PEDIATRIC;RARE DISEASES;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOENGINEERING;DIGESTIVE DISEASES;HEART DISEASE - CORONARY HEART DISEASE;CANCER;HEMATOLOGY;PEDIATRIC CANCER;TRANSPLANTATION;CHILDHOOD LEUKEMIA;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIABETES","28;21;11;11;11;7;6;5;4;4;4;4;4;3;3;3;3;2;2;2","CARDIOVASCULAR;METABOLIC AND ENDOCRINE;CANCER;INFECTION;ORAL AND GASTROINTESTINAL;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;STROKE","9;3;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","18;5;4;3;1;1;1","LEUKEMIA / LEUKAEMIA;BLOOD CANCER;COLON AND RECTAL CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER","2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1",2,5434036,421663.72,6,13.5,6,1,7.5,455002.352695767,0.175823266684274,"AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AZIENDA OSPEDALIERA DI PADOVA;HOSPITAL CLÍNIC DE BARCELONA;UNIVERSITY OF PADUA;ALPHA BIORESEARCH (SPAIN);ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;CORLIFE (GERMANY);EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE;HANNOVER MEDICAL SCHOOL;INSTITUT CATALÀ DE LA SALUT;KU LEUVEN;LEIBNIZ UNIVERSITY HANNOVER;LEIDEN UNIVERSITY MEDICAL CENTER;MADRID HEALTH SERVICE;MAST CARBON (UNITED KINGDOM);ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF BERN;UNIVERSITY OF BOLOGNA;UNIVERSITY OF BRIGHTON","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);H2020-PHC-2014-SINGLE-STAGE (CALL FOR PROPOSAL);H2020-PHC-2014-TWO-STAGE (CALL FOR PROPOSAL)","2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;3207 MEDICAL MICROBIOLOGY","2;1;1;1;1","ALCOHOLISM, ALCOHOL USE AND HEALTH;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;HEART DISEASE;HEPATITIS;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;REGENERATIVE MEDICINE;SUBSTANCE MISUSE;TRANSPLANTATION","1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL","1;1;1","5.1 PHARMACEUTICALS","1","LIVER CANCER","1",NA,NA,"A01 CLINICAL MEDICINE;B12 ENGINEERING","1;1","3 GOOD HEALTH AND WELL BEING","1",10,"PUBLIC LIBRARY OF SCIENCE","10","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;49 MATHEMATICAL SCIENCES;3103 ECOLOGY;3105 GENETICS;3203 DENTISTRY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;4904 PURE MATHEMATICS","13;4;3;2;2;2;1;1;1;1;1;1","GENETICS;PEDIATRIC;CANCER;RARE DISEASES;CLINICAL RESEARCH;HUMAN GENOME;PEDIATRIC CANCER;AUTOIMMUNE DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETIC TESTING;HEMATOLOGY;LYMPHOMA","4;4;3;3;2;2;2;1;1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","3;1;1;1","CLINICAL","3","CLINICAL MEDICINE AND SCIENCE","3","SARCOMA;NON-HODGKIN'S LYMPHOMA","2;1",NA,NA
"AOU_PADOVA",2016,107,12.2242990654206,2.10280373831776,0.214953271028037,0.224299065420561,0.308411214953271,1.46103896103896,1.21052631578947,1.09090909090909,1.22222222222222,0.532710280373832,0,61,29,8,3,0.57,0.27,0.07,0.03,30.5,0.939096246916355,5.31698113207547,0.317757009345794,0.962616822429907,0.44,0.337,0.35,0.356,"VITTORINA ZAGONEL;GIUSEPPE BASSO;ALESSANDRO VITALE;LUISA MURER;LUISA BELLU;DANIELE TREVISANUTO;GIORGIO ARRIGONI;ALESSANDRO DELLA PUPPA;GIUSEPPE LOMBARDI;PASQUALE FIDUCCIA;DOMENICO D’AVELLA;EMANUELE BERTAGLIA;SABINA ZAMBON;MARIO PLEBANI;UMBERTO CILLO;NICOLA VERONESE;GIUSEPPE SERGI;GIOVANNELLA BAGGIO;ENZO MANZATO;ELISA BENETTI","7;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","MARIO PLEBANI;DANIELE TREVISANUTO;RAFFAELLA COLOMBATTI;ALESSANDRO VITALE;ALESSANDRO DELLA PUPPA;DOMENICO D’AVELLA;VITTORINA ZAGONEL;GIORGIO ARRIGONI;LAURA SAINATI;GIUSEPPE LOMBARDI;LUISA BELLU;PASQUALE FIDUCCIA;HEIKE JAHNKE;RENATO SCIENZA;LUISA MURER;UMBERTO CILLO;ARDI PAMBUKU;GAYA SPOLVERATO;ORIELA RUSTEMI;GIUSEPPE BASSO","0.83;0.78;0.74;0.73;0.72;0.65;0.65;0.6;0.59;0.54;0.5;0.5;0.5;0.49;0.48;0.46;0.45;0.43;0.42;0.42","GIUSEPPE BASSO;ALESSANDRO VITALE;LUISA MURER;DANIELE TREVISANUTO;GIORGIO ARRIGONI;ALESSANDRO DELLA PUPPA;EMANUELE BERTAGLIA;MARIO PLEBANI;UMBERTO CILLO;GIOVANNELLA BAGGIO;ELISA BENETTI;R. D’INCÀ;RAFFAELLA COLOMBATTI;MARINA PAOLA GARDIMAN;FEDERICO MIGLIORE;MARIA CATERINA PUTTI;MARTINA PERAZZOLO MARRA;CINZIA FRANCHIN;ANNA MARIA CATTELAN;LOIRA LEONI","6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3","MARIO PLEBANI;DANIELE TREVISANUTO;RAFFAELLA COLOMBATTI;ALESSANDRO VITALE;ALESSANDRO DELLA PUPPA;GIORGIO ARRIGONI;LAURA SAINATI;RENATO SCIENZA;LUISA MURER;UMBERTO CILLO;GAYA SPOLVERATO;ORIELA RUSTEMI;GIUSEPPE BASSO;ELISA BENETTI;MARINA PAOLA GARDIMAN;ANNA MARIA CATTELAN;NICOLETTA DOGLIONI;MARIA BARBIERATO;MARIA LUISA SCAPELLATO;GIUSEPPE TANZILLO","0.83;0.78;0.74;0.73;0.72;0.6;0.59;0.49;0.48;0.46;0.43;0.42;0.42;0.42;0.41;0.34;0.34;0.33;0.33;0.33","A. PREZOTTI;A.C. SANDOVAL GONZALEZ;AMAL EL‐BESHLAWY;ANUPAM SACHDEVA;BRIAN M. WICKLUND;BÜLENT ANTMEN;BÜLENT ZÜLFIKAR;CECIL ROSS;CHRISTOPH MALE;DANIELA NEME;DINESH NAYAK;E. MARZOUKA;ELENA SANTAGOSTINO;EZIO ZANON;FLORA PEYVANDI;FRITS R. ROSENDAAL;GUY YOUNG;ISABELLA GARAGIOLA;JOHNNY MAHLANGU;KAAN KAVAKLI","436;436;436;436;436;436;436;436;436;436;436;436;436;436;436;436;436;436;436;436","EZIO ZANON;MARTINA PERAZZOLO MARRA;GIOVANNELLA BAGGIO;R MARCOLONGO;ALESSANDRO ZORZI;ALICE NIERO;ANGELA SUSANA;ANTONIO PELLICCIA;BARBARA BAUCE;BENEDETTA GIORGI;CRISTINA BASSO;DOMENICO CORRADO;ELIA DE MARIA;FEDERICO MIGLIORE;GAETANO THIENE;GIAMPIERO PATRIZI;GIORGIO DE CONTI;ILARIA RIGATO;KALLIOPI PILICHOU;LUIS SERRATOSA","436;361;278;273;269;269;269;269;269;269;269;269;269;269;269;269;269;269;269;269","ALESSANDRO VITALE;GIORGIO ARRIGONI;LUISA MURER;DANIELE TREVISANUTO;ELISA BENETTI;R. D’INCÀ;RAFFAELLA COLOMBATTI;ALESSANDRO DELLA PUPPA;GIOVANNELLA BAGGIO;EMANUELE BERTAGLIA;ANNA MARIA CATTELAN;CINZIA FRANCHIN;GERMANA LONGO;GIUSEPPE BASSO;LOIRA LEONI;MARIA CATERINA PUTTI;MARIO PLEBANI;UMBERTO CILLO;MARINA PAOLA GARDIMAN;ALBERTO BURLINA","6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;COMPUTER SCIENCE;GEOLOGY;MATHEMATICS;ART;BUSINESS;MATERIALS SCIENCE;PHILOSOPHY","104;26;12;9;8;6;6;6;5;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;CARDIOLOGY;GENETICS;PATHOLOGY;PEDIATRICS;CANCER RESEARCH;IMMUNOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;OPTICS;BIOCHEMISTRY;ANESTHESIA;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;EMERGENCY MEDICINE;LAW;NURSING;PALEONTOLOGY","83;32;19;15;14;14;14;14;11;11;11;10;10;9;8;7;7;6;6;6;6","COHORT;DISEASE;GENE;INCIDENCE (GEOMETRY);POPULATION;CANCER;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;CONFIDENCE INTERVAL;MAGNETIC RESONANCE IMAGING;PREGNANCY;ALTERNATIVE MEDICINE;ANTIBODY;DIABETES MELLITUS;GLIOBLASTOMA;TRANSPLANTATION;ABLATION;ATRIAL FIBRILLATION;BLOOD PRESSURE;COMPLICATION;HEART FAILURE;PROSPECTIVE COHORT STUDY;THROMBOSIS","19;15;10;10;9;8;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4","BREAST CANCER;CLINICAL ENDPOINT;PLACEBO;CATHETER ABLATION;COLORECTAL CANCER;FETUS;INFLAMMATORY BOWEL DISEASE;NEONATAL RESUSCITATION;PULMONARY VEIN;SICKLE CELL ANEMIA;TITER;ASTROCYTOMA;CUMULATIVE INCIDENCE;DEEP VEIN;DEFERIPRONE;DIASTOLE;EJECTION FRACTION;GENE EXPRESSION;HMGB1;LEFT BUNDLE BRANCH BLOCK;METASTASIS;NEURORADIOLOGY;PAROXYSMAL ATRIAL FIBRILLATION;PHENOTYPE;RESPIRATORY DISEASE;RITUXIMAB;SALVAGE THERAPY;VENTRICULAR PACING;VIRAL LOAD","4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANAPLASTIC ASTROCYTOMA;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;COLONOSCOPY;DOUBLE BLIND;EXOME SEQUENCING;METASTATIC BREAST CANCER;PRENATAL DIAGNOSIS;ALTERNATIVE COMPLEMENT PATHWAY;AMPHIREGULIN;ANTIBODY TITER;ATYPICAL HEMOLYTIC UREMIC SYNDROME;BRAIN METASTASIS;BRONCHOPLEURAL FISTULA;BRONCHUS;CALPROTECTIN;CD40;CD46;CLASSICAL HODGKIN LYMPHOMA;COGNITIVE DECLINE;CORONAVIRUS DISEASE 2019 (COVID-19);DEHYDROEPIANDROSTERONE SULFATE;DIASTOLIC FUNCTION;DNA METHYLATION;DOPPLER ECHOCARDIOGRAPHY;DRUG-ELUTING STENT;ECULIZUMAB;FACTOR H;FAMILY PLANNING;FETAL HEART;FETAL HEMOGLOBIN;FRACTIONAL ANISOTROPY;GATA3;GERIATRIC DEPRESSION SCALE;GLOMERULOPATHY;GLYCATED HEMOGLOBIN;GP41;GRANULOMATOSIS WITH POLYANGIITIS;HAPLOINSUFFICIENCY;HORMONAL THERAPY;INEFFECTIVE ERYTHROPOIESIS;INFLAMMATORY BOWEL DISEASES;INTERMITTENT PNEUMATIC COMPRESSION;IRINOTECAN;JAG1;KAPOSI'S SARCOMA;LEUCONOSTOC;MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;MICROSCOPIC POLYANGIITIS;MILAN CRITERIA;MONONEURITIS MULTIPLEX;NEUROPSYCHOLOGICAL ASSESSMENT;OXALIPLATIN;PAPILLARY CARCINOMA;PENETRANCE;PLEURAL DISEASE;PRESYNCOPE;REACTOGENICITY;RETICULOCYTE;RIVAROXABAN;SYSTEMIC THERAPY;SYSTEMIC VASCULITIS;TAMOXIFEN;TRANSCRIPTOME;TRANSFERRIN SATURATION;TRASTUZUMAB;UBIQUITIN LIGASE;UREA CYCLE;VERBAL FLUENCY TEST","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;ITALY;AGED;MIDDLE AGED;ADULT;ADOLESCENT;CHILD;AGED, 80 AND OVER;BRAIN NEOPLASMS;PROSPECTIVE STUDIES;RISK FACTORS;TREATMENT OUTCOME;YOUNG ADULT;CHILD, PRESCHOOL;RETROSPECTIVE STUDIES;MAGNETIC RESONANCE IMAGING;BACTEREMIA","68;47;44;38;25;23;22;18;14;14;12;12;12;11;11;11;10;10;9;8","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GLIOMAS;ATRIAL FIBRILLATION;CHOLANGIOCARCINOMA;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ACUTE MYELOID LEUKEMIA;BIOCHEMISTRY OF DIABETIC COMPLICATIONS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;MOLECULAR RESEARCH ON BREAST CANCER;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATOPIC DERMATITIS AND SKIN MICROBIOME;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CHOLESTEROL-LOWERING TREATMENT","5;5;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL ENDPOINT;GLIOBLASTOMA;SICKLE-CELL DISEASE;ACUTE MYELOID LEUKEMIA;FRAILTY;NEONATAL RESUSCITATION;ANAPLASTIC ASTROCYTOMA;ANTICOAGULANT THERAPY;ATRIAL FIBRILLATION;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOVASCULAR EVALUATION;CATHETER ABLATION;CONSENSUS CONFERENCE;CUMULATIVE INCIDENCE;DEFERIPRONE;EXOME;FETAL CARDIAC DISEASE;GOLD STANDARD (TEST);HEMATOLOGY","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LONGITUDINAL STUDY;SICKLE CELL;ATRIAL FIBRILLATION;BOWEL DISEASE;BREAST CANCER;GLIOBLASTOMA GBM;INFLAMMATORY BOWEL;ITALIAN REGISTRY;LEFT VENTRICULAR;OBSERVATIONAL STUDY;REAL-LIFE EXPERIENCE;ANAPLASTIC ASTROCYTOMA;ANZIANI LONGITUDINAL;ASTROCYTOMA AA;CELL ANEMIA;CELL DISEASE;COGNITIVE IMPAIRMENT;CONSENSUS CONFERENCE;CONTROLLED TRIAL;CRYOBALLOON ABLATION;DOVE STUDY;DRUG-ELUTING STENT;DUAL ANTIPLATELET;ELDERLY PATIENTS;ENDOSCOPIC REMISSION;FECAL HMGB;GENETIC BIOBANKS;HEPATOCELLULAR CARCINOMA;HMGB REVEALS;INTRAHEPATIC CHOLANGIOCARCINOMA","4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","AFRICAMIDDLE EAST;ECOG PS;NEONATAL RESUSCITATION;NORTH AFRICAMIDDLE;CLINICAL OUTCOME;RESEARCH FUNDING;CROHNS DISEASE;HR CI;RECURRENT PERICARDITIS;ITALY DEPARTMENT;MG KG;POSTBARIATRIC SURGERY;PROGNOSTIC FACTORS;PTS PERFORMED;ULCERATIVE COLITIS;UNDERWENT SURGERY;ATOPIC DERMATITIS;COMPANY EMPLOYMENT;ORAL REHYDRATION;PATIENTS UNDERGOING;RADICAL SURGERY;SEVERE ATOPIC;WOOLEN CAP;BONE MARROW;CARDIAC RESYNCHRONIZATION;CD EXPRESSION;CHILDREN AGED;CLINICAL TRIALS;COMPANY RESEARCH;CONFIDENCE INTERVAL","9;9;9;9;8;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4",40,0.37,9.75,11.75,3,1,2.5,10,6.5,0,1,12.75,0,1,10.5,0,0,2,5.5,9,4,0,0,77.25,78,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,3.9,734.66,19.46,16,0.55,80.66,0,0,10,0,8,0,1,10,0,22,7,0,0,0,0,0,0,28,0,1,29,0,0,0,0,0,0,0,0,0,"Germany;Japan;United States;Italy;France","5;5;5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","27;17;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;AUTOIMMUNE DISEASE;CANCER;NEUROSCIENCES;PREVENTION;BRAIN DISORDERS;CARDIOVASCULAR;PEDIATRIC;HEART DISEASE;ORPHAN DRUG;BEHAVIORAL AND SOCIAL SCIENCE;DIGESTIVE DISEASES;HEMATOLOGY;LUNG;NEURODEGENERATIVE;ATHEROSCLEROSIS;COMPLEMENTARY AND INTEGRATIVE HEALTH","27;17;10;9;6;6;6;6;5;5;5;4;4;3;3;3;3;3;2;2","CARDIOVASCULAR;CANCER;NEUROLOGICAL;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;METABOLIC AND ENDOCRINE;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","6;5;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","20;3;2;1;1;1","LUNG CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;BREAST CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;SARCOMA","2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","6",1,7941665,317666.6,6,25,14,1,11,507946.7860291,0.210651987458131,"ANDALUSIAN HEALTH SERVICE;AZIENDA OSPEDALIERA DI PADOVA;BAMBINO GESÙ CHILDREN'S HOSPITAL;CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES;CHILDREN'S HEALTH IRELAND AT CRUMLIN;CINECA;CLALIT HEALTH SERVICES;CLINIQUES UNIVERSITAIRES SAINT-LUC;INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL;INSTITUTO MAIMÓNIDES DE INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA;KIEL UNIVERSITY;LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN;MEDICAL UNIVERSITY OF GDAŃSK;MEVIS MEDICAL SOLUTIONS (GERMANY);NEWCASTLE UNIVERSITY;OSLO UNIVERSITY HOSPITAL;PRINCESS MÁXIMA CENTER;ST ANNA CHILDREN'S HOSPITAL;UNIVERSITY HOSPITAL BONN;UNIVERSITY HOSPITAL IN MOTOL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2015-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;LIVER CANCER;LIVER DISEASE;PATIENT SAFETY;PEDIATRIC;PREVENTION;RARE DISEASES","1;1;1;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL","1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.4 SURGERY","1;1;1","LIVER CANCER","1",NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",10,"PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS","9;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","11;2;2;1;1;1;1;1;1;1","BIOMEDICAL IMAGING;CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;FOODBORNE ILLNESS;HEPATITIS;INFECTIOUS DISEASES;LIVER DISEASE;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD","1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","1;1;1;1;1;1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","4;1","HEAD AND NECK CANCER;THYROID CANCER","1;1",NA,NA
"AOU_PADOVA",2017,111,17.4144144144144,1.82882882882883,0.126126126126126,0.162162162162162,0.216216216216216,1.42957746478873,1,0.947368421052632,1.04347826086957,0.558558558558559,1,67,21,12,7,0.6,0.19,0.11,0.06,21.93,0.743949372944501,4.99826086956521,0.252252252252252,0.981981981981982,0.396,0.355,0.349,0.37,"VITTORINA ZAGONEL;PIERFRANCO CONTÉ;ENRICO ORVIETO;GAIA GRIGUOLO;VALENTINA GUARNERI;EMANUELE BERTAGLIA;CINZIA FRANCHIN;ANNA MARIA CATTELAN;GIAMPAOLO TORTORA;GIUSEPPE STABILE;FRANCESCO CAVALLIN;GIORGIO ARRIGONI;MAURIZIO MALACRIDA;PAOLA DEL BIANCO;MARIA VITTORIA DIECI;MARIA CATERINA PUTTI;SIMONE CESARO;GIAN LUCA DE SALVO;MARCO SCARPA;GIANCARLO OROFINO","7;7;7;7;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4","RAFFAELLA COLOMBATTI;VITTORINA ZAGONEL;CINZIA FRANCHIN;GIORGIO ARRIGONI;A. MANGANO;FABRIZIO MORO;ANNA MARIA CATTELAN;FRANCESCO CAVALLIN;PIERFRANCO CONTÉ;ENRICO ORVIETO;GAIA GRIGUOLO;PAOLA DEL BIANCO;ARDI PAMBUKU;EZIO ZANON;VALENTINA GUARNERI;GIULIA PESERICO;FRANCESCO FASCETTI LEON;LUISA BELLU;GIACOMO MEZZAPELLE;EMANUELE BERTAGLIA","1.1;0.62;0.5;0.5;0.5;0.5;0.46;0.44;0.43;0.43;0.43;0.42;0.39;0.38;0.35;0.35;0.34;0.34;0.33;0.33","PIERFRANCO CONTÉ;ENRICO ORVIETO;GAIA GRIGUOLO;VALENTINA GUARNERI;EMANUELE BERTAGLIA;CINZIA FRANCHIN;ANNA MARIA CATTELAN;GIORGIO ARRIGONI;MARIA CATERINA PUTTI;TOMMASO GIARRATANO;R. D’INCÀ;LAURA SAINATI;CARMELO LACOGNATA;MARIO PLEBANI;PAOLA LAGO;CLAUDIA MESCOLI;GIUSEPPE VERLATO;RENATO ZAMBELLO;RAFFAELLA COLOMBATTI;MARINA PAOLA GARDIMAN","7;7;7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","RAFFAELLA COLOMBATTI;CINZIA FRANCHIN;GIORGIO ARRIGONI;A. MANGANO;ANNA MARIA CATTELAN;PIERFRANCO CONTÉ;ENRICO ORVIETO;GAIA GRIGUOLO;EZIO ZANON;VALENTINA GUARNERI;GIULIA PESERICO;EMANUELE BERTAGLIA;ANDREA BARTOLINI;VALERIA BESUTTI;MARCO PUTHENPARAMPIL;GIULIA ZORZI;LISA FEDERLE;MAURO BUTTARELLO;PAOLA PERINI;CLAUDIA MESCOLI","1.1;0.5;0.5;0.5;0.46;0.43;0.43;0.43;0.38;0.35;0.35;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.3","ADAM SHLIEN;BEN GEORGE;BRITTANY CAMPBELL;DAVID MALKIN;DAVID S. ZIEGLER;DAVID SAMUEL;DUNCAN STEARNS;ENRICO OPOCHER;KRISTINA A. COLE;M. STEPHEN MEYN;MAGNUS SABEL;NICHOLAS LIGHT;URI TABORI;VALÉRIE LAROUCHE;ÉRIC BOUFFET;ANNIE HUANG;ANNIKA BRONSEMA;CAROL DURNO;CHRISTIAN P. KRATZ;CYNTHIA HAWKINS","665;665;665;665;665;665;665;665;665;665;665;665;665;665;665;664;664;664;664;664","ENRICO OPOCHER;MONICA VEDOVATO;GIORGIO ARRIGONI;AUGUSTO D’ONOFRIO;ANNA MARIA CATTELAN;CHIARA BRIANI;LUISA MURER;PAOLA LAGO;CINZIA FRANCHIN;MARIA CATERINA PUTTI;LUCA CESARO;MARIO PLEBANI;LUCIA DE FRANCESCHI;MARTINA ZANINOTTO;STEFANO SCALCO;PAOLO SANTONASTASO;EUGENIO BARALDI;ROBERTA POZZATO;ELEONORA BIZZOTTO;RAFFAELLA COLOMBATTI","665;255;195;134;108;99;97;96;91;72;60;55;52;45;44;42;40;40;38;37","ENRICO ORVIETO;ANNA MARIA CATTELAN;GIORGIO ARRIGONI;MARIA CATERINA PUTTI;R. D’INCÀ;CINZIA FRANCHIN;GIUSEPPE VERLATO;MARIO PLEBANI;CARMELO LACOGNATA;CLAUDIA MESCOLI;PAOLA LAGO;RENATO ZAMBELLO;ANNA COLPO;AUGUSTO D’ONOFRIO;CA GIORGI;CRISTINA FALCI;CRISTINA GHIOTTO;ELEONORA MIORANZA;ELISABETTA SARACENI;ENRICO OPOCHER","7;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;MATHEMATICS;SOCIOLOGY;BUSINESS;ECONOMICS;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE","105;27;8;7;7;7;5;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;ENVIRONMENTAL HEALTH;PATHOLOGY;ONCOLOGY;GASTROENTEROLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;CARDIOLOGY;PSYCHIATRY;CANCER RESEARCH;PALEONTOLOGY;ANESTHESIA;NURSING;OPTICS;MECHANICAL ENGINEERING;CELL BIOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE","90;28;18;18;17;15;15;13;11;11;9;9;9;8;8;6;6;6;5;4;4;4","CANCER;COHORT;DISEASE;POPULATION;GENE;CHEMOTHERAPY;PROSPECTIVE COHORT STUDY;COHORT STUDY;INCIDENCE (GEOMETRY);LOGISTIC REGRESSION;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION;ADVERSE EFFECT;ANTIBODY;CLINICAL TRIAL;MULTIVARIATE ANALYSIS;REGIMEN;STAGE (STRATIGRAPHY);CONFIDENCE INTERVAL;LYMPH NODE;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;RANDOMIZED CONTROLLED TRIAL","20;14;14;14;11;9;9;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;B CELL;CROHN'S DISEASE;VIRAL LOAD;ANAL CANCER;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BONE MINERAL;CD8;COMPLEMENT SYSTEM;CRISPR;CYCLOPHOSPHAMIDE;DNA REPAIR;EJECTION FRACTION;ESOPHAGEAL CANCER;FETUS;GERMLINE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMATINIB;INFLAMMATORY BOWEL DISEASE;METASTASIS;MUTATION;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PLACEBO;PROGRESSION-FREE SURVIVAL;PROTEIN KINASE A;PROTEIN SUBUNIT;PROTEOMICS;SALVAGE THERAPY;SICKLE CELL ANEMIA;TEMOZOLOMIDE;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS","7;6;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACUTE CHEST SYNDROME;ANTIRETROVIRAL THERAPY;DNA MISMATCH REPAIR;ESOPHAGECTOMY;GERMLINE MUTATION;IMATINIB MESYLATE;INVASIVE DUCTAL CARCINOMA;SOMATIC HYPERMUTATION;ABDOMINOPERINEAL RESECTION;ALTERNATIVE COMPLEMENT PATHWAY;ANAPLASTIC ASTROCYTOMA;B-CELL ACTIVATING FACTOR;BONE HEALTH;BONE MARROW FAILURE;BUSULFAN;CARDIAC RESYNCHRONIZATION THERAPY;CASEIN KINASE 1;CD38;CILIOPATHY;COGNITIVE DECLINE;COLECTOMY;COMPLEMENT FACTOR B;CROHN DISEASE;CYCLIN-DEPENDENT KINASE 2;DABIGATRAN;DASATINIB;DUCTAL CARCINOMA;ECULIZUMAB;ESTROGEN RECEPTOR;EXCESS WEIGHT;EXOME SEQUENCING;FACTOR H;FETAL HEMOGLOBIN;FLUDARABINE;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;FRACTIONAL FLOW RESERVE;GLIMEPIRIDE;GLOMERULOPATHY;GP41;HOLOPROSENCEPHALY;HORMONAL THERAPY;HUMAN BOCAVIRUS;LEFT ATRIAL APPENDAGE OCCLUSION;LIPOPROTEIN(A);LRRK2;MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;METHYLTRANSFERASE;MICROSATELLITE;NILOTINIB;OSTEOCALCIN;OXALIPLATIN;PEAK INSPIRATORY PRESSURE;PHOSPHOGLYCERATE MUTASE;PIOGLITAZONE;PLEIOTROPY;PNEUMONIA SEVERITY INDEX;POSACONAZOLE;PRENATAL DIAGNOSIS;PRIMARY TUMOR;PROTEIN PHOSPHORYLATION;REGORAFENIB;RETICULOCYTE;RIVAROXABAN;RUNX2;STABLE ISOTOPE LABELING BY AMINO ACIDS IN CELL CULTURE;THIOTEPA;THYMOGLOBULIN;TOTAL MESORECTAL EXCISION;TRIPLE-NEGATIVE BREAST CANCER;TUMOR-INFILTRATING LYMPHOCYTES;VINCRISTINE","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;ITALY;HIV INFECTIONS;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED, 80 AND OVER;CHILD;ADOLESCENT;YOUNG ADULT;FOLLOW-UP STUDIES;ANEMIA, SICKLE CELL;ANTI-HIV AGENTS;CHILD, PRESCHOOL;HIV-1","55;54;45;42;31;29;28;18;17;16;14;12;12;11;11;9;8;8;8;8","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MOLECULAR RESEARCH ON BREAST CANCER;GLIOMAS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;CHOLESTEROL-LOWERING TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MOLECULAR MECHANISMS OF RAS SIGNALING PATHWAYS;PEDIATRIC PAIN ASSESSMENT AND MANAGEMENT;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;TREATMENT AND MANAGEMENT OF ANAL CANCER;14-3-3 PROTEINS: STRUCTURE, FUNCTION, AND REGULATION;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ANORECTAL SURGICAL PROCEDURES;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH","6;6;4;4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","TREATMENT;REGIMEN;CLINICAL ENDPOINT;ANTIRETROVIRAL THERAPY;BREAST CANCER;CROSS-SECTIONAL STUDY;GLIOBLASTOMA;ACUTE CHEST SYNDROME;ANAL CANCER;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CARDIAC SURGERY RISK MODELS;CARDIOVASCULAR RISK ASSESSMENT;CAREGIVER BURDEN;CONCOMITANT;DIABETES;DISCONTINUATION;ESOPHAGECTOMY;HEART VALVE SURGERY;HELP-SEEKING BEHAVIORS;HEMATOPOIETIC CELL TRANSPLANTATION","7;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CELL TRANSPLANTATION;CLINICAL TRIAL;PROSPECTIVE MULTICENTER;STEM CELL;ADJUVANT CLINICAL;CANCER PATIENTS;CELL DISEASE;CLINICAL DECISIONS;CROHNS DISEASE;ECCO-EPICOM COHORT;EUROPEAN POPULATION-BASED;GENE RECURRENCE;GLIOBLASTOMA GBM;INCEPTION COHORT;ITALIAN STUDY;MULTICENTER ITALIAN;MYELOID LEUKEMIA;POPULATION-BASED INCEPTION;PROSPECTIVE EUROPEAN;PROSPECTIVE STUDY;RECURRENCE SCORE;RETROSPECTIVE STUDY;SICKLE CELL;ABSTRACT P--;ANAL ULCERS;AUTOLOGOUS STEM;BC PATIENTS;CANCER BC;CARDIAC SURGERY","6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","MEDIAN AGE;PATIENT ENGAGEMENT;PRIMARY MALIGNANCIES;BIOLOGICAL THERAPY;CI NA;CLINICAL DATA;ECOG PS;LYMPH NODE;NODAL SKIP;SKIP METASTASIS;BRAIN TUMORS;CLINICAL PRACTICE;COLONIC MUCOSA;COX REGRESSION;ENDOMETRIAL CANCER;FOLLOW-UP PERIOD;HUMAN COLONIC;IN-HOSPITAL MORTALITY;LV LEAD;MUTATION BURDEN;NON-ACS CARDIAC;NUTRITIONAL SUPPORT;PATIENTS AGED;PATIENTS ENROLLED;REGRESSION ANALYSES;REPLICATION REPAIR;UC PATIENTS;ADULT PATIENTS;ALTERNATIVE PATHWAY;ANNULAR RUPTURE","10;9;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4",46,0.41,6.18,6.75,1.25,1,1,2,4.75,0,1.75,7,0,0,6,1,1,2,2,5,2,0,0,80,80,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,3.62,742.26,31.25,20,0.5,65.45,0,0,8,0,9,0,3,20,0,24,16,0,0,0,0,0,0,40,0,0,38,0,0,2,0,0,0,0,0,0,"United States;Italy;Japan;United Kingdom;Belgium;Australia;Estonia;France;Germany;Greece;Spain","8;7;3;3;2;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;52 PSYCHOLOGY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;5202 BIOLOGICAL PSYCHOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;4012 FLUID MECHANICS AND THERMAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4205 NURSING;5203 CLINICAL AND HEALTH PSYCHOLOGY","40;24;5;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;CARDIOVASCULAR;HEART DISEASE;PATIENT SAFETY;AGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;COMPARATIVE EFFECTIVENESS RESEARCH;HEMATOLOGY;LIVER DISEASE;PREVENTION;RARE DISEASES;CANCER;NUTRITION;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;INFECTIOUS DISEASES;INFLAMMATORY BOWEL DISEASE","33;19;11;9;8;8;6;5;5;5;5;5;5;4;4;3;3;3;3;3","CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;CANCER;RESPIRATORY;EYE;INFECTION;MENTAL HEALTH;RENAL AND UROGENITAL","8;8;3;2;1;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.7 PHYSICAL","21;3;3;2;1;1;1;1","LIVER CANCER;COLON AND RECTAL CANCER;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;1.4 CANCER PROGRESSION AND METASTASIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1;1",1,5998800,299940,7,20,7,1,101,396654.80617562,0.279840300109346,"ACADEMIC MEDICAL CENTER;ALFASIGMA (ITALY);ALTA (ITALY);ANAXOMICS (SPAIN);ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;AZIENDA OSPEDALIERA DI PADOVA;EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE;GOETHE UNIVERSITY FRANKFURT;HOSPITAL CLÍNIC DE BARCELONA;POMPEU FABRA UNIVERSITY;UNIVERSITY COLLEGE LONDON;UNIVERSITY HOSPITAL BONN;UNIVERSITY OF BOLOGNA;UNIVERSITY OF PADUA;UNIVERSITY OF ZURICH;VALL D'HEBRON HOSPITAL UNIVERSITARI;WITTEN/HERDECKE UNIVERSITY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;LIVER DISEASE","1;1;1;1;1","ORAL AND GASTROINTESTINAL","1","6.1 PHARMACEUTICALS","1","LIVER CANCER","1",NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,15,"PUBLIC LIBRARY OF SCIENCE","15","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3203 DENTISTRY;4207 SPORTS SCIENCE AND EXERCISE;44 HUMAN SOCIETY;4904 PURE MATHEMATICS;4905 STATISTICS;51 PHYSICAL SCIENCES","16;6;3;2;2;1;1;1;1;1;1;1","CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;LIVER DISEASE;GENETICS;INFECTIOUS DISEASES","2;2;2;2;2;2;2;1;1","INFECTION;ORAL AND GASTROINTESTINAL","3;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","6;1;1;1;1","CLINICAL;BIOMEDICAL","5;2","CLINICAL MEDICINE AND SCIENCE","9","LIVER CANCER","4",NA,NA
"AOU_PADOVA",2018,124,16.1370967741935,1.87903225806452,0.185483870967742,0.145161290322581,0.298387096774194,1.43827160493827,1.0952380952381,1.5,1.19354838709677,0.564516129032258,2,70,25,10,9,0.56,0.2,0.08,0.07,28.1,0.921220809782368,5.00803858520901,0.387096774193548,0.967741935483871,0.462,0.286,0.279,0.301,"ANNA MARIA CATTELAN;MASSIMO RUGGE;FRANCESCO CAVALLIN;VALENTINA GUARNERI;MARCO ZECCA;R. D’INCÀ;EDOARDO SAVARINO;MARIA VITTORIA DIECI;FEDERICA MIGLIETTA;PAOLO GROSSI;MARIO PLEBANI;FRANCO LOCATELLI;VITTORINA ZAGONEL;MARCO SCARPA;DANIELE TREVISANUTO;PIETRO ZUCCHETTA;ALESSANDRO DELLA PUPPA;GIUSEPPE LOMBARDI;RAFFAELLA COLOMBATTI;GAIA GRIGUOLO","7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","ROMEO MARTINI;MAURO TURRIN;EDOARDO SAVARINO;MATTEO MARTINATO;VITTORIO LUCCHETTA;ASTRID URSULA BEHR;FRANCESCO CAVALLIN;MASSIMO RUGGE;PIETRO ZUCCHETTA;FABRIZIO MORO;ANDREA BAGNO;RENATO SALVADOR;GIOVANNI CAPOVILLA;STEFANO MERIGLIANO;DANIELE TREVISANUTO;MARIO COSTANTINI;VALENTINA GUARNERI;MARIA VITTORIA DIECI;RAFFAELLA COLOMBATTI;M. PAIUSCO","1.5;1;0.98;0.79;0.7;0.7;0.65;0.65;0.6;0.5;0.5;0.47;0.47;0.47;0.47;0.47;0.45;0.45;0.44;0.4","ANNA MARIA CATTELAN;MASSIMO RUGGE;R. D’INCÀ;EDOARDO SAVARINO;MARIO PLEBANI;DANIELE TREVISANUTO;PIETRO ZUCCHETTA;ALESSANDRO DELLA PUPPA;RAFFAELLA COLOMBATTI;MARINA PAOLA GARDIMAN;LAURA SAINATI;RENATO SALVADOR;MATTEO MARTINATO;GIOVANNI CAPOVILLA;VASSILENA TSVETKOVA;STEFANO MERIGLIANO;RENATO ZAMBELLO;ENRICO ORVIETO;MARIO COSTANTINI;ELISABETTA CALORE","7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ROMEO MARTINI;MAURO TURRIN;EDOARDO SAVARINO;MATTEO MARTINATO;VITTORIO LUCCHETTA;MASSIMO RUGGE;PIETRO ZUCCHETTA;RENATO SALVADOR;GIOVANNI CAPOVILLA;STEFANO MERIGLIANO;DANIELE TREVISANUTO;MARIO COSTANTINI;RAFFAELLA COLOMBATTI;FABIO ZATTONI;ALESSANDRO DELLA PUPPA;MARIO PLEBANI;ANNA MARIA CATTELAN;R. D’INCÀ;CARMELO LACOGNATA;VASSILENA TSVETKOVA","1.5;1;0.98;0.79;0.7;0.65;0.6;0.47;0.47;0.47;0.47;0.47;0.44;0.39;0.35;0.34;0.33;0.31;0.31;0.31","A. FINK‐WAGNER;ALAIN TAÏEB;ANDREAS WOLLENBERG;ANTONELLA MURARO;ANTONIO TORRELO;DAGMAR SIMON;GIAMPIERO GIROLOMONI;JACEK C. SZEPIETOWSKI;JOHANNES RING;MAGDALENA CZARNECKA‐OPERACZ;METTE DELEURAN;PETER SCHMID‐GRENDELMEIER;S. BARBAROT;S. LAU;STÉPHANIE CHRISTEN‐ZAECH;T. SCHÄFER;THOMAS BIEBER;THOMAS WERFEL;UWE GIELER;ZSUZSANNA SZALAI","978;978;978;978;978;978;978;978;978;978;978;978;978;978;978;978;978;978;978;978","ANTONELLA MURARO;ANNA MARIA CATTELAN;DAVIDE COLETTO;LUDOVICA CIPRIANI;UMBERTO CILLO;RAFFAELLA COLOMBATTI;DAVIDE PECORI;STEFANO NICOLÈ;STEFANO VERDENELLI;LAURA SAINATI;MASSIMO RUGGE;LUISA MURER;EDOARDO SAVARINO;ELISA VALENTINI;FABIO FARINATI;IRENE COATI;MATTEO FASSAN;ALESSANDRO DELLA PUPPA;BARBARA BULDINI;GIORGIO ARRIGONI","978;444;278;278;237;140;139;139;139;130;127;126;121;120;120;120;120;107;107;107","ANNA MARIA CATTELAN;EDOARDO SAVARINO;R. D’INCÀ;ALESSANDRO DELLA PUPPA;DANIELE TREVISANUTO;RAFFAELLA COLOMBATTI;LAURA SAINATI;ELISABETTA CALORE;MARIO PLEBANI;MASSIMO RUGGE;GIOVANNI CAPOVILLA;MARIO COSTANTINI;MATTEO MARTINATO;RENATO SALVADOR;RENATO ZAMBELLO;STEFANO MERIGLIANO;ALBERTO RUOL;AMELIA RUFFATTI;CARMELO LACOGNATA;DARIO BRISCOLINI","7;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2","MEDICINE;BIOLOGY;ECONOMICS;ENGINEERING;PHYSICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE;MATHEMATICS;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY","119;30;9;8;8;8;7;6;5;4;3;2;2;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;IMMUNOLOGY;ONCOLOGY;PEDIATRICS;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;RADIOLOGY;PSYCHIATRY;NURSING;ANESTHESIA;CANCER RESEARCH;INTENSIVE CARE MEDICINE;CARDIOLOGY;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;OPTICS","98;39;20;19;18;18;17;13;12;12;12;10;9;8;8;8;7;7;7;7","CANCER;DISEASE;GENE;TRANSPLANTATION;POPULATION;COHORT;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;HEALTH CARE;RADIATION THERAPY;ADVERSE EFFECT;ATRIAL FIBRILLATION;CLINICAL TRIAL;COHORT STUDY;DIABETES MELLITUS;ESOPHAGUS;OBSERVATIONAL STUDY;PROPORTIONAL HAZARDS MODEL;QUALITY OF LIFE (HEALTHCARE)","19;19;14;13;12;9;8;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","INFLAMMATORY BOWEL DISEASE;CROHN'S DISEASE;BREAST CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;COLORECTAL CANCER;HAZARD RATIO;PROSTATE;PROSTATE CANCER;ULCERATIVE COLITIS;ACHALASIA;CLINICAL ENDPOINT;GENE EXPRESSION;LENALIDOMIDE;SALVAGE THERAPY;ACUTE LEUKEMIA;ANTIBIOTIC RESISTANCE;AUTOANTIBODY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CD8;CHEMORADIOTHERAPY;CHRONIC HEPATITIS;CINAHL;CUMULATIVE INCIDENCE;DNA REPAIR;ESOPHAGEAL CANCER;FOXP3;GENOTYPE;GERMLINE;GRAFT-VERSUS-HOST DISEASE;HEPATITIS C VIRUS;IMAGE QUALITY;IMMUNOTHERAPY;INNATE IMMUNE SYSTEM;LIVER TRANSPLANTATION;LUNG TRANSPLANTATION;MACROPHAGE;MEDIAN FOLLOW-UP;PLACEBO;PROGRESSION-FREE SURVIVAL;TEMOZOLOMIDE;TITER;TOLERABILITY;TYPE 2 DIABETES;WARFARIN","7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DNA MISMATCH REPAIR;MYOTOMY;ANTIVIRAL TREATMENT;CD163;GERMLINE MUTATION;HIGH RESOLUTION MANOMETRY;MASTECTOMY;TRASTUZUMAB;TUMOR-INFILTRATING LYMPHOCYTES;ACROMEGALY;ADIPOKINE;ALCOHOL INTOXICATION;ANDROGEN RECEPTOR;ANTIMICROBIAL STEWARDSHIP;ANTIRETROVIRAL THERAPY;ARABIDOPSIS;ATP HYDROLYSIS;BIOLOGICAL PATHWAY;BREAST SURGERY;BUSULFAN;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;CASPASE;CASPASE 3;CD33;CEREBRAL MALARIA;COMPOUND HETEROZYGOSITY;CRITICAL LIMB ISCHEMIA;CYSTECTOMY;CYTOGENETICS;DASATINIB;DEFIBROTIDE;DIPEPTIDYL PEPTIDASE-4;DISCRETE WAVELET TRANSFORM;DNA METHYLATION;ESOPHAGEAL MOTILITY DISORDER;ESTROGEN RECEPTOR;EXOME SEQUENCING;FRAMESHIFT MUTATION;GENE SIGNATURE;GP41;HEPATIC VENO-OCCLUSIVE DISEASE;IDH1;IMIPENEM;KAPOSI'S SARCOMA;LDL APHERESIS;LIPOPROTEIN(A);LOW LEVEL LASER THERAPY;MANIA;MICROSATELLITE;MISSENSE MUTATION;NEOADJUVANT THERAPY;PIM1;PIMECROLIMUS;PLACENTAL GROWTH FACTOR;PNEUMONIA SEVERITY INDEX;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;PTEN;QUANTITATIVE PROTEOMICS;REGORAFENIB;RIVAROXABAN;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATIC HYPERMUTATION;SYSTEMIC THERAPY;TAMOXIFEN;TLR2;TOTAL MESORECTAL EXCISION;TRANSCRIPTOME;TRIPLE-NEGATIVE BREAST CANCER;TUMOR SUPPRESSOR GENE;UREA CYCLE;VANCOMYCIN","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;AGED;MIDDLE AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADOLESCENT;CHILD;CHILD, PRESCHOOL;YOUNG ADULT;AGED, 80 AND OVER;HIV INFECTIONS;PROSTATIC NEOPLASMS;RISK FACTORS;TIME FACTORS;CARDIOVASCULAR DISEASES","63;60;49;46;33;33;24;16;16;15;13;11;11;11;10;10;10;9;9;8","GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEMATOPOIETIC STEM CELL BIOLOGY;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;GLIOMAS;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EMERGENCY DEPARTMENT CROWDING;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;ESOPHAGEAL INTERVENTION TECHNIQUES;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF VALVULAR HEART DISEASE;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;PROSTATE CANCER RESEARCH AND TREATMENT;SARCOMA RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA","6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","TREATMENT;TUMOR MICROENVIRONMENT;CLINICAL ENDPOINT;CROSS-SECTIONAL STUDY;ESOPHAGEAL PERFORATION;HEMATOPOIETIC CELL TRANSPLANTATION;INFLAMMATORY BOWEL DISEASE;NEPHROLOGY;PET/CT;REGIMEN;RELAPSE RISK;SALVAGE THERAPY;STROKE (ENGINE);TREATMENT OUTCOMES;ANTIVIRAL TREATMENT;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CD163;CHEMORADIOTHERAPY;CINAHL;CONCOMITANT","9;5;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","CELL TRANSPLANTATION;STEM CELL;SICKLE CELL;BOWEL DISEASE;BREAST CANCER;CELL DISEASE;INFLAMMATORY BOWEL;ESOPHAGEAL ACHALASIA;HEMATOPOIETIC STEM;PROSPECTIVE STUDY;PROSTATE CANCER;ACTIVITY REDUCTION;ACUTE LEUKEMIA;AORTIC VALVE;AUTOLOGOUS STEM;CARDIOVASCULAR EVENTS;CASE-CONTROL STUDY;CLINICAL EXPERIENCE;COHORT STUDY;CROHNS DISEASE;DATA ANALYSIS;EMERGENCY DEPARTMENT;EPI-IBD COHORT;ESOPHAGEAL CANCER;EUROPEAN POPULATION-BASED;INNATE IMMUNITY;ITALIAN MULTICENTER;LAPAROSCOPIC TREATMENT;LIVER TRANSPLANTATION;LONG-TERM FOLLOW-UP","6;6;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;ADVISORY BOARD;HONORARIA MEMBERSHIP;HR CI-;IBD PATIENTS;NOVO NORDISK;FUNDING SPEAKERS;ATRIAL FIBRILLATION;INFLAMMATORY BOWEL;VAGINAL CUFF;BOWEL DISEASE;CONSULTANCY HONORARIA;CUFF RECURRENCE;RISK FACTORS;SIMOCTOCOG ALFA;COMMITTEES SPEAKERS;F-ATP SYNTHASE;IGG SUBCLASSES;INHIBITOR PERSISTENCE;NURSING CARE;BUREAU SHIRE;CROHNS DISEASE;CSL BEHRING;HR CI;ANTI-FVIII IGG;BUREAU NOVO;BUREAU ROCHE","66;47;47;23;15;15;14;14;13;12;11;11;11;10;10;10;10;10;9;9;9;9;9;8;8;8;8;7;7;7",44,0.35,9.8,10.25,2.5,1,1.75,1.75,1.5,0,2,11.25,0,1,9.5,1,1.75,1.25,3,7,4,0,0,91.25,91.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,3.95,900.64,27.56,16,0.37,77.44,0,1,10,2,14,0,1,14,1,31,11,0,0,0,0,0,0,42,0,1,41,1,1,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan;Spain","11;5;4;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","41;27;9;8;4;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;PEDIATRIC;AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;INFLAMMATORY BOWEL DISEASE;RARE DISEASES;CANCER;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;NUTRITION;PREVENTION;BRAIN DISORDERS;KIDNEY DISEASE;LUNG;AGING;COMPARATIVE EFFECTIVENESS RESEARCH;CROHN'S DISEASE","39;31;16;11;9;8;7;7;5;4;4;4;4;4;3;3;3;2;2;2","ORAL AND GASTROINTESTINAL;CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;NEUROLOGICAL;RENAL AND UROGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","7;4;3;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","29;2;2;1;1","COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;KIDNEY CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;SARCOMA","5;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","6;1;1;1;1;1;1",1,399985,66664.17,4,6,5,1,12,338132.877917475,0.366719736819747,"AZIENDA OSPEDALIERA DI PADOVA;INSTITUTE CURIE;KLINIKUM DORTMUND;MEDICAL UNIVERSITY OF GDAŃSK;ST ANNA CHILDREN'S HOSPITAL;UNIVERSITY OF TÜBINGEN","1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","3RD HEALTH PROGRAMME (PROGRAMME)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4604 CYBERSECURITY AND PRIVACY","1;1;1",NA,NA,"CANCER","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","10 REDUCED INEQUALITIES","1",23,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS","14;7;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3204 IMMUNOLOGY;49 MATHEMATICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;38 ECONOMICS;3801 APPLIED ECONOMICS;42 HEALTH SCIENCES;4905 STATISTICS;52 PSYCHOLOGY","26;15;7;4;3;3;2;1;1;1;1;1;1;1;1;1","NUTRITION;AUTOIMMUNE DISEASE;CLINICAL RESEARCH;KIDNEY DISEASE;AGING;DIGESTIVE DISEASES;GENETICS;LUPUS;ARTHRITIS;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;DEPRESSION;DIABETES;EMERGING INFECTIOUS DISEASES;HEART DISEASE","4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM;CANCER;CARDIOVASCULAR;INFECTION;MENTAL HEALTH;METABOLIC AND ENDOCRINE;RENAL AND UROGENITAL;STROKE","3;1;1;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","7;2;1;1","BIOMEDICAL;CLINICAL","6;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","9;3","LIVER CANCER;STOMACH CANCER","1;1",NA,NA
"AOU_PADOVA",2019,112,18.1428571428571,1.77678571428571,0.0982142857142857,0.125,0.205357142857143,1.36301369863014,0.916666666666667,1.27272727272727,1,0.607142857142857,1,58,26,8,4,0.52,0.23,0.07,0.04,24.02,0.987702779941048,5.29064748201439,0.4375,0.964285714285714,0.435,0.446,0.362,0.422,"RAFFAELLA COLOMBATTI;BABA INUSA;MARCO SCARPA;LAURA SAINATI;GIORGIO ARRIGONI;MADDALENA CASALE;R. D’INCÀ;MIRELLA RUGGERI;CINZIA FRANCHIN;SILVERIO PERROTTA;MIGUEL R. ABBOUD;ANTONIO LASALVIA;CARLO CASTORO;BIREE ANDEMARIAM;MASSIMO RUGGE;MARIANE DE MONTALEMBERT;GIOVANNI DE GIROLAMO;MARTINA PERAZZOLO MARRA;CATERINA P. MINNITI;CAMILLO ALIBERTI","11;7;7;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","ROMEO MARTINI;RAFFAELLA COLOMBATTI;GIORGIO ARRIGONI;MARCO SCARPA;BABA INUSA;CINZIA FRANCHIN;LORENZO A. CALÒ;LAURA SAINATI;MADDALENA CASALE;DANIELE TREVISANUTO;ENZO EMANUELLI;MASSIMO ROBIONY;FÁBIO COSTA;LEONARDO FRANZ;ALESSANDRO TEL;CARLO CASTORO;MARTINA PERAZZOLO MARRA;CAMILLO ALIBERTI;SABINO ILICETO;STEFANO MAZZOLENI","1;0.8;0.71;0.7;0.54;0.48;0.46;0.44;0.42;0.41;0.37;0.37;0.37;0.37;0.37;0.37;0.34;0.34;0.34;0.33","RAFFAELLA COLOMBATTI;MARCO SCARPA;LAURA SAINATI;GIORGIO ARRIGONI;R. D’INCÀ;CINZIA FRANCHIN;CAMILLO ALIBERTI;FRANCESCO CAUSIN;DANIELE TREVISANUTO;RENATO ZAMBELLO;GIOVANNI STELLIN;MARIA CATERINA PUTTI;EMANUELE BERTAGLIA;CHIARA TESSARI;CARMELO LACOGNATA;SILVIA IMBERGAMO;LORENZO A. CALÒ;ANGELA VERONESE;LUISA MURER;FABIANA ZINGONE","11;7;6;6;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2","ROMEO MARTINI;RAFFAELLA COLOMBATTI;GIORGIO ARRIGONI;MARCO SCARPA;CINZIA FRANCHIN;LORENZO A. CALÒ;LAURA SAINATI;DANIELE TREVISANUTO;ENZO EMANUELLI;LEONARDO FRANZ;CAMILLO ALIBERTI;GIOVANNA MAGNI;PAOLO SPINELLA;FRANCINI-PESENTI FRANCINI;R. D’INCÀ;BARBARA BAUCE;CRISTINA BASSO;GIACOMO CARLO STURNIOLO;GIORGIO DE CONTI;CARMELO LACOGNATA","1;0.8;0.71;0.7;0.48;0.46;0.44;0.41;0.37;0.37;0.34;0.33;0.33;0.33;0.33;0.3;0.26;0.25;0.24;0.22","ALBERTUS BEISHUIZEN;ANDREA LAY‐HOON KWA;CHARLES‐ÉDOUARD LUYT;ERIC H. GLUCK;G. GAVAZZI;GIULIO TOCCAFONDI;JENNIFER TOWNSEND;JENS‐ULRIK STÆHR JENSEN;JUAN GONZÁLEZ DEL CASTILLO;KORDO SAEED;M. BROYLES;MARIO PLEBANI;MICHAEL OPPERT;PHILIPP SCHÜETZ;PÉTER KANIZSAI;RICARD FERRER;SERGEY SHLYAPNIKOV;STEFAN KRUEGER;TOBIAS WELTE;ABEER M. ELNAKERA","215;215;215;215;215;215;215;215;215;215;215;215;215;215;215;215;215;215;215;206","MARIO PLEBANI;CRISTIANA CAROLLO;ALESSANDRO DELLA PUPPA;BEATRICE DALLA BARBA;ANTONELLA MURARO;ANTONIO MARZOLLO;GIORGIO ARRIGONI;LUISA MURER;ALESSANDRA BANZATO;FRANCESCO CAUSIN;FRANCESCO PIAZZA;CLAUDIO BARACCHINI;MAURIZIO CLEMENTI;RAFFAELLA COLOMBATTI;GIOVANNI STELLIN;MASSIMO A. PADALINO;LORENZO A. CALÒ;LUISA SANTORO;ENZO EMANUELLI;LEONARDO FRANZ","215;206;140;138;123;121;106;105;94;88;81;71;63;61;60;60;53;51;49;49","RAFFAELLA COLOMBATTI;LAURA SAINATI;GIORGIO ARRIGONI;MARCO SCARPA;CINZIA FRANCHIN;R. D’INCÀ;DANIELE TREVISANUTO;FRANCESCO CAUSIN;RENATO ZAMBELLO;ANGELA VERONESE;ANNA MARIA CATTELAN;AUGUSTO D’ONOFRIO;BEATRICE DALLA BARBA;CARMELO LACOGNATA;CLAUDIO BARACCHINI;CRISTINA BASSO;EMANUELE BERTAGLIA;ENZO EMANUELLI;FRANCESCO BARBARO;FRANCESCO PIAZZA","9;6;6;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;ENGINEERING;BUSINESS;HISTORY;GEOGRAPHY;MATERIALS SCIENCE","106;25;13;11;10;7;6;6;5;4;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;PEDIATRICS;IMMUNOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CARDIOLOGY;GASTROENTEROLOGY;GENETICS;INTENSIVE CARE MEDICINE;FAMILY MEDICINE;PSYCHIATRY;RADIOLOGY;OPTICS;PHYSICAL THERAPY;ONCOLOGY;NURSING;CLINICAL PSYCHOLOGY;DEMOGRAPHY;ECONOMIC GROWTH","85;29;22;20;20;17;15;14;14;12;12;9;9;9;8;8;7;6;5;5;5","DISEASE;POPULATION;CANCER;COHORT;GENE;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);EPIDEMIOLOGY;PREGNANCY;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;ALTERNATIVE MEDICINE;ANTIBODY;CHEMOTHERAPY;HEALTH CARE;PROSPECTIVE COHORT STUDY;TRANSPLANTATION;LOGISTIC REGRESSION;MULTIPLE MYELOMA;RANDOMIZED CONTROLLED TRIAL;VIRUS","27;14;12;12;11;9;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4","SICKLE CELL ANEMIA;CLINICAL ENDPOINT;INFLAMMATORY BOWEL DISEASE;LENALIDOMIDE;ULCERATIVE COLITIS;CD8;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;ESOPHAGEAL CANCER;PHENOTYPE;PLACEBO;ANTIPHOSPHOLIPID SYNDROME;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BIPOLAR DISORDER;BREAST CANCER;CARDIOMYOPATHY;CHOP;CROHN'S DISEASE;DIFFUSE LARGE B-CELL LYMPHOMA;GESTATIONAL AGE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IDIOPATHIC PULMONARY FIBROSIS;LIFE EXPECTANCY;MALONDIALDEHYDE;METABOLIC SYNDROME;POSITIVE AND NEGATIVE SYNDROME SCALE;PROTEIN KINASE A;RITUXIMAB;THROMBOLYSIS;VASCULAR ACCESS","6;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACUTE CHEST SYNDROME;ESOPHAGECTOMY;CLINICAL PHENOTYPE;COLONOSCOPY;RETINOPATHY OF PREMATURITY;VINCRISTINE;ALTERNATIVE COMPLEMENT PATHWAY;AMNIOTIC FLUID;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN RECEPTOR;ANTIBIOTIC STEWARDSHIP;ANTIMICROBIAL STEWARDSHIP;ANTIRETROVIRAL THERAPY;ATROPHIC GASTRITIS;ATYPICAL HEMOLYTIC UREMIC SYNDROME;AUTOIMMUNE GASTRITIS;BIOTIC STRESS;BREAST SURGERY;C2C12;CALPROTECTIN;CARDIAC RESYNCHRONIZATION THERAPY;CAREGIVER BURDEN;CHEMILUMINESCENT IMMUNOASSAY;CHEMOIMMUNOTHERAPY;CHILD ABUSE;CORONAVIRUS DISEASE 2019 (COVID-19);CRITICAL LIMB ISCHEMIA;CRIZOTINIB;CYCLIN-DEPENDENT KINASE 2;CYTOGENETICS;DISEASE MANAGEMENT;DNA METHYLATION;ECULIZUMAB;ETV6;FORAMEN SECUNDUM;GENOTYPE-PHENOTYPE DISTINCTION;GLUTATHIONE PEROXIDASE;HISTONE METHYLTRANSFERASE;INFLAMMATORY BOWEL DISEASES;IPILIMUMAB;KRAS;LAMIVUDINE;LOWER URINARY TRACT SYMPTOMS;LYMPH NODE METASTASIS;MANIA;MESALAZINE;MODIFIED RANKIN SCALE;MYELOID-DERIVED SUPPRESSOR CELL;NEOADJUVANT THERAPY;NIVOLUMAB;PEMBROLIZUMAB;PROCTITIS;PROCTOCOLECTOMY;PROTEIN PHOSPHORYLATION;RECURRENT MISCARRIAGE;SEXUAL ABUSE;SOD1;THIOTEPA;TOLL-LIKE RECEPTOR;UREA CYCLE;VASO-OCCLUSIVE CRISIS","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ITALY;ADULT;AGED;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;CHILD;AGED, 80 AND OVER;PSYCHOTIC DISORDERS;YOUNG ADULT;ADOLESCENT;ANTIVIRAL AGENTS;ESOPHAGEAL NEOPLASMS;POSTOPERATIVE COMPLICATIONS;INFANT, NEWBORN;PROSPECTIVE STUDIES","57;52;40;40;24;21;18;18;14;14;11;10;10;10;9;9;9;9;8;8","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MANAGEMENT OF VALVULAR HEART DISEASE;ACUTE MYELOID LEUKEMIA;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;HEPATITIS C INFECTION AND TREATMENT;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANTIBIOTIC RESISTANCE IN AQUATIC ENVIRONMENTS AND WASTEWATER;ASTHMA;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL SIGNIFICANCE OF POLICOSANOL IN LIPID MANAGEMENT;CORNEAL TISSUE ENGINEERING AND REGENERATION","12;6;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","SICKLE-CELL DISEASE;TREATMENT;ACUTE CHEST SYNDROME;CLINICAL ENDPOINT;STROKE (ENGINE);TRANSCATHETER AORTIC-VALVE REPLACEMENT;ESOPHAGECTOMY;PROSTHETIC VALVES EVALUATION;ANTIPHOSPHOLIPID SYNDROME;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CARDIAC IMAGING;CLINICAL PHENOTYPE;DELPHI METHOD;DEMOGRAPHICS;DUCTUS ARTERIOSUS;HISTOPATHOLOGY;IDIOPATHIC PULMONARY FIBROSIS;IMMUNOSUPPRESSION;INBORN ERRORS OF METABOLISM;INTERIM","9;5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2","SICKLE CELL;CELL DISEASE;STEM CELL;ASSESSMENT SURVEY;CELL TRANSPLANTATION;CELL WORLD;CENTRAL NERVOUS;INTERNATIONAL SICKLE;NATIONAL SURVEY;NERVOUS SYSTEM;SURVEY SWAY;WORLD ASSESSMENT;ANTIPHOSPHOLIPID SYNDROME;ANTIVIRAL TREATMENT;AORTIC VALVE;B-CELL LYMPHOMA;BCELL LYMPHOMA;CARDIAC SURGERY;CLINICAL RESEARCH;DATA ANALYSIS;EDUCATIONAL STUDY;EUROPEAN MULTI-CENTRE;EUROPEAN SOCIETY;INTERIM RESULTS;ITALY RESULTS;MINIMALLY INVASIVE;MULTI-CENTRE PERSPECTIVE;PAEDIATRIC SICKLE;PREVIOUSLY UNTREATED;PULMONARY FIBROSIS","14;10;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;CONSULTANCY HONORARIA;HONORARIA MEMBERSHIP;TRAVEL SUPPORT;HONORARIA RESEARCH;COMMITTEES RESEARCH;SICKLE CELL;CENTRAL NERVOUS;COMMITTEES SPEAKERS;NERVOUS SYSTEM;SCD PATIENTS;ANTIPHOSPHOLIPID SYNDROME;BLOOD THERAPEUTICS;CELL DISEASE;CONSULTANCY RESEARCH;GLOBAL BLOOD;MEDIAN FOLLOW-UP;SYSTEM DISEASE;CLINICAL TRIAL;FLOW CYTOMETRY;LIC VALUES;TRAINING PROGRAM;AGE RANGE;CLINICAL TRIALS;DISEASE SCD;MEDIAN AGE;MINIMALLY INVASIVE","84;69;69;26;18;18;16;14;13;13;11;11;11;10;9;9;9;9;9;9;9;8;8;8;8;7;7;7;7;7",50,0.45,10.66,9.75,2,1,0,2,1,1,1,9.75,1,1,11,1,2,2,4.5,7.75,4.75,0,0,56,56,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,4.41,699.76,26.62,18,0.49,80.51,0,0,9,2,12,0,1,13,0,29,8,0,0,0,0,0,0,37,0,0,37,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Spain;United Kingdom;France;Portugal;Switzerland","13;11;4;3;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3213 PAEDIATRICS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","35;26;5;4;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;PREVENTION;RARE DISEASES;PATIENT SAFETY;AUTOIMMUNE DISEASE;CANCER;HEMATOLOGY;INFLAMMATORY BOWEL DISEASE;PEDIATRIC;BRAIN DISORDERS;CHRONIC LIVER DISEASE AND CIRRHOSIS;LIVER DISEASE;NUTRITION;AGING;NEUROSCIENCES;CARDIOVASCULAR;LUNG;NEURODEGENERATIVE","36;26;11;11;11;9;7;7;6;6;6;5;5;5;5;4;4;3;3;3","ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;NEUROLOGICAL;RESPIRATORY;CANCER;MUSCULOSKELETAL;BLOOD;GENERIC HEALTH RELEVANCE;MENTAL HEALTH;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","7;4;3;3;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.7 PHYSICAL;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","25;4;3;2;2;1;1;1","COLON AND RECTAL CANCER;BLOOD CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","3;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","6;2;1",2,21189996,323477.43,7,47,12,1,30.5,346994.844366717,0.322771366255904,"AZIENDA OSPEDALIERA DI PADOVA;DÉLÉGATION PARIS 11;UNIVERSITY COLLEGE LONDON;ACADEMIC MEDICAL CENTER;AHMADU BELLO UNIVERSITY;ALACRIS (GERMANY);AMERICAN UNIVERSITY OF BEIRUT;AMSTERDAM UMC LOCATION VUMC;ANDALUSIAN HEALTH SERVICE;ANDALUSIAN SCHOOL OF PUBLIC HEALTH;ASTRAZENECA (SWEDEN);AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST;CAPITAL REGION OF DENMARK;CENTRE FOR GENOMIC REGULATION;CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE BREST;CENTRE HOSPITALIER UNIVERSITAIRE DE NANCY;CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CLINIQUES UNIVERSITAIRES SAINT-LUC","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2018-14-TWO-STAGE (CALL FOR PROPOSAL);H2020-MSCA-RISE-2018 (CALL FOR PROPOSAL);MSCA-RISE - MARIE SKŁODOWSKA-CURIE RESEARCH AND INNOVATION STAFF EXCHANGE (RISE) (FUNDING SCHEME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;1;1;1;1","CLINICAL RESEARCH;GENETICS;HEALTH SERVICES;HEMATOLOGY;PAIN RESEARCH;PEDIATRIC;PREVENTION;RARE DISEASES;SICKLE CELL DISEASE","2;1;1;1;1;1;1;1;1","BLOOD;INFLAMMATORY AND IMMUNE SYSTEM","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)","1;1;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1;1",NA,NA,22,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;SPRINGER NATURE;MENDELEY DATA","13;4;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;34 CHEMICAL SCIENCES;42 HEALTH SCIENCES;3213 PAEDIATRICS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;44 HUMAN SOCIETY;3203 DENTISTRY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;38 ECONOMICS;3801 APPLIED ECONOMICS;4202 EPIDEMIOLOGY;4206 PUBLIC HEALTH;4405 GENDER STUDIES;48 LAW AND LEGAL STUDIES;4804 LAW IN CONTEXT;4901 APPLIED MATHEMATICS","19;5;5;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;HEADACHES;MIGRAINES;NEUROSCIENCES;PAIN RESEARCH;PEDIATRIC;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;HIV/AIDS;INFECTIOUS DISEASES;LIVER DISEASE","4;3;3;3;3;3;1;1;1;1;1;1;1;1","NEUROLOGICAL;CANCER;CARDIOVASCULAR;INFECTION","3;1;1;1","2.4 SURVEILLANCE AND DISTRIBUTION;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;1;1","CLINICAL;BIOMEDICAL","5;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","9;1","LIVER CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA","1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_PADOVA",2020,151,18.9337748344371,1.97350993377483,0.145695364238411,0.158940397350993,0.23841059602649,1.51530612244898,1.15789473684211,1.2,1.02857142857143,0.649006622516556,2,84,29,13,8,0.56,0.19,0.09,0.05,44.73,1.77504052649291,6.65786163522013,0.410596026490066,0.973509933774834,0.442,0.409,0.456,0.43,"GIORGIO ARRIGONI;CRISTINA BASSO;ANNA MARIA CATTELAN;CINZIA FRANCHIN;FRANCESCO ONELIA;RAFFAELLA COLOMBATTI;ROBERTO VETTOR;CLAUDIO TONDO;STEFANIA RIZZO;MONIA PACENTI;HERIBERT KNECHTEN;LAURA SAINATI;RORY GUNSON;LEANA MAREE;ALESSIO GASPERETTI;GAETANO THIENE;ANGELO PAOLO DEI TOS;ROBERT EHRET;VALENTINA GUARNERI;AJITH M. JOSEPH","11;9;8;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4","ROMEO MARTINI;GIORGIO ARRIGONI;CRISTINA BASSO;GAETANO THIENE;CINZIA FRANCHIN;STEFANIA RIZZO;CHRISTOPHER J. BLACK;ALEXANDER C. FORD;BRIGIDA BARBERIO;EDOARDO SAVARINO;SALVATORE ROSSITTO;PAOLO SPAGNOLO;MARTA SBARAGLIA;ROBERTO STRAMARE;ROBERTO VETTOR;CHIARA GIRAUDO;PAOLO NAVALESI;ANNA MARIA CATTELAN;ELISA CARTURAN;DERIS GIANNI BOEMO","2;1.06;0.98;0.65;0.63;0.55;0.54;0.54;0.54;0.54;0.5;0.5;0.4;0.4;0.37;0.37;0.37;0.36;0.34;0.31","GIORGIO ARRIGONI;CRISTINA BASSO;ANNA MARIA CATTELAN;CINZIA FRANCHIN;FRANCESCO ONELIA;RAFFAELLA COLOMBATTI;ROBERTO VETTOR;STEFANIA RIZZO;MONIA PACENTI;LAURA SAINATI;GAETANO THIENE;ANGELO PAOLO DEI TOS;PAOLO NAVALESI;FRANCESCO CAUSIN;CLAUDIO BARACCHINI;RENATO ZAMBELLO;MARCELLO MELE;MARTA SBARAGLIA;MARIA CATERINA PUTTI;EMANUELE BERTAGLIA","11;9;8;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3","ROMEO MARTINI;GIORGIO ARRIGONI;CRISTINA BASSO;GAETANO THIENE;CINZIA FRANCHIN;STEFANIA RIZZO;BRIGIDA BARBERIO;EDOARDO SAVARINO;PAOLO SPAGNOLO;MARTA SBARAGLIA;ROBERTO VETTOR;PAOLO NAVALESI;ANNA MARIA CATTELAN;ELISA CARTURAN;DERIS GIANNI BOEMO;GIORGIO DE CONTI;MARCELLO MELE;NICOLA ZADRA;ANGELO PAOLO DEI TOS;FRANCESCO ONELIA","2;1.06;0.98;0.65;0.63;0.55;0.54;0.54;0.5;0.4;0.37;0.37;0.36;0.34;0.31;0.3;0.3;0.29;0.28;0.28","CHRISTL A. DONNELLY;CONSTANZE CIAVARELLA;GINA CUOMO-DANNENBURG;ILARIA DORIGATTI;KATY A. M. GAYTHORPE;LORENZO CATTARINO;NEIL M. FERGUSON;ANNA MARIA CATTELAN;ANTONELLA CASTAGNA;ANU OSINUSI;ANUJ GAGGAR;ARUN J. SANYAL;CHRISTIANA BLAIR;CHRISTOPH D. SPINNER;DEVI SENGUPTA;DIANA M. BRAINARD;ENOS BERNASCONI;FRANCISCO M. MARTY;GERARD J. CRINER;GREGORY HUHN","1960;1960;1960;1960;1960;1960;1960;1341;1168;1153;1153;1153;1153;1153;1153;1153;1153;1153;1153;1153","ANNA MARIA CATTELAN;MONIA PACENTI;DANIELE DONATO;GIOVANNI CARRETTA;ETTORE DE CANALE;LUCIANO FLOR;LUCÍA ROSSI;MANUELA SCIRO;MARIA CRISTINA VANUZZO;VALERIA BESUTTI;P. BERTOMORO;CRISTINA BASSO;STEFANIA RIZZO;T. PRAYER-GALETTI;MONICA DE GASPARI;RENATO ZAMBELLO;GIORGIO ARRIGONI;LINDA NICOLARDI;RITA CHIARI;CINZIA FRANCHIN","1341;1037;1005;1005;980;980;980;980;980;980;654;577;554;511;434;325;316;172;172;131","GIORGIO ARRIGONI;CRISTINA BASSO;ANNA MARIA CATTELAN;RAFFAELLA COLOMBATTI;MONIA PACENTI;CINZIA FRANCHIN;STEFANIA RIZZO;CLAUDIO BARACCHINI;MARCELLO MELE;MARTA SBARAGLIA;RENATO ZAMBELLO;LAURA SAINATI;GAETANO THIENE;BRIGIDA BARBERIO;DANIELE DONATO;DERIS GIANNI BOEMO;EDOARDO SAVARINO;EMANUELE BERTAGLIA;ENRICO OPOCHER;FRANCESCO CAUSIN","11;8;8;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;ECONOMICS;MATHEMATICS;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;PSYCHOLOGY","141;46;16;12;8;6;6;5;5;4;3;3;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;GENETICS;ONCOLOGY;PEDIATRICS;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;VIROLOGY;RADIOLOGY;PSYCHIATRY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;EMERGENCY MEDICINE;ENDOCRINOLOGY;FAMILY MEDICINE;NURSING;OPTICS;PHYSICAL THERAPY","111;37;27;24;20;20;20;19;18;17;16;15;12;11;10;10;7;7;7;7;7;7","DISEASE;CANCER;COHORT;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;OUTBREAK;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;POPULATION;PNEUMONIA;CLINICAL TRIAL;ADVERSE EFFECT;ALTERNATIVE MEDICINE;HEART FAILURE;HORMONE;INCIDENCE (GEOMETRY);RETROSPECTIVE COHORT STUDY;EPIDEMIOLOGY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;MAGNETIC RESONANCE IMAGING;MECHANICAL VENTILATION;MYOCARDIAL INFARCTION;PATHOLOGICAL;PROSPECTIVE COHORT STUDY;REGIMEN","31;21;19;18;12;11;11;11;11;10;9;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;2019-20 CORONAVIRUS OUTBREAK;HAZARD RATIO;CLINICAL ENDPOINT;EJECTION FRACTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;LENALIDOMIDE;MULTICENTER STUDY;PLACEBO;PROSTATE CANCER;PROTEOMICS;VIRAL LOAD;AUTOIMMUNE PANCREATITIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BORTEZOMIB;BRONCHIOLITIS;CARDIOMYOPATHY;CATHETER ABLATION;COLORECTAL CANCER;CONJUGATED SYSTEM;DOCETAXEL;ENDOCRINE SYSTEM;ESOPHAGEAL CANCER;GENOTYPE;GERMLINE;GROWTH HORMONE;HAEMATOPOIESIS;IMMUNE THROMBOCYTOPENIA;INSULIN RESISTANCE;ISCHEMIC STROKE;LIVER TRANSPLANTATION;LYSINE;METASTASIS;MUTATION;MYELIN;NEUROPSYCHOLOGY;PHYLOGENETIC TREE;PROGRAMMED CELL DEATH;PROSTATE;RITUXIMAB;THROMBOLYSIS;TRANSCRIPTION FACTOR;TROPONIN I;UBIQUITIN","20;7;6;6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);ANTIRETROVIRAL THERAPY;ANTHRACYCLINE;BUSULFAN;DEUBIQUITINATING ENZYME;ESOPHAGECTOMY;HORMONE RECEPTOR;NEOADJUVANT THERAPY;NIVOLUMAB;OLIGODENDROCYTE;TAXANE;UBIQUITIN LIGASE;ANAPLASTIC ASTROCYTOMA;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIGEN PRESENTATION;ANTIGEN-PRESENTING CELL;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;ATRX;BUNDLE BRANCHES;CARDIAC RESYNCHRONIZATION THERAPY;CARFILZOMIB;CATENIN;CEFTAZIDIME;CHEMOIMMUNOTHERAPY;COLECTOMY;CONNEXIN;CRITICAL LIMB ISCHEMIA;CTGF;CYCLIN D1;DABIGATRAN;DNA FRAGMENTATION;DNA MISMATCH REPAIR;DUMPING SYNDROME;ELECTROCHEMOTHERAPY;ELTROMBOPAG;EPIRUBICIN;ERYTHROPOIETIC PROTOPORPHYRIA;ESTROGEN RECEPTOR;FAMILIAL ADENOMATOUS POLYPOSIS;FASTING GLUCOSE;FEBRILE NEUTROPENIA;FETAL HEART;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;FOLLICLE-STIMULATING HORMONE;FRAMESHIFT MUTATION;FUSION TRANSCRIPT;GENOME INSTABILITY;GESTATIONAL DIABETES;HEMATOPOIETIC CELL;HUMAN GROWTH HORMONE;IDH1;INDUCED PLURIPOTENT STEM CELL;INTRAVENOUS IRON;IPILIMUMAB;ISCHEMIC CARDIOMYOPATHY;KEAP1;LIPOARABINOMANNAN;MALE INFERTILITY;MAMMARY GLAND;MAMMARY TUMOR;MARCUS THEORY;MEROPENEM;MICROSATELLITE;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;MODIFIED RANKIN SCALE;MULTIPLEX POLYMERASE CHAIN REACTION;MYCOBACTERIUM INFECTIONS;MYELOID-DERIVED SUPPRESSOR CELL;OLIGODENDROGLIOMA;PDGFRA;PEMBROLIZUMAB;PENTOSE PHOSPHATE PATHWAY;PHENOL EXTRACTION;PNEUMOCOCCAL INFECTIONS;POLYCYSTIC OVARY;POMALIDOMIDE;PROOFREADING;PROSTATECTOMY;REMYELINATION;RIVAROXABAN;SEMEN ANALYSIS;SHOTGUN PROTEOMICS;SINGLE-NUCLEOTIDE POLYMORPHISM;SINOATRIAL NODE;SOMATROPIN;SOX2;STAT PROTEIN;THIOTEPA;THROMBOPOIETIN;TOTAL BODY IRRADIATION;TRANSCRIPTOME;TRANSFERRIN SATURATION;VERBAL ABUSE;WORKPLACE VIOLENCE","19;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;ITALY;AGED;ADULT;COVID-19;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;CHILD;TREATMENT OUTCOME;ADOLESCENT;AGED, 80 AND OVER;BETACORONAVIRUS;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;YOUNG ADULT;ANEMIA, SICKLE CELL","78;69;52;51;37;31;30;27;26;20;20;17;15;14;12;11;11;11;11;9","CORONAVIRUS DISEASE 2019;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GLIOMAS;MOLECULAR RESEARCH ON BREAST CANCER;SARCOMA RESEARCH AND TREATMENT;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GASTRIC CANCER RESEARCH AND TREATMENT;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MANAGEMENT OF PRIMARY ALDOSTERONISM;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS","7;6;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CLINICAL PRACTICE;NEOADJUVANT THERAPY;REGIMEN;TREATMENT;CARDIAC IMAGING;CLINICAL ENDPOINT;CARDIAC ELECTROPHYSIOLOGY;CLINICAL CHARACTERISTICS;CORONA VIRUS;CUMULATIVE INCIDENCE;INFARCTION TREATMENT;PROSTATE CANCER;SICKLE-CELL DISEASE;STROKE (ENGINE);ACUTE PANCREATITIS;ANTIRETROVIRAL THERAPY;ANTIVIRAL TREATMENT;AUTOIMMUNE PANCREATITIS","10;5;5;5;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2","SICKLE CELL;CELL DISEASE;LONG-TERM OUTCOME;NEOADJUVANT CHEMOTHERAPY;OBSERVATIONAL STUDY;ASSAY PERFORMANCE;BREAST CANCER;CANCER PATIENTS;CELL TRANSPLANTATION;CLINICAL PRACTICE;HIGH-GRADE GLIOMAS;MULTICENTER CLINICAL;NEGATIVE BREAST;PATIENTS TREATED;STEM CELL;ABSTRACT P--;AUTOIMMUNE PANCREATITIS;CANCER BURDEN;CHRONIC IMMUNE;CLINICAL DATA;CLINICAL EVALUATION;CLINICAL SAMPLES;CONJUGATE PREPARATIONS;CONTROLLED TRIAL;CORONAVIRUS DISEASE;DAILY PRACTICE;DATA DIAGNOSIS;DIAGNOSED MULTIPLE;DIAGNOSIS TREATMENT;DISEASE PATIENTS","6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;HR CI;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;CONSULTANCY HONORARIA;HONORARIA RESEARCH;LR PTS;STANDARD CARE;PATIENTS RECEIVING;COMMITTEES SPEAKERS;CANCER PATIENTS;CLINICAL PRACTICE;CLINICAL STATUS;DISCLOSURE DATA;GA VERSUS;GILEAD SCIENCES;MATERIAL SUPPORT;MEDIAN AGE;REVIEW PANEL;ADVERSE EVENTS;AMGEN HONORARIA;AOR CI;NLR PTS;RESEARCH STUDY;SCIENTIFIC RESEARCH;SICKLE CELL;CLINICAL TRIALS;COMMITTEES RESEARCH","67;67;56;38;37;36;32;21;15;14;13;12;11;11;11;11;11;11;11;11;11;10;10;10;10;10;10;10;9;9",78,0.52,10.38,9,1,10.5,0,39.75,4.75,1,5,11,3,1,9,1.75,2.25,3,4,6,4,0,0,69.5,69.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,3.23,55877.11,23.91,22,0.5,56.68,0,2,6,1,10,0,0,25,0,25,19,0,0,0,0,0,0,44,0,0,41,0,0,3,0,0,0,0,0,0,"Italy;United States;United Kingdom;Germany;France;Netherlands;Norway;Switzerland","17;11;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3213 PAEDIATRICS;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4205 NURSING","42;27;9;7;4;3;3;3;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;PEDIATRIC;PREVENTION;CANCER;AUTOIMMUNE DISEASE;INFECTIOUS DISEASES;LIVER DISEASE;LUNG;CARDIOVASCULAR;NEURODEGENERATIVE;NEUROSCIENCES;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;VACCINE RELATED;AGING","39;21;15;13;11;10;10;9;6;6;6;5;4;4;4;3;3;3;3;2","CANCER;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;RESPIRATORY;BLOOD;EYE;GENERIC HEALTH RELEVANCE;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","5;4;3;3;2;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.7 PHYSICAL;8.1 ORGANISATION AND DELIVERY OF SERVICES","17;3;3;2;1;1;1;1;1","COLON AND RECTAL CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BRAIN TUMOR;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","5;3;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.2 SURVEILLANCE","4;2;2;2;1;1;1;1;1",3,3098231,191566.54,5,7.66666666666667,4.66666666666667,0.666666666666667,10,315916.78908894,0.477973964079159,"AZIENDA OSPEDALIERA DI PADOVA;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;BARCELONA SUPERCOMPUTING CENTER;CHILDREN'S MEMORIAL HEALTH INSTITUTE;ERASMUS MC;EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (SWITZERLAND);HOSPITAL CLÍNIC DE BARCELONA;INSTITUT CATALÀ DE LA SALUT;MADRID HEALTH SERVICE;PARC DE SALUT;POMPEU FABRA UNIVERSITY;REGION OF SOUTHERN DENMARK;SAARLAND UNIVERSITY;STOCKHOLM REGIONAL COUNCIL;UNIVERSITY COLLEGE LONDON;UNIVERSITY HOSPITAL DUBRAVA;UNIVERSITY MEDICAL CENTER OF THE JOHANNES GUTENBERG UNIVERSITY MAINZ;UNIVERSITY OF NOTTINGHAM;UNIVERSITY OF ZAGREB","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH","2;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","2;2;1","3RD HEALTH PROGRAMME (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;2;2;1;1","CLINICAL RESEARCH;ALCOHOLISM, ALCOHOL USE AND HEALTH;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;HEALTH SERVICES;HEPATITIS;LIVER DISEASE;ORGAN TRANSPLANTATION;PREVENTION;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;SUBSTANCE MISUSE;TRANSPLANTATION","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL","1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1;1;1","COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;NOT SITE-SPECIFIC CANCER","1;1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH","1;1;1;1;1","A01 CLINICAL MEDICINE","3","3 GOOD HEALTH AND WELL BEING","1",31,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;AMERICAN CHEMICAL SOCIETY;KARGER PUBLISHERS;SCIELO JOURNALS;TAYLOR & FRANCIS GROUP","15;6;4;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;52 PSYCHOLOGY;40 ENGINEERING;44 HUMAN SOCIETY;49 MATHEMATICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3208 MEDICAL PHYSIOLOGY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;37 EARTH SCIENCES;3704 GEOINFORMATICS;4003 BIOMEDICAL ENGINEERING","37;14;14;5;4;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;PEDIATRIC;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BIOTECHNOLOGY;CARDIOVASCULAR;PREVENTION;AGING;EMERGING INFECTIOUS DISEASES;HEART DISEASE;HEMATOLOGY;INFECTIOUS DISEASES;RARE DISEASES;BIOMEDICAL IMAGING;BRAIN DISORDERS;CONGENITAL STRUCTURAL ANOMALIES;DIGESTIVE DISEASES;EPILEPSY;EYE DISEASE AND DISORDERS OF VISION","13;6;5;4;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1","METABOLIC AND ENDOCRINE;CANCER;CARDIOVASCULAR;INFECTION;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","4;2;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","6;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","7;3;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","15;2;2","SARCOMA;BRAIN TUMOR;NOT SITE-SPECIFIC CANCER;NON-HODGKIN'S LYMPHOMA","3;2;2;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_PADOVA",2021,160,21.36875,2.60625,0.1625,0.16875,0.21875,1.38538205980066,1.23809523809524,1.22727272727273,1.34615384615385,0.7,3,85,31,14,5,0.53,0.19,0.09,0.03,15.77,1.02256955124264,7.70258136924804,0.425,0.9625,0.615,0.419,0.336,0.429,"PIERO NICOLAI;MARCO FERRARI;ANGELO PAOLO DEI TOS;CRISTINA BASSO;STEFANO TABONI;SABINO ILICETO;MARTA SBARAGLIA;RAFFAELLA COLOMBATTI;IGNAZIO CASTAGLIUOLO;ANNA MARIA CATTELAN;MARIO PLEBANI;PAOLO BOSSI;MARCO SCARPA;TOMMASO GUALTIERI;ALBERTO DEGANELLO;LAURA SAINATI;MARTINA PERAZZOLO MARRA;GRAZIA MARIA VERNACI;MELANIA SCARPA;ROBERTO VETTOR","11;9;8;8;7;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4","C. ANGELINI;PIERO NICOLAI;CRISTINA BASSO;MARCO FERRARI;ROBERTO VETTOR;SABINO ILICETO;IGNAZIO CASTAGLIUOLO;MARCO SCARPA;STEFANO TABONI;VALENTINA PEGORARO;DE RIENZO;DE NUNZIO;GIORGIO ARRIGONI;MELANIA SCARPA;ANNA MARIA CATTELAN;RAFFAELLA COLOMBATTI;ANGELO PAOLO DEI TOS;LUCA BUSETTO;MARTA SBARAGLIA;MARTINA PERAZZOLO MARRA","3.5;0.76;0.73;0.71;0.68;0.61;0.61;0.59;0.58;0.5;0.5;0.5;0.5;0.49;0.48;0.46;0.46;0.44;0.44;0.43","PIERO NICOLAI;MARCO FERRARI;ANGELO PAOLO DEI TOS;CRISTINA BASSO;STEFANO TABONI;SABINO ILICETO;MARTA SBARAGLIA;RAFFAELLA COLOMBATTI;ANNA MARIA CATTELAN;MARIO PLEBANI;MARCO SCARPA;LAURA SAINATI;MARTINA PERAZZOLO MARRA;ROBERTO VETTOR;C. ANGELINI;GIORGIO ARRIGONI;CLAUDIO BARACCHINI;MONICA DE GASPARI;GIULIA REGGIANI;ALBERTO CIPRIANI","11;9;8;8;7;7;7;7;6;5;5;4;4;4;4;4;4;4;3;3","C. ANGELINI;PIERO NICOLAI;CRISTINA BASSO;MARCO FERRARI;ROBERTO VETTOR;SABINO ILICETO;MARCO SCARPA;STEFANO TABONI;DE RIENZO;GIORGIO ARRIGONI;ANNA MARIA CATTELAN;RAFFAELLA COLOMBATTI;ANGELO PAOLO DEI TOS;LUCA BUSETTO;MARTA SBARAGLIA;MARTINA PERAZZOLO MARRA;MONICA DE GASPARI;RAFFAELLA MOTTA;MARIO PLEBANI;GAETANO THIENE","3.5;0.76;0.73;0.71;0.68;0.61;0.59;0.58;0.5;0.5;0.48;0.46;0.46;0.44;0.44;0.43;0.41;0.39;0.38;0.33","ANGELO PAOLO DEI TOS;MARTA SBARAGLIA;GIOVANNI GRIGNANI;ALESSANDRO GRONCHI;AXEL LE CESNE;HANS GELDERBLOM;HEIKKI JOENSUU;JAVIER MARTÍN‐BROTO;JEAN‐YVES BLAY;MARIA A. PANTALEO;NADIA HINDI;OLIVIER MIR;PAOLO G. CASALI;PETER HOHENBERGER;PETER REICHARDT;PIOTR RUTKOWSKI;ROBIN L. JONES;SEBASTIAN BAUER;SILVIA GASPERONI;WINAN J. VAN HOUDT","832;829;807;804;804;804;804;804;804;804;804;804;804;804;804;804;804;804;804;804","MARTA SBARAGLIA;ANGELO PAOLO DEI TOS;FRANCESCO PIAZZA;UMBERTO CILLO;FRANCO SCHIAVON;ROBERTO PADOAN;MARCO FERRARI;RENATO ZAMBELLO;MARCELLO MELE;STEFANO TABONI;PIERO NICOLAI;ALBERTO MARCHET;VASSILENA TSVETKOVA;GIORGIO VESCOVO;ANNA MARIA CATTELAN;CLAUDIO BARACCHINI;MONIA PACENTI;CRISTINA BASSO;GERMANA LONGO;GIORGIO ARRIGONI","823;813;181;128;102;102;73;72;68;66;62;57;57;50;49;45;44;43;43;42","PIERO NICOLAI;MARCO FERRARI;ANNA MARIA CATTELAN;CRISTINA BASSO;STEFANO TABONI;MARTA SBARAGLIA;ANGELO PAOLO DEI TOS;MARCO SCARPA;GIORGIO ARRIGONI;LAURA SAINATI;MONICA DE GASPARI;RAFFAELLA COLOMBATTI;MARTINA PERAZZOLO MARRA;CLAUDIO BARACCHINI;FRANCESCO CAUSIN;GERMANA LONGO;MONIA PACENTI;RENATO ZAMBELLO;STEFANIA RIZZO;GIORGIO PIGATO","10;8;6;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;ENGINEERING;ECONOMICS;PHYSICS;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;COMPUTER SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;GEOGRAPHY;PHILOSOPHY;MATERIALS SCIENCE;ART;BUSINESS","153;44;12;9;9;8;8;8;6;6;5;4;3;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;ONCOLOGY;CARDIOLOGY;RADIOLOGY;IMMUNOLOGY;PEDIATRICS;PSYCHIATRY;GASTROENTEROLOGY;FAMILY MEDICINE;CANCER RESEARCH;INTENSIVE CARE MEDICINE;VIROLOGY;ENVIRONMENTAL HEALTH;ANATOMY;EMERGENCY MEDICINE;ENDOCRINOLOGY;MECHANICAL ENGINEERING","117;41;36;22;22;20;20;18;17;16;15;13;12;12;12;11;9;7;7;7","DISEASE;CANCER;COHORT;GENE;CHEMOTHERAPY;HEART FAILURE;POPULATION;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION;CONFIDENCE INTERVAL;MAGNETIC RESONANCE IMAGING;MULTIVARIATE ANALYSIS;STROKE (ENGINE);ANTIBODY;CLINICAL TRIAL;IMMUNOHISTOCHEMISTRY;OUTBREAK;PROSPECTIVE COHORT STUDY;REGIMEN;VIRUS","44;22;22;15;11;10;10;10;9;7;7;7;7;6;6;6;6;6;6;6","INFECTIOUS DISEASE (MEDICAL SPECIALTY);UNIVARIATE ANALYSIS;2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;EJECTION FRACTION;HAZARD RATIO;CARDIOMYOPATHY;PHENOTYPE;SICKLE CELL ANEMIA;CARDIAC MAGNETIC RESONANCE;CLINICAL ENDPOINT;COLORECTAL CANCER;HEAD AND NECK CANCER;IMMUNOTHERAPY;MOTOR NEURON;MYOCARDIAL FIBROSIS;PARKINSON'S DISEASE;PHASES OF CLINICAL RESEARCH;RITUXIMAB;UNIVARIATE","18;7;6;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);HEAD AND NECK SQUAMOUS-CELL CARCINOMA;NEOADJUVANT THERAPY;VASO-OCCLUSIVE CRISIS;ACUTE CHEST SYNDROME;DEEP BRAIN STIMULATION;DNA MISMATCH REPAIR;ESTROGEN RECEPTOR;GENOME INSTABILITY;LOWER URINARY TRACT SYMPTOMS;MODIFIED RANKIN SCALE;RIVAROXABAN;TREATMENT-RESISTANT DEPRESSION;VAGUS NERVE STIMULATION;VINCRISTINE;ADIPOKINE;ADIPONECTIN;ADJUVANT CHEMOTHERAPY;AMPK;ANTIRETROVIRAL THERAPY;AUTOIMMUNE ENCEPHALITIS;BENDAMUSTINE;BUSULFAN;CALSEQUESTRIN;CANCER IMMUNOTHERAPY;CARDIAC RESYNCHRONIZATION THERAPY;CARFILZOMIB;CATECHIN;CD40;COLPOSCOPY;CORONARY CALCIUM SCORE;DARATUMUMAB;DIFFERENCE GEL ELECTROPHORESIS;DIFFUSING CAPACITY;DIGITAL POLYMERASE CHAIN REACTION;DNA METHYLATION;FIBROMUSCULAR DYSPLASIA;FRACTIONAL FLOW RESERVE;GASTRIC BYPASS;GLI1;GRANULOMATOSIS WITH POLYANGIITIS;HAEMOPHILUS PARAINFLUENZAE;HBSAG;HEART RATE VARIABILITY;HEREDITARY SPASTIC PARAPLEGIA;HISTONE METHYLTRANSFERASE;HPV INFECTION;IMMUNOGLOBULIN M;INTERNATIONAL PROGNOSTIC INDEX;ISCHEMIC CARDIOMYOPATHY;KEAP1;KYNURENIC ACID;KYNURENINE;LIMB-GIRDLE MUSCULAR DYSTROPHY;LIPOARABINOMANNAN;LOSS FUNCTION;LYMPHOPLASMACYTIC LYMPHOMA;MEPOLIZUMAB;METASTATIC BREAST CANCER;MONTREAL COGNITIVE ASSESSMENT;MYOGENIN;NEUROPSYCHOLOGICAL ASSESSMENT;NIVOLUMAB;PEMBROLIZUMAB;POMALIDOMIDE;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER;PRIMARY TUMOR;PROANTHOCYANIDIN;QUANTITATIVE PROTEOMICS;REGORAFENIB;RIBAVIRIN;RUXOLITINIB;SEROPREVALENCE;SEROSTATUS;SEXUALLY TRANSMITTED DISEASE;SOLID ORGAN;SOLITARY FIBROUS TUMOR;SOMATOSTATIN RECEPTOR 2;TERIFLUNOMIDE;TISSUE TROPISM;TRANSURETHRAL RESECTION OF THE PROSTATE;TRIPLE-NEGATIVE BREAST CANCER;TROCHLEAR NERVE;TUMOR-INFILTRATING LYMPHOCYTES;UPPER MOTOR NEURON;VITAMIN K ANTAGONIST;VOXEL-BASED MORPHOMETRY;WEIGHT CHANGE","18;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;ITALY;COVID-19;AGED;MIDDLE AGED;ADULT;SARS-COV-2;RETROSPECTIVE STUDIES;NEOPLASM RECURRENCE, LOCAL;YOUNG ADULT;ADOLESCENT;STROKE;NEOPLASMS;SARCOMA;TREATMENT OUTCOME;ANEMIA, SICKLE CELL;ORBIT","95;63;32;31;26;20;19;19;18;15;14;12;10;9;9;8;8;8;7;7","ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF VALVULAR HEART DISEASE;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;LYMPHOID NEOPLASMS;SARCOMA RESEARCH AND TREATMENT;CORONAVIRUS DISEASE 2019 RESEARCH;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;BIOACTIVE PEPTIDES IN FOOD AND HEALTH;CANCER IMMUNOTHERAPY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS","8;7;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;UNIVARIATE ANALYSIS;CARDIAC IMAGING;REGIMEN;SICKLE-CELL DISEASE;STROKE (ENGINE);CARDIOVASCULAR RISK ASSESSMENT;TREATMENT;CARDIAC MAGNETIC RESONANCE;CLINICAL ENDPOINT;DEPRESSION (ECONOMICS);NEOADJUVANT THERAPY;PROSTHETIC VALVES EVALUATION;CLINICAL PRACTICE GUIDELINES;CONCOMITANT;DILATED CARDIOMYOPATHY;EWING'S SARCOMA;LEFT VENTRICULAR FUNCTION;MOTOR NEURON","12;7;7;6;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3","COVID- PANDEMIC;CELL DISEASE;SICKLE CELL;BREAST CANCER;CELL CARCINOMA;CLINICAL PRACTICE;LOCALLY ADVANCED;LONG-TERM CLINICAL;NATURAL HISTORY;OBSERVATIONAL STUDY;ORGAN TRANSPLANTATION;PATIENTS TREATED;PHASE II;RETROSPECTIVE STUDY;SOLID ORGAN;SQUAMOUS CELL;ACUTE ISCHEMIC;ANTIBODY DYNAMICS;AORTIC VALVE;ARRHYTHMIC MITRAL;ARRHYTHMOGENIC CARDIOMYOPATHY;B-CELL LYMPHOMA;BLAST CRISIS;BONE MARROW;CANCER PATIENTS;CARBON ION-BASED;CAROTID ARTERY;CASE-CONTROL STUDY;CHEMOTHERAPY IC;CLINICAL FEATURES","7;6;6;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;CROSSREF PUBMED;SPEAKERS BUREAU;CORONAVIRUS DISEASE;COVID- PANDEMIC;HR CI;ONCOL -ABSTRACT;MEDIAN AGE;DISEASE COVID-;PB- PB-;CLINICAL PRACTICE;CONSULTANCY HONORARIA;DM PATIENTS;SARS-COV- INFECTION;BIELACK SS;HONORARIA MEMBERSHIP;STUDY PERIOD;ADVISORY BOARD;BLOOD THERAPEUTICS;COVID- INFECTION;GLOBAL BLOOD;LUNG CANCER;BREAST CANCER;COMMITTEES RESEARCH;GILEAD SCIENCES;MARCH APRIL;MVP PATIENTS","67;52;52;32;30;22;20;18;18;17;16;15;15;14;14;13;12;11;11;11;10;10;10;10;10;9;9;9;9;9",78,0.49,6.44,8,4,2.25,0,2,1,0,1.5,9,2.5,0,7.75,0,1,2,3,4.5,3,0,0,34,34,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,3.4,1154.63,17.89,19,0.37,61.92,0,0,5,2,12,0,2,30,0,29,20,0,0,0,0,0,1,49,1,1,49,1,0,0,0,0,1,0,0,0,"Italy;United States;United Kingdom;France;Netherlands;Germany;Switzerland;Argentina;Belgium;Brazil;Denmark;Ireland;Japan;Poland;Portugal;Russia;Spain;Thailand","17;8;5;4;4;2;2;1;1;1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3207 MEDICAL MICROBIOLOGY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES;48 LAW AND LEGAL STUDIES","49;34;4;4;4;3;2;2;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;PREVENTION;CARDIOVASCULAR;HEMATOLOGY;PEDIATRIC;LUNG;HEART DISEASE;INFECTIOUS DISEASES;TRANSPLANTATION;AUTOIMMUNE DISEASE;BRAIN DISORDERS;CANCER;DIGESTIVE DISEASES;AGING;BIOMEDICAL IMAGING;NEURODEGENERATIVE;NEUROSCIENCES","46;25;19;16;12;10;9;9;8;7;7;7;6;6;6;6;4;4;4;4","CARDIOVASCULAR;CANCER;INFECTION;ORAL AND GASTROINTESTINAL;NEUROLOGICAL;RESPIRATORY;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;MUSCULOSKELETAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","9;5;4;4;3;3;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;8.1 ORGANISATION AND DELIVERY OF SERVICES","25;4;3;3;1;1;1;1;1;1;1;1","BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER;SARCOMA;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GASTROINTESTINAL TRACT;HODGKIN'S DISEASE;KIDNEY CANCER;LIVER CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA","2;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,"FRONTIERS;KARGER PUBLISHERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;SAGE JOURNALS;TAYLOR & FRANCIS GROUP","19;6;4;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3207 MEDICAL MICROBIOLOGY;3213 PAEDIATRICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3105 GENETICS;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4202 EPIDEMIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY;3009 VETERINARY SCIENCES;3204 IMMUNOLOGY;4207 SPORTS SCIENCE AND EXERCISE;4610 LIBRARY AND INFORMATION STUDIES","48;15;12;9;5;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;PREVENTION;INFECTIOUS DISEASES;PEDIATRIC;CANCER;LUNG;EMERGING INFECTIOUS DISEASES;GENETICS;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BIODEFENSE;CARDIOVASCULAR;DIGESTIVE DISEASES;HEMATOLOGY;MENTAL HEALTH;NEUROSCIENCES;SEPSIS;VACCINE RELATED;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY","16;11;7;7;6;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;CARDIOVASCULAR;RESPIRATORY;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","5;5;5;3;2;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.4 SURGERY","9;2;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","16;9;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","20;3;2;1","BREAST CANCER;PANCREATIC CANCER;KIDNEY CANCER;MELANOMA","2;2;1;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_PADOVA",2022,125,18.52,2.448,0.176,0.192,0.192,1.41666666666667,1.15789473684211,1.2,1.04347826086957,0.752,1,53,19,12,7,0.42,0.15,0.1,0.06,8.93,1.00013347824531,6.78748651564187,0.408,0.952,0.433,0.248,0.426,0.46,"CRISTINA BASSO;GIORGIO ARRIGONI;GIUSEPPE TARANTINI;ILARIA BATTISTI;RAFFAELLA COLOMBATTI;AUGUSTO D’ONOFRIO;GINO GEROSA;MONICA DE GASPARI;SAMANTHA SARTORI;ELENA CAMPELLO;ROXANA MEHRAN;MARIO PLEBANI;GIANFRANCO SINAGRA;PAOLO SIMIONI;SABINO ILICETO;MATTEO FASSAN;GEORGE DANGAS;CIRO INDOLFI;PIERGIUSEPPE AGOSTONI;ANDREA PADOAN","11;8;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","CRISTINA BASSO;EZIO ZANON;GIORGIO ARRIGONI;MONICA DE GASPARI;ILARIA BATTISTI;GINO GEROSA;NICOLETTA FINATO;ANDREA MESSORI;MARCO CHIUMENTE;DANIELE MENGATO;ELENA CAMPELLO;PAOLO SIMIONI;SABINO ILICETO;ANDREA ERMOLAO;RAFFAELLA COLOMBATTI;ANDREA SANNA;G TOSCANO;LUCA ZANELLA;LUCA FELICIONI;ROBERTO COLA","1;1;0.81;0.67;0.59;0.57;0.5;0.44;0.44;0.44;0.42;0.42;0.38;0.36;0.36;0.33;0.33;0.33;0.33;0.33","CRISTINA BASSO;GIORGIO ARRIGONI;GIUSEPPE TARANTINI;ILARIA BATTISTI;RAFFAELLA COLOMBATTI;AUGUSTO D’ONOFRIO;GINO GEROSA;MONICA DE GASPARI;ELENA CAMPELLO;PAOLO SIMIONI;SABINO ILICETO;MATTEO FASSAN;ANDREA PADOAN;SALVATORE PUCCIARELLI;MARCO SENZOLO;ANGELO PAOLO DEI TOS;ANNA MARIA CATTELAN;THOMAS BOCHATON;MARCO SCARPA;ANDREA ERMOLAO","11;8;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","CRISTINA BASSO;EZIO ZANON;GIORGIO ARRIGONI;MONICA DE GASPARI;ILARIA BATTISTI;GINO GEROSA;DANIELE MENGATO;ELENA CAMPELLO;PAOLO SIMIONI;SABINO ILICETO;ANDREA ERMOLAO;RAFFAELLA COLOMBATTI;ANDREA SANNA;G TOSCANO;LUCA ZANELLA;ROBERTO COLA;ANNA MARIA CATTELAN;MANUEL DE LAZZARI;MARCO SENZOLO;MATTEO FASSAN","1;1;0.81;0.67;0.59;0.57;0.44;0.42;0.42;0.38;0.36;0.36;0.33;0.33;0.33;0.33;0.32;0.32;0.31;0.3","CRISTINA BASSO;MONICA DE GASPARI;STEFANIA RIZZO;MARCO MARINI;AHMAD HAYEK;AITOR URIBARRI;ALAIN COMBES;ALBERT ARIZA‐SOLÉ;ANNALISA TURCO;ANTONIO CANNATÀ;AURELIA GROSU;CARLO VITTORIO CANNISTRACI;CAROLINE M. VAN DE HEYNING;CRISTINA GIANNATTASIO;DANIEL I. BROMAGE;DANIELE BRIGUGLIA;DAVIDE FARINA;ENRICO AMMIRATI;ERIC ADLER;F TURRINI","235;183;179;176;174;174;174;174;174;174;174;174;174;174;174;174;174;174;174;174","CRISTINA BASSO;MONICA DE GASPARI;STEFANIA RIZZO;MARCO SENZOLO;ALBERTO ZANETTO;PATRIZIA BURRA;GIORGIO ARRIGONI;FILIPPO PELIZZARO;FRANCESCO PAOLO RUSSO;ILARIA BATTISTI;CATERINA BOLDRIN;MARGHERITA CATTAI;MONIA PACENTI;CARLA SCARONI;FILIPPO CECCATO;R. D’INCÀ;DARIA MANIERO;EDOARDO SAVARINO;MATTEO GHISA;MARIA TERESA SARTORI","234;183;179;117;80;80;73;70;64;60;46;46;46;43;43;40;38;38;38;37","CRISTINA BASSO;GIORGIO ARRIGONI;ILARIA BATTISTI;AUGUSTO D’ONOFRIO;MONICA DE GASPARI;RAFFAELLA COLOMBATTI;ANNA MARIA CATTELAN;GINO GEROSA;GIUSEPPE TARANTINI;MARCO SCARPA;MARCO SENZOLO;STEFANIA RIZZO;ALBERTO ZANETTO;ANGELO PAOLO DEI TOS;BIAGIO CASTALDI;CARLA SCARONI;CARMELO LACOGNATA;CATERINA BOLDRIN;CESARE RUFFOLO;CHIARA SIMION","10;8;6;5;5;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;MATERIALS SCIENCE;PSYCHOLOGY;BUSINESS;SOCIOLOGY;ART;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE","121;28;12;11;11;6;6;4;3;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;GENETICS;FAMILY MEDICINE;OPTICS;ECONOMIC GROWTH;EMERGENCY MEDICINE;ENDOCRINOLOGY;MECHANICAL ENGINEERING;PHYSICAL THERAPY","101;46;25;22;21;16;16;16;13;13;13;11;10;7;7;6;6;6;6;6","DISEASE;CANCER;COHORT;POPULATION;GENE;HEART FAILURE;MAGNETIC RESONANCE IMAGING;CLINICAL TRIAL;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;THROMBOSIS;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;BLOOD PRESSURE;CHEMOTHERAPY;HEALTH CARE;INCIDENCE (GEOMETRY);ATRIAL FIBRILLATION;CONFIDENCE INTERVAL;ENZYME;MYOCARDITIS;OBSERVATIONAL STUDY","30;14;13;13;12;11;11;10;9;9;8;7;7;6;6;6;6;5;5;5;5;5","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;COLORECTAL CANCER;WARFARIN;BREAST CANCER;CARDIOMYOPATHY;EJECTION FRACTION;PERCUTANEOUS CORONARY INTERVENTION;ALLELE;HAZARD RATIO;PLACEBO;REFLUX;SICKLE CELL ANEMIA;VENOUS THROMBOEMBOLISM;VENOUS THROMBOSIS;2019-20 CORONAVIRUS OUTBREAK;AORTIC DISSECTION;CARDIAC MAGNETIC RESONANCE IMAGING;CARDIOGENIC SHOCK;CORONARY ANGIOGRAPHY;DEEP VEIN;DNA LIGASE;EOSINOPHILIC ESOPHAGITIS;H&E STAIN;HEART TRANSPLANTATION;HEAT SHOCK PROTEIN;HEMATOLOGIST;INFLAMMATORY BOWEL DISEASE;KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;MAPK/ERK PATHWAY;MITRAL VALVE PROLAPSE;MYELOFIBROSIS;MYOCARDIAL FIBROSIS;NEPRILYSIN;PROTEOMICS;RENIN–ANGIOTENSIN SYSTEM;RITUXIMAB;SOFT TISSUE SARCOMA;TOLERABILITY;TRANSCRIPTION FACTOR;UBIQUITIN;UNIVARIATE ANALYSIS;VALSARTAN","9;6;6;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);RIVAROXABAN;ANTHRACYCLINE;COLONOSCOPY;GERD;HSP70;HSP90;MICROSATELLITE;NEOADJUVANT THERAPY;SACUBITRIL;TAXANE;TRABECTEDIN;UBIQUITIN LIGASE;ABSOLUTE NEUTROPHIL COUNT;ACUTE CHEST SYNDROME;ANGIOTENSIN RECEPTOR;ANTIFIBRINOLYTIC;ATHERECTOMY;ATROPHIC GASTRITIS;AUTOIMMUNE GASTRITIS;B-CELL ACTIVATING FACTOR;BENDAMUSTINE;BIOMARKER DISCOVERY;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;CERTOLIZUMAB PEGOL;CHIMERIC ANTIGEN RECEPTOR;COLORECTAL ADENOMA;COLPOSCOPY;CORONARY STENT;CUTANEOUS MASTOCYTOSIS;DARATUMUMAB;DISEASE MANAGEMENT;ELEPHANT TRUNKS;EMPAGLIFLOZIN;ENALAPRIL;ENDOCRINE DISEASE;ESOPHAGITIS;FACET (PSYCHOLOGY);FLUORESCENCE IN SITU HYBRIDIZATION;FORAMEN SECUNDUM;FRACTIONAL FLOW RESERVE;GASTRIC BYPASS;GLUTAREDOXIN;GLYCOGEN STORAGE DISEASE TYPE I;HEARTBURN;IFOSFAMIDE;INTERPERSONAL REACTIVITY INDEX;INTRAUTERINE GROWTH RESTRICTION;LARYNGOPHARYNGEAL REFLUX;LEFT MAIN CORONARY ARTERY DISEASE;LYMPHOCYTIC PLEOCYTOSIS;MACE;MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY;METASTATIC BREAST CANCER;MODEL FOR END-STAGE LIVER DISEASE;MULTICENTER TRIAL;MYELOPROLIFERATIVE NEOPLASM;OBINUTUZUMAB;ONCOGENE;P-SELECTIN;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PLATEAU PRESSURE;PNEUMOCOCCAL DISEASE;PNEUMOCOCCAL INFECTIONS;PNEUMOCOCCAL VACCINE;POLYCYSTIC OVARY;REPRESSOR;RESTRICTIVE CARDIOMYOPATHY;RIOCIGUAT;RUXOLITINIB;SACUBITRIL, VALSARTAN;SOX2;SUGAMMADEX;SYSTEMIC THERAPY;T-CELL RECEPTOR;TRAMETINIB;TRANSCRIPTOME;TRIPLE-NEGATIVE BREAST CANCER;UNDERWEIGHT;VEMURAFENIB;VO2 MAX","9;5;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;COVID-19;FEMALE;RETROSPECTIVE STUDIES;MALE;ADULT;MIDDLE AGED;MYOCARDITIS;COLORECTAL NEOPLASMS;SARS-COV-2;HEART FAILURE;PROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED;ANGIOTENSIN RECEPTOR ANTAGONISTS;INFLAMMATORY BOWEL DISEASES;REGISTRIES;TETRAZOLES;DEGLUTITION DISORDERS","66;55;25;17;15;14;12;10;10;9;9;7;7;7;6;6;6;6;6;5","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF VALVULAR HEART DISEASE;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;CORONAVIRUS DISEASE 2019 RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF HEART FAILURE;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY;ADVANCEMENTS IN LUNG CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANESTHESIA AND SEDATION MANAGEMENT","9;5;5;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","CARDIAC IMAGING;SICKLE-CELL DISEASE;CLINICAL ENDPOINT;PANDEMIC;TREATMENT;DILATED CARDIOMYOPATHY;INTERQUARTILE RANGE;MYOCARDITIS;PROSTHETIC VALVES EVALUATION;PROTEOME;STROKE (ENGINE);ETIOLOGY;LEFT VENTRICULAR;REGIMEN;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TRANSFUSION THERAPY;VENOUS THROMBOEMBOLISM;2019-20 CORONAVIRUS OUTBREAK;AFRICAN DESCENT;ANTICOAGULANT THERAPY","8;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2","SICKLE CELL;CELL DISEASE;COLORECTAL CANCER;ITALIAN SOCIETY;AORTIC VALVE;HEART FAILURE;POSITION PAPER;TRANSCATHETER AORTIC;VALVE IMPLANTATION;COVID- PATIENTS;SARS-COV- INFECTION;VENOUS THROMBOEMBOLISM;ACUTE MYOCARDITIS;AORTIC DISSECTION;ARRHYTHMIC MITRAL;ARTERY DISSECTION;ASSESSMENT SURVEY;CANCER SCREENING;CARDIAC MAGNETIC;CARDIOLOGY SIC;CELL WORLD;CEREBROSPINAL FLUID;CERVICAL ARTERY;CHAPERONEINDEPENDENT UBIQUITINATION;CONNECT REGISTRY;CONTROLLED TRIAL;COVID- PANDEMIC;DECOMPENSATED CIRRHOSIS;DISEASE SCD;DISEASE UNDERGOING","10;7;5;5;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CROSSREF PUBMED;PUBMED SCOPUS;MELANOMA CELLS;MVP PATIENTS;SICKLE CELL;SOX PROTEIN;MEDIAN AGE;MYOCARDIAL INFARCTION;ARRHYTHMIC MVP;CELL DISEASE;HR CI;RISK FACTORS;HEART FAILURE;SCD CENTERS;STATISTICALLY SIGNIFICANT;WESTERN BLOT;ADAPTIVE RESPONSE;ADVERSE EVENTS;CARE SETTING;ELEVATION MYOCARDIAL;IRON OVERLOAD;LEFT VENTRICULAR;MAGNETIC RESONANCE;MAJOR BLEEDING;MONTHS NA;PATIENTS UNDERGOING;SCD PATIENTS;BRAF INHIBITION;CENTERCOMMUNITY HOSPITAL;ENDOMYOCARDIAL BIOPSY","22;22;21;18;14;14;13;13;10;10;10;10;9;9;9;9;8;8;8;8;8;8;8;8;8;8;8;7;7;7",68,0.54,9.02,8.75,1,1,0,1,0,1,0,10.5,1,1,10.25,0,0,2,7,7,4,0,0,15.25,15.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,3.47,1144.11,17.82,6,0.17,77.19,0,0,2,0,11,0,1,22,0,22,14,0,0,0,0,0,0,34,2,0,34,0,0,2,0,0,0,0,0,0,"Italy;United States;Germany;Australia;Brazil;Canada;Denmark;Finland;Japan;Netherlands;Spain;United Kingdom","11;11;2;1;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3208 MEDICAL PHYSIOLOGY;3209 NEUROSCIENCES;3215 REPRODUCTIVE MEDICINE;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;4203 HEALTH SERVICES AND SYSTEMS","34;21;6;4;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;LUNG;NEUROSCIENCES;BIOENGINEERING;BRAIN DISORDERS;CARDIOVASCULAR;DIGESTIVE DISEASES;PREVENTION;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;CANCER;NUTRITION;AGING;HEART DISEASE;HEMATOLOGY;NEURODEGENERATIVE;OBESITY","34;23;13;10;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3","CARDIOVASCULAR;RESPIRATORY;CANCER;ORAL AND GASTROINTESTINAL;NEUROLOGICAL;GENERIC HEALTH RELEVANCE;RENAL AND UROGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;INJURIES AND ACCIDENTS;METABOLIC AND ENDOCRINE;STROKE","5;5;4;4;3;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","16;4;4;3;3;1;1;1;1;1","LUNG CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER","2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","3;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","56;12;7;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4203 HEALTH SERVICES AND SYSTEMS;40 ENGINEERING;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;37 EARTH SCIENCES;4003 BIOMEDICAL ENGINEERING;44 HUMAN SOCIETY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;3704 GEOINFORMATICS","79;23;23;20;20;10;9;8;7;7;4;4;4;3;2;2;2;2;2;2","CLINICAL RESEARCH;PEDIATRIC;PREVENTION;RARE DISEASES;INFECTIOUS DISEASES;GENETICS;BIOTECHNOLOGY;LUNG;CANCER;DIGESTIVE DISEASES;CARDIOVASCULAR;HEMATOLOGY;HEALTH SERVICES;NEUROSCIENCES;BIOENGINEERING;BRAIN DISORDERS;PATIENT SAFETY;REGENERATIVE MEDICINE;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE","43;21;17;15;14;13;12;12;11;9;8;8;7;7;6;6;6;5;4;4","CANCER;GENERIC HEALTH RELEVANCE;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;INFECTION;METABOLIC AND ENDOCRINE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;STROKE","8;7;6;3;2;1;1;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;8.1 ORGANISATION AND DELIVERY OF SERVICES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","18;12;7;4;3;2;2;2;1;1;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS","25;19;11","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","39;11;7","LEUKEMIA / LEUKAEMIA;BRAIN TUMOR;LIVER CANCER;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;NON-HODGKIN'S LYMPHOMA","7;3;2;2;1;1;1","3 GOOD HEALTH AND WELL BEING;16 PEACE, JUSTICE AND STRONG INSTITUTIONS","14;1"
"AOU_PADOVA",2023,126,18.1349206349206,2.50793650793651,0.222222222222222,0.182539682539683,0.23015873015873,1.38766519823789,1.21739130434783,1.04545454545455,1.16,0.746031746031746,0,60,29,6,5,0.48,0.23,0.05,0.04,5.06,1.15523357287716,6.19226957383549,0.325396825396825,0.952380952380952,0.398,0.381,0.42,0.396,"CRISTINA BASSO;GIUSEPPE TARANTINI;FRANCESCO PAOLO RUSSO;ANTONELLA MELONI;MARIA CATERINA PUTTI;FILIPPO CADEMARTIRI;FEDERICA LESSI;LAURA PISTOIA;STEFANIA RIZZO;MONICA DE GASPARI;VINCENZO POSITANO;ANNA SPASIANO;MARTINA PERAZZOLO MARRA;ALBERTO ZANETTO;VITTORINA ZAGONEL;SABINO ILICETO;GIANLUCA RIGATELLI;EDOARDO SAVARINO;MARIO SAÏA;MARCO BARBANTI","8;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4","GIANLUCA RIGATELLI;ALBERTO ZANETTO;MARCO SENZOLO;MARCO ZUIN;CRISTINA BASSO;MARCO ZUIN;FILIPPO PELIZZARO;MARTA SBARAGLIA;FRANCESCO PAOLO RUSSO;GIORGIO ARRIGONI;ANTONELLA MELONI;MARIA CATERINA PUTTI;FILIPPO CADEMARTIRI;LAURA PISTOIA;VINCENZO POSITANO;MONICA DE GASPARI;STEFANIA RIZZO;A. BUSATTO;B. PERINI;E. BAGLIONE","1.13;0.78;0.61;0.6;0.58;0.53;0.48;0.48;0.47;0.47;0.45;0.45;0.45;0.45;0.45;0.45;0.4;0.4;0.4;0.4","CRISTINA BASSO;GIUSEPPE TARANTINI;FRANCESCO PAOLO RUSSO;MARIA CATERINA PUTTI;FEDERICA LESSI;STEFANIA RIZZO;MONICA DE GASPARI;MARTINA PERAZZOLO MARRA;ALBERTO ZANETTO;SABINO ILICETO;GIANLUCA RIGATELLI;EDOARDO SAVARINO;PATRIZIA BURRA;AUGUSTO D’ONOFRIO;GIORGIO ARRIGONI;FILIPPO PELIZZARO;MARTA SBARAGLIA;FRANCO CHIOFFI;MAURIZIO CORBETTA;FABIO FARINATI","8;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;3","GIANLUCA RIGATELLI;ALBERTO ZANETTO;MARCO SENZOLO;CRISTINA BASSO;FILIPPO PELIZZARO;MARTA SBARAGLIA;FRANCESCO PAOLO RUSSO;GIORGIO ARRIGONI;MARIA CATERINA PUTTI;MONICA DE GASPARI;STEFANIA RIZZO;A. BUSATTO;GIUSEPPE TARANTINI;MARTINA PERAZZOLO MARRA;SABINO ILICETO;LUCIA FORNASIERO;MAURO TURRIN;MAURIZIO CORBETTA;EDOARDO SAVARINO;PATRIZIA BURRA","1.13;0.78;0.61;0.58;0.48;0.48;0.47;0.47;0.45;0.45;0.4;0.4;0.4;0.39;0.39;0.33;0.33;0.3;0.3;0.3","ANDREA SARKOZY;ANDRZEJ LUBIŃSKI;AXEL BRANDES;BÉLA MERKELY;DAN WICHTERLE;EMANUELE BERTAGLIA;GHEORGHE‐ANDREI DAN;JORIS R. DE GROOT;KIM RAJAPPAN;LLUÍS MONT;NUNO CABANELAS;PAULUS KIRCHHOF;TOBIAS TOENNIS;VASIL VELCHEV;WOLFGANG DICHTL;ÉLOI MARIJON;A. JOHN CAMM;ANDREAS GOETTE;ANN‐KATHRIN OZGA;ANTONIA ZAPF","227;227;227;227;227;227;227;227;227;227;227;227;227;227;227;227;205;205;205;205","EMANUELE BERTAGLIA;LAURA PASIN;PIETRO INVERNIZZI;PATRIZIA COCCO;FRANCESCO PAOLO RUSSO;FRANCO CHIOFFI;ALBERTO ZANETTO;PAOLA ZANAGA;MARIO PLEBANI;MARTINA ZANINOTTO;ELIA SPAGNOLO;MARCO SENZOLO;PATRIZIA BURRA;ANDREA LUIGI CAMILLO CAROBBIO;FILIPPO PELIZZARO;GIANNI SORARÙ;MARCO BUCCI;MARIA CATERINA PUTTI;ELENA PEGORARO;GERMANA LONGO","227;47;44;43;24;23;18;16;15;15;14;14;14;12;12;12;12;12;11;10","FRANCESCO PAOLO RUSSO;FEDERICA LESSI;MARIA CATERINA PUTTI;EDOARDO SAVARINO;GIANLUCA RIGATELLI;STEFANIA RIZZO;ALBERTO ZANETTO;CRISTINA BASSO;FRANCO CHIOFFI;MARTINA PERAZZOLO MARRA;MONICA DE GASPARI;PATRIZIA BURRA;SABINO ILICETO;GIORGIO ARRIGONI;ANDREA LUIGI CAMILLO CAROBBIO;EMANUELE BERTAGLIA;FILIPPO PELIZZARO;MARCO SENZOLO;MARTA SBARAGLIA;RAFFAELLA COLOMBATTI","7;6;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;SOCIOLOGY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;POLITICAL SCIENCE","123;25;11;10;8;5;4;4;3;3;3;2","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;GASTROENTEROLOGY;PATHOLOGY;ONCOLOGY;BIOCHEMISTRY;RADIOLOGY;IMMUNOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;CANCER RESEARCH;ENDOCRINOLOGY;GENETICS;MECHANICAL ENGINEERING;OPTICS;CELL BIOLOGY;PSYCHIATRY;DEMOGRAPHY;DERMATOLOGY;FAMILY MEDICINE;GENERAL SURGERY;NEUROSCIENCE;PALEONTOLOGY;PHYSICAL THERAPY","109;33;29;27;23;22;17;17;14;11;10;9;8;8;7;7;7;5;5;4;4;4;4;4;4;4","DISEASE;CANCER;GENE;CIRRHOSIS;COHORT;TRANSPLANTATION;POPULATION;RETROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;ADVERSE EFFECT;CONFIDENCE INTERVAL;HEART FAILURE;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;MYOCARDIAL INFARCTION;OVERALL SURVIVAL;PROSPECTIVE COHORT STUDY;MYELOID LEUKEMIA;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;STROKE (ENGINE)","25;19;16;11;11;10;9;9;8;7;7;7;7;7;7;7;7;6;6;6;6","COLORECTAL CANCER;CROHN'S DISEASE;GENE EXPRESSION;HAZARD RATIO;HEPATITIS C VIRUS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);LIVER TRANSPLANTATION;ADENOCARCINOMA;BREAST CANCER;CHROMOSOME;CYTARABINE;GENOTYPE;INFLAMMATORY BOWEL DISEASE;INFLIXIMAB;METHYLATION;MUTATION;NEURODEGENERATION;PROGRESSION-FREE SURVIVAL;ACHALASIA;ADALIMUMAB;AMYOTROPHIC LATERAL SCLEROSIS;CARDIAC FUNCTION CURVE;CARDIAC MAGNETIC RESONANCE IMAGING;CAUSE OF DEATH;CHRONIC LIVER DISEASE;CORONARY ANGIOGRAPHY;DNA LIGASE;HEAD AND NECK CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;ISOCITRATE DEHYDROGENASE;LEFT ATRIUM;MYOCARDIAL FIBROSIS;PLACEBO;PORTAL VEIN THROMBOSIS;PROINFLAMMATORY CYTOKINE;PROTEOMICS;SEROLOGY;SPINAL MUSCULAR ATROPHY;TEMOZOLOMIDE;TOLERABILITY;TUMOR MICROENVIRONMENT;UBIQUITIN;VALVE REPLACEMENT;WARFARIN;WHITE MATTER","7;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLONOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);KARYOTYPE;USTEKINUMAB;DNA METHYLATION;METHYLTRANSFERASE;MILAN CRITERIA;TAUOPATHY;UBIQUITIN LIGASE;ANEMIA OF CHRONIC DISEASE;BASOPHIL;BILIARY TRACT CANCER;CAPECITABINE;CEBPA;COLORECTAL ADENOMA;CONNECTIVE TISSUE DISEASE;DABIGATRAN;DNA MISMATCH REPAIR;ELTROMBOPAG;ESOPHAGEAL MOTILITY DISORDER;ESOPHAGEAL VARICES;ESTROGEN RECEPTOR;FORAMEN SECUNDUM;GASTRIC BYPASS;GENE SIGNATURE;GENETICALLY MODIFIED MOUSE;GENOTYPING;GERIATRIC DEPRESSION SCALE;GERMLINE MUTATION;GIANT CELL ARTERITIS;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HEMATOPOIETIC CELL;HIGH RESOLUTION MANOMETRY;HORMONE RECEPTOR;HPV INFECTION;IDH1;INSULIN PUMP;INTERATRIAL SEPTUM;IPILIMUMAB;LEUKAPHERESIS;LYMPHOPLASMACYTIC LYMPHOMA;MEROPENEM;MESALAZINE;MICROSCOPIC COLITIS;MONTREAL COGNITIVE ASSESSMENT;MYOTOMY;ONCOSTATIN M;OSTEOCALCIN;PANCREATIC CARCINOMA;PANCREATIC DUCTAL ADENOCARCINOMA;PLASMA RENIN ACTIVITY;PROMOTER;RELAXOMETRY;RENAL SYMPATHETIC DENERVATION;RIVAROXABAN;ROS1;SANGER SEQUENCING;SEED DORMANCY;SINGLE-NUCLEOTIDE POLYMORPHISM;SOD1;STABLE ISOTOPE LABELING BY AMINO ACIDS IN CELL CULTURE;SUBSTANTIA NIGRA;TAMOXIFEN;TELOMERASE REVERSE TRANSCRIPTASE;TRAMETINIB;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;TROPONIN COMPLEX;TUMOR-INFILTRATING LYMPHOCYTES;VEMURAFENIB;VENETOCLAX;VIRAL MENINGITIS;WILD TYPE","5;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;RETROSPECTIVE STUDIES;STROKE;ADULT;AGED;BRAIN NEOPLASMS;GLIOBLASTOMA;PROGNOSIS;PROSPECTIVE STUDIES;ANEMIA, SICKLE CELL;ATRIAL FIBRILLATION;CHILD;LIVER CIRRHOSIS;MYOCARDIUM;BETA-THALASSEMIA;IRON OVERLOAD;ITALY","67;58;19;17;14;14;13;10;9;8;8;8;7;7;7;7;7;6;6;6","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;ACUTE MYELOID LEUKEMIA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MANAGEMENT OF VALVULAR HEART DISEASE;GLIOMAS;ATRIAL FIBRILLATION;CORONAVIRUS DISEASE 2019 RESEARCH;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEPATOCELLULAR CARCINOMA;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;HEPATITIS C INFECTION AND TREATMENT;MECHANISMS OF ALZHEIMER'S DISEASE;PANCREATIC CANCER RESEARCH AND TREATMENT;SARCOMA RESEARCH AND TREATMENT;SURGICAL VENTRICULAR RECONSTRUCTION IN MYOCARDIAL INFARCTION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCES IN METABOLOMICS RESEARCH","8;6;6;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1","STROKE (ENGINE);PROSTHETIC VALVES EVALUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC IMAGING;SURGICAL AORTIC-VALVE REPLACEMENT;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;HEART VALVE SURGERY;TREATMENT;AML;ANTICOAGULANT THERAPY;CARDIOVASCULAR EVALUATION;CARDIOVASCULAR RISK ASSESSMENT;CONCOMITANT;DISCONTINUATION;GLIOBLASTOMA;HEPATITIS C;LIVER CIRRHOSIS;PROGRESSION-FREE SURVIVAL;SPINAL MUSCULAR ATROPHY","7;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","AORTIC VALVE;TRANSCATHETER AORTIC;ACUTE MYELOID;MYELOID LEUKEMIA;VALVE REPLACEMENT;ATRIAL HIGH-RATE;BREAST CANCER;CARDIAC MAGNETIC;CROHNS DISEASE;HEPATOCELLULAR CARCINOMA;HIGH-RATE EPISODES;MAGNETIC RESONANCE;OBSERVATIONAL STUDY;AMYLOIDS PROMOTED;CARDIAC IRON;CELL CARCINOMA;CELL DISEASE;CELL TRANSPLANTATION;CHRONIC HEPATITIS;CHRONIC LIVER;CLINICAL RISK;COHORT STUDY;COVID- VACCINES;DISEASE PATIENTS;GLIOBLASTOMA PATIENTS;GREENLIGHT LASER;INSULIN PUMP;ITALIAN PATIENTS;LIGASE CHIP;PATIENTS AFFECTED","6;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SARS-COV- INFECTION;MEDIAN OS;TERT PROMOTER;WM PATIENTS;WM TREATMENT;NEWLY DIAGNOSED;ENDOSCOPIC RECURRENCE;MEDIAN AGE;RISK FACTORS;ACUTE MYELOID;GBM PATIENTS;IDH WILD-TYPE;MYELOID LEUKEMIA;PATIENTS UNDERGOING;PRIMARY OUTCOME;COVID- SEVERITY;DISEASE PROGRESSION;GLUCOSE METABOLISM;MEDIAN TIME;PANCREATIC FF;ADJ CT;AZIENDA OSPEDALIERA;CARDIAC DEATH;ELN RISK;FACIAL VEIN;MEDIAN FOLLOW-UP;MYELOID SARCOMA;PADOVA ITALY;PATIENTS AGED;RECURRENCE RATE","33;16;15;13;13;11;10;10;10;9;9;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7",56,0.44,11.31,9,1.5,2.25,0,4,0,1,0,10,2,0,10,1,0,3,5.75,8.75,6,0,0,7.5,7.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,2.57,233.57,11.11,4,0.17,45.87,0,0,3,0,3,0,0,17,0,14,9,0,0,0,0,0,0,22,1,0,23,0,0,0,0,0,0,0,0,0,"Italy;United States;Australia;Japan","8;4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;4203 HEALTH SERVICES AND SYSTEMS;4204 MIDWIFERY","22;14;6;4;3;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;DIGESTIVE DISEASES;AUTOIMMUNE DISEASE;BIOENGINEERING;BIOMEDICAL IMAGING;CANCER;LIVER DISEASE;CARDIOVASCULAR;DIGESTIVE DISEASES - (GALLBLADDER);LUNG;TRANSPLANTATION;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC PAIN;HEART DISEASE;HEMATOLOGY;INFLAMMATORY BOWEL DISEASE;LIVER CANCER","20;13;9;8;6;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;RESPIRATORY;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","4;3;3;3;1;1;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;3.3 NUTRITION AND CHEMOPREVENTION;5.1 PHARMACEUTICALS;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES","7;3;1;1;1;1","LIVER CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;LUNG CANCER;MYELOMA","3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","3;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,"FRONTIERS;SPRINGER NATURE;PUBLIC LIBRARY OF SCIENCE;ZENODO","16;6;4;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3213 PAEDIATRICS;3211 ONCOLOGY AND CARCINOGENESIS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3103 ECOLOGY;3204 IMMUNOLOGY;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3502 BANKING, FINANCE AND INVESTMENT;40 ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;4901 APPLIED MATHEMATICS;50 PHILOSOPHY AND RELIGIOUS STUDIES","45;14;9;4;4;3;3;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;BRAIN DISORDERS;NEUROSCIENCES;PEDIATRIC;RARE DISEASES;CANCER;NEURODEGENERATIVE;PREVENTION;HEALTH SERVICES;LUNG;BIOMEDICAL IMAGING;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;INFANT MORTALITY;LIVER DISEASE;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PHYSICAL REHABILITATION;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;REHABILITATION;TRANSPLANTATION","14;9;7;6;6;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2","CANCER;NEUROLOGICAL;INFECTION;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","4;4;3;1;1;1;1","5.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS;6.7 PHYSICAL;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","3;3;2;1;1;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","13;3;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH;PUBLIC HEALTH","16;1;1;1","NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;BRAIN TUMOR;LIVER CANCER","2;2;1;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_PADOVA",2024,94,17.9148936170213,2.77659574468085,0.223404255319149,0.25531914893617,0.308510638297872,1.2488038277512,1.10526315789474,1.26315789473684,1.16,0.659574468085106,3,46,17,7,4,0.49,0.18,0.07,0.04,0.67,0.70127612150563,5.23076923076923,0.393617021276596,0.957446808510638,0.444,0.306,0.326,0.339,"ANTONELLA MELONI;MARIA CATERINA PUTTI;MARCO PUTHENPARAMPIL;MATTEO FASSAN;LAURA PISTOIA;EDOARDO SAVARINO;VINCENZO POSITANO;FRANCESCA RINALDI;FILIPPO CADEMARTIRI;ALESSANDRO MISCIOSCIA;ANNA SPASIANO;ANGELO PAOLO DEI TOS;TOMMASO CASINI;PAOLO GALLO;PAOLA PERINI;LICIA PERUZZI;MARCO FERRARI;GIANLUCA RIGATELLI;DARIA MANIERO;FILIPPO CECCATO","6;6;6;6;6;6;6;6;5;4;4;4;4;4;4;3;3;3;3;3","NICLA CAMPOBASSO;C. ANGELINI;AMIR MARI;MARCO PUTHENPARAMPIL;FRANCESCA RINALDI;PAOLA PERINI;MARCO ZUIN;MARTINA CACCIAPUOTI;CALÒ LORENZO;ANTONELLA MELONI;MARIA CATERINA PUTTI;LAURA PISTOIA;VINCENZO POSITANO;MATTEO FASSAN;ALESSANDRO MISCIOSCIA;PAOLO GALLO;MARTA GAGGIOLA;FILIPPO CADEMARTIRI;PAOLO GALLO;BIANCA GATTARI","1;1;1;0.73;0.73;0.51;0.48;0.48;0.48;0.42;0.42;0.42;0.42;0.4;0.4;0.39;0.36;0.35;0.34;0.33","MARIA CATERINA PUTTI;MARCO PUTHENPARAMPIL;MATTEO FASSAN;EDOARDO SAVARINO;FRANCESCA RINALDI;ALESSANDRO MISCIOSCIA;ANGELO PAOLO DEI TOS;PAOLO GALLO;PAOLA PERINI;MARCO FERRARI;GIANLUCA RIGATELLI;DARIA MANIERO;FILIPPO CECCATO;MARTA SBARAGLIA;CRISTINA BASSO;MARTA GAGGIOLA;PAOLO GALLO;PIERO NICOLAI;ROBERTO BOVO;GAETANO GALLO","6;6;6;6;6;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2","NICLA CAMPOBASSO;C. ANGELINI;AMIR MARI;MARCO PUTHENPARAMPIL;FRANCESCA RINALDI;PAOLA PERINI;MARTINA CACCIAPUOTI;CALÒ LORENZO;MARIA CATERINA PUTTI;MATTEO FASSAN;ALESSANDRO MISCIOSCIA;PAOLO GALLO;MARTA GAGGIOLA;PAOLO GALLO;BIANCA GATTARI;GIANLUCA RIGATELLI;NICOLA GASPARETTO;GIANLUCA RIGATELLI;GIANLUCA CUVA;D BETTA","1;1;1;0.73;0.73;0.51;0.48;0.48;0.42;0.4;0.4;0.39;0.36;0.34;0.33;0.33;0.33;0.33;0.33;0.33","EDOARDO SAVARINO;DARIA MANIERO;ANTONELLA MELONI;FILIPPO CADEMARTIRI;LAURA PISTOIA;MARIA CATERINA PUTTI;VINCENZO POSITANO;ADOLFO SUÁREZ;ADRIANA ORTEGA LARRODÉ;ALFREDO J. LUCENDO;ALICIA GRANJA NAVACERRADA;ANNA SPASIANO;ANNE LUND KRARUP;ANTONIA PERELLÓ;ANTONIO GUARDIOLA‐ARÉVALO;CARLOS TERUEL;CAROLINA GUTIÉRREZ‐JUNQUERA;CECILIO SANTANDER;DANILA GUAGNOZZI;EDURNE AMORENA","15;13;10;10;10;10;10;9;9;9;9;9;9;9;9;9;9;9;9;9","EDOARDO SAVARINO;DARIA MANIERO;MARIA CATERINA PUTTI;MATTEO GHISA;GIANLUCA RIGATELLI;GIORGIO DE CONTI;LUISA MURER;RAFFAELLA MOTTA;CRISTINA BASSO;FRANCESCA RINALDI;MARCO PUTHENPARAMPIL;PAOLO GALLO;ANNA BELLONI FORTINA;FEDERICA DE NAPOLI;FRANCESCA CAROPPO;GUILHERME ZANOTELLI;MARTA GAGGIOLA;P. PERINI;ROBERTO BOVO;VA MAUCERI","15;13;10;9;6;6;6;6;4;4;4;4;3;3;3;3;3;3;3;3","EDOARDO SAVARINO;MARIA CATERINA PUTTI;PAOLO GALLO;FRANCESCA RINALDI;MARCO PUTHENPARAMPIL;GIANLUCA RIGATELLI;DARIA MANIERO;MARTA GAGGIOLA;CRISTINA BASSO;MATTEO GHISA;ROBERTO BOVO;STEFANIA RIZZO;ALESSANDRO MISCIOSCIA;ANNA BELLONI FORTINA;ANNALISA ANGELINI;CESARE RUFFOLO;E INSACCO;FABIANA ZINGONE;FEDERICA DE NAPOLI;FRANCESCA CAROPPO","6;6;6;6;6;5;3;3;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;ECONOMICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE;HISTORY","90;21;11;9;7;5;5;4;4;4;2;2;1;1;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;IMMUNOLOGY;CARDIOLOGY;GASTROENTEROLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;ONCOLOGY;GENETICS;AUDIOLOGY;BIOCHEMISTRY;DERMATOLOGY;PALEONTOLOGY;PEDIATRICS;CANCER RESEARCH;ENVIRONMENTAL HEALTH;NURSING;PHARMACOLOGY;PHYSICAL THERAPY;QUANTUM MECHANICS","70;22;20;18;16;13;10;9;8;7;6;5;5;5;5;5;4;4;4;4;4;4","DISEASE;CANCER;COHORT;HEART FAILURE;CHEMOTHERAPY;GENE;MULTIPLE SCLEROSIS;THALASSEMIA;IMMUNE SYSTEM;POPULATION;RETROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS;ANTIBODY;COGNITION;CONTEXT (ARCHAEOLOGY);HEALTH CARE;KIDNEY;MAGNETIC RESONANCE IMAGING;MEDICAL PRESCRIPTION;MYOCARDIAL INFARCTION;NEUROLOGY;OTORHINOLARYNGOLOGY;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;TERM (TIME);THROMBOSIS;TRANSPLANTATION","24;10;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","REFLUX;BETA THALASSEMIA;INFECTIOUS DISEASE (MEDICAL SPECIALTY);NEURORADIOLOGY;BRAIN CANCER;BREAST CANCER;CARDIOMYOPATHY;CERVICAL CANCER;COLORECTAL CANCER;EOSINOPHILIC ESOPHAGITIS;GLOMERULONEPHRITIS;INFLAMMATORY BOWEL DISEASE;LIVER TRANSPLANTATION;NATALIZUMAB;PHENOTYPE;VASCULITIS;2019-20 CORONAVIRUS OUTBREAK;ACHALASIA;ADALIMUMAB;ADENOCARCINOMA;ALPRAZOLAM;ANTIANGIOGENIC THERAPY;ANTIBIOTIC PROPHYLAXIS;ANTIDIURETIC;ANTIOXIDANT CAPACITY;ANTIPHOSPHOLIPID SYNDROME;ASEPTIC MENINGITIS;AUTOIMMUNE DISEASE;AUTOIMMUNITY;BETA OXIDATION;BEVACIZUMAB;BIPOLAR DISORDER;BISOPROLOL;BLEPHAROPLASTY;BLOOD–BRAIN BARRIER;BRAIN BIOPSY;BUDESONIDE;CANCER REGISTRY;CARCINOEMBRYONIC ANTIGEN;CARDIAC AMYLOIDOSIS;CARDIAC FUNCTION CURVE;CARDIAC MAGNETIC RESONANCE;CARDIAC MAGNETIC RESONANCE IMAGING;CARDIAC TOXICITY;CERVIX;CHEMOKINE;COGNITIVE IMPAIRMENT;COGNITIVE TEST;COMPASSIONATE USE;COMPLETE REMISSION;CONNECTOME;CONTINUOUS POSITIVE AIRWAY PRESSURE;CORONARY ANGIOGRAPHY;CROHN'S DISEASE;CYCLOPHOSPHAMIDE;DEFERASIROX;DEFERIPRONE;DEMENTIA;DEMYELINATING DISORDER;DISEASE REGISTRY;EJECTION FRACTION;ENDOCRINE SYSTEM;EOSINOPHIL;EPIDERMAL GROWTH FACTOR;EPIDERMAL GROWTH FACTOR RECEPTOR;EPITOPE;ESOPHAGEAL DISEASE;EVIDENCE-BASED MEDICINE;EXOCRINE PANCREATIC INSUFFICIENCY;EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;FABRY DISEASE;FACTOR XIII;FATTY ACID METABOLISM;FLUTICASONE;FLUTICASONE PROPIONATE;FOLLICULAR LYMPHOMA;FRACTION OF INSPIRED OXYGEN;GESTATIONAL AGE;HEALTH RELATED QUALITY OF LIFE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS B VIRUS;HIGH-POWER FIELD;HIP FRACTURE;HUMAN LEUKOCYTE ANTIGEN;HYDROCHLOROTHIAZIDE;IMMUNE DYSREGULATION;IMMUNIZATION;IMMUNODEFICIENCY;IMMUNOGLOBULIN G;IMMUNOTHERAPY;INFARCTION;INHERITANCE (GENETIC ALGORITHM);INTERIM ANALYSIS;KIDNEY CANCER;LARYNGOSCOPY;LEFT BEHIND;LEFT BUNDLE BRANCH BLOCK;LEUKOPENIA;LIQUID BIOPSY;MACROPHAGE;MAJOR HISTOCOMPATIBILITY COMPLEX;METASTASIS;MITRAL VALVE PROLAPSE;MOLECULAR MIMICRY;MYELIN;NATURAL HISTORY STUDY;NEUROPATHOLOGY;NEUTROPENIA;PARKINSON'S DISEASE;POISSON REGRESSION;PRIMARY ALDOSTERONISM;PRIMARY IMMUNODEFICIENCY;PRIMARY SCLEROSING CHOLANGITIS;PROSTATE;PROSTATE CANCER;PROTEASE;PROTEINURIA;PROTEOMICS;PROTOCOL (SCIENCE);PTX3;QUALITY MANAGEMENT;REPERFUSION THERAPY;RETINITIS PIGMENTOSA;RITUXIMAB;SCLERODERMA (FUNGUS);SEPTIC SHOCK;SERUM FERRITIN;SICKLE CELL TRAIT;SIGMOID SINUS;SUNITINIB;SYSTEMATIC REVIEW;SYSTEMIC MASTOCYTOSIS;TELEMEDICINE;TEST STRATEGY;THROMBOLYSIS;THYROID CANCER;TIMED UP AND GO TEST;TRANSCRIPTION FACTOR;TUMOR MICROENVIRONMENT;ULCERATIVE COLITIS;VASCULAR TUMORS;VENOUS THROMBOEMBOLISM;VON WILLEBRAND FACTOR;WARFARIN;WECHSLER ADULT INTELLIGENCE SCALE;WEIGHT LOSS","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORONAVIRUS DISEASE 2019 (COVID-19);GERD;COLPOSCOPY;ESOPHAGITIS;GLOMERULOPATHY;ABSOLUTE NEUTROPHIL COUNT;AXITINIB;BRONCHOPULMONARY DYSPLASIA;CD163;CERVICAL INTRAEPITHELIAL NEOPLASIA;CERVICAL SCREENING;COGNITIVE DECLINE;CONNECTIVE TISSUE DISEASE;CUTANEOUS MASTOCYTOSIS;ESOPHAGEAL MOTILITY DISORDER;GASTRIC BYPASS;GATA3;HBSAG;HEALTH UTILITIES INDEX;HIGH RESOLUTION MANOMETRY;IMMUNOGLOBULIN A;INTRAVENTRICULAR HEMORRHAGE;LARYNGOPHARYNGEAL REFLUX;LENVATINIB;LYMPHOVASCULAR INVASION;MHC CLASS I;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;NIVOLUMAB;OBINUTUZUMAB;OMIM : ONLINE MENDELIAN INHERITANCE IN MAN;PCA3;PEMBROLIZUMAB;PERIVENTRICULAR LEUKOMALACIA;PROSTATE BIOPSY;PROSTATE-SPECIFIC ANTIGEN;REFLUX ESOPHAGITIS;RETINOPATHY OF PREMATURITY;SURFACTANT THERAPY;SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION;SYSTEMIC VASCULITIS;TELEHEALTH;TRAIL MAKING TEST;TRANSFERRIN SATURATION;TRASTUZUMAB;TRIAMTERENE;USTEKINUMAB;VEDOLIZUMAB;VITAMIN K ANTAGONIST","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;MAGNETIC RESONANCE IMAGING;RETROSPECTIVE STUDIES;ADOLESCENT;CHILD;YOUNG ADULT;PROSPECTIVE STUDIES;IRON OVERLOAD;PROGNOSIS;REGISTRIES;RISK FACTORS;TREATMENT OUTCOME;BETA-THALASSEMIA;CHILD, PRESCHOOL","54;39;21;19;15;12;8;7;7;6;6;6;5;4;4;4;4;4;3;3","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;ACUTE MYELOID LEUKEMIA;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GLIOMAS;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;IMPACT OF HEARING LOSS ON COGNITIVE FUNCTION;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;VASCULAR TUMORS AND ANGIOSARCOMA;APELIN SIGNALING AND PHYSIOLOGY;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES","6;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","TREATMENT;BETA THALASSEMIA;EOSINOPHILIC ESOPHAGITIS;NEURORADIOLOGY;TRANSFUSION THERAPY;ACUTE MYELOID LEUKEMIA;AGE-RELATED HEARING LOSS;ANTICOAGULANT THERAPY;BRAIN METASTASES;CARDIAC IMAGING;CLOSURE (PSYCHOLOGY);COCHLEAR IMPLANTS;CROSS-SECTIONAL STUDY;DIAGNOSTIC CRITERIA;ESOPHAGITIS;GASTROESOPHAGEAL REFLUX DISEASE;GLOMERULOPATHY;IMAGING IN VASCULITIS;IRON OVERLOAD;NATALIZUMAB","5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE SCLEROSIS;RHEUMATOID ARTHRITIS;ACUTE MYELOID;ADULT PATIENTS;BETA-THALASSEMIA MAJOR;BOWEL DISEASE;BRAIN METASTASES;BREAST CANCER;COHORT STUDY;COLORECTAL CANCER;CONNECT REGISTRY;EOE CONNECT;EOSINOPHILIC ESOPHAGITIS;HYPERTROPHIC CARDIOMYOPATHY;INFLAMMATORY BOWEL;ITALIAN SOCIETY;LIVER TRANSPLANTATION;MAGNETIC RESONANCE;MYELOID LEUKEMIA;NEWLY DIAGNOSED;OXIDATIVE STRESS;PANCREATIC IRON;QUALITY IMPROVEMENT;SCLEROSIS PATIENTS;AB INCREASED;ABSENT CONTRACTILITY;ACID OXIDATION;ACID PROTECTS;ACREULAR ANTIPHOSPHOLIPID;ACUTE APPENDICITIS","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","HR CI;QALB MS;RISK FACTORS;PRIMARY BC;BBB DAMAGE;BIO-PLEX PRO;MS PATIENTS;PD PATIENTS;PLEX PANEL;PRO HUMAN;PROSTATE CANCER;REPERFUSION THERAPIES;RETROGRADE FLOW;ADRENAL STEROIDS;ATRIAL FIBRILLATION;CORONARY ARTERY;FUNCTIONAL OUTCOME;HEARING LOSS;LAMINAR FLOW;MEDIAN AGE;MULTIPLE SCLEROSIS;MYOCARDIAL INFARCTION;PATIENTS TREATED;SIGNIFICANTLY LOWER;SURFACTANT ADMINISTRATION;ARTERY DISEASE;BIFURCATION LESION;BLOOD PRESSURE;CLINICAL OUTCOMES;CORONARY ARTERIES","12;12;8;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4",2,0.02,4.51,10.5,0,0,0,0,0,0,0,10.75,0,0,10.5,0,0,1,0,7.5,3,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,7,50,0.5,0,0,27,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;PATIENT SAFETY;RARE DISEASES","1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1","MYELOMA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,"FRONTIERS;TAYLOR & FRANCIS GROUP","4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","10;5;1","CLINICAL RESEARCH;DIGESTIVE DISEASES;IMMUNIZATION;VACCINE RELATED;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;LIVER DISEASE;ORGAN TRANSPLANTATION;PREVENTION;TRANSPLANTATION;CANCER;INFLAMMATORY BOWEL DISEASE;NUTRITION;PATIENT SAFETY","5;4;4;4;3;3;3;3;3;3;3;1;1;1;1","INFECTION;CANCER","3;1","3.4 VACCINES;6.1 PHARMACEUTICALS","3;1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","2","LIVER CANCER;LUNG CANCER","3;1","3 GOOD HEALTH AND WELL BEING","3"
